<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" dtd-version="1.3">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Biosci</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Biosci</journal-id>
      <journal-title-group>
        <journal-title>Journal of Biosciences</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0250-5991</issn>
      <issn pub-type="epub">0973-7138</issn>
      <publisher>
        <publisher-name>Springer India</publisher-name>
        <publisher-loc>New Delhi</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">33410425</article-id>
      <article-id pub-id-type="pmc">7683586</article-id>
      <article-id pub-id-type="publisher-id">114</article-id>
      <article-id pub-id-type="doi">10.1007/s12038-020-00114-6</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>COVID-19: Advances in diagnostic tools, treatment strategies, and vaccine development</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Sreepadmanabh</surname>
            <given-names>M</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sahu</surname>
            <given-names>Amit Kumar</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0003-2210-5180</contrib-id>
          <name>
            <surname>Chande</surname>
            <given-names>Ajit</given-names>
          </name>
          <address>
            <email>ajitg@iiserb.ac.in</email>
          </address>
          <xref ref-type="aff" rid="Aff1"/>
        </contrib>
        <aff id="Aff1"><institution-wrap><institution-id institution-id-type="GRID">grid.462376.2</institution-id><institution-id institution-id-type="ISNI">0000 0004 1763 8131</institution-id><institution>Molecular Virology Laboratory, </institution><institution>Indian Institute of Science Education and Research, </institution></institution-wrap>Bhopal, India </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>24</day>
        <month>11</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2020</year>
      </pub-date>
      <volume>45</volume>
      <issue>1</issue>
      <elocation-id>148</elocation-id>
      <history>
        <date date-type="received">
          <day>26</day>
          <month>6</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>15</day>
          <month>10</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; Indian Academy of Sciences 2020</copyright-statement>
        <license>
          <license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <p id="Par1">An unprecedented worldwide spread of the SARS-CoV-2 has imposed severe challenges on healthcare facilities and medical infrastructure. The global research community faces urgent calls for the development of rapid diagnostic tools, effective treatment protocols, and most importantly, vaccines against the pathogen. Pooling together expertise across broad domains to innovate effective solutions is the need of the hour. With these requirements in mind, in this review, we provide detailed critical accounts on the leading efforts at developing diagnostics tools, therapeutic agents, and vaccine candidates. Importantly, we furnish the reader with a multidisciplinary perspective on how conventional methods like serology and RT-PCR, as well as cutting-edge technologies like CRISPR/Cas and artificial intelligence/machine learning, are being employed to inform and guide such investigations. We expect this narrative to serve a broad audience of both active and aspiring researchers in the field of biomedical sciences and engineering and help inspire radical new approaches towards effective detection, treatment, and prevention of this global pandemic.</p>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Artificial intelligence</kwd>
        <kwd>CRISPR/Cas</kwd>
        <kwd>SARS-CoV-2</kwd>
        <kwd>treatment strategies</kwd>
        <kwd>viral diagnostics</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Indian Academy of Sciences 2020</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p id="Par2">The ongoing COVID-19 pandemic has had devastating effects on populations, social structures, and economic growth. These are further exacerbated by the increasing extent of global connectivity and geographical mobility, which expedite infection spread at an uncontrollable pace. The causative agent of this outbreak has been identified as the recently discovered SARS-CoV-2 coronavirus. Effective control and containment of this pathogen require reliable diagnostic assays and potent therapeutic agents. Recent advances in computational technology and biomedical engineering have placed a toolkit of immense potential in our hands, with a formerly unimaginable capability to enable multidisciplinary innovations and highly accelerated discoveries. In this review, we provide a critical evaluation of diagnostic techniques and treatment strategies targeted at the SARS-CoV-2. Alongside an eclectic selection of such reports, our analysis also focuses on the applications, advantages, and pitfalls of emerging technologies like CRISPR/Cas, immune-informatics, artificial intelligence, and machine learning.</p>
    </sec>
    <sec id="Sec2">
      <title>Diagnostic tools for detecting SARS-CoV-2</title>
      <p id="Par3">Figure&#xA0;<xref rid="Fig1" ref-type="fig">1</xref> provides a graphical summary of the various approaches discussed herein.<fig id="Fig1"><label>Figure&#xA0;1</label><caption><p>Summary of the various approaches towards diagnosis of SARS CoV-2 infection.</p></caption><graphic xlink:href="12038_2020_114_Fig1_HTML" id="MO1"/></fig></p>
      <sec id="Sec3">
        <title>RT-PCR</title>
        <p id="Par4">PCR-based methods are considered the gold standard for viral detection. SARS-CoV-2 requires RT-PCR-based approaches, by virtue of being an RNA virus. In this section, we highlight some interesting developments as well as possible pitfalls of this technique, in the context of viral diagnosis.</p>
        <p id="Par5">One of the earliest workflows set up in response to the outbreak was by Christian Dorsten and colleagues (Corman <italic>et al.</italic>
<xref ref-type="bibr" rid="CR23">2020</xref>). The team established an accurate, sensitive, and specific RT-PCR protocol against the SARS-CoV-2. Later research, including a comparative study by Nalla <italic>et al.</italic>, have attested to its superior sensitivity (Nalla <italic>et al.</italic>
<xref ref-type="bibr" rid="CR79">2020</xref>). A notable feature of this pioneering work was that the assays were designed without access to any actual SARS-CoV-2 genomic specimens or patient samples, by relying on genome information sourced from Chinese researchers and synthetic nucleic acid technology. An interesting comparison between two commercially available testing kits &#x2013; (the TaqMan&#x2122; 2019-nCoV Assay Kit v1 (ThermoFisher) and the 2019-nCoV CDC qPCR Probe Assay (Integrated DNA Technologies)) &#x2013; was recently reported, results from which indicate that the former is capable of reliably detecting SARS-CoV-2 presence in nasopharyngeal swab samples without any RNA extraction steps (Beltr&#xE1;n-Pavez <italic>et al.</italic>
<xref ref-type="bibr" rid="CR7">2020</xref>). Most diagnostic devices relying on RT-PCR-based amplification suffer from the drawback of requiring either sample lysis or purified nucleic acid samples, a step that involves additional reagents, increased testing time, human errors and costs, in addition to significant compromises on the field-applicability of the test. Subject to further validation, the above result represents a potential breakthrough for rapid and accessible diagnosis in low-resource settings, by enabling the development of accessible point-of-care devices. Additionally, while nasopharyngeal/oropharyngeal swabs are recommended sample collection techniques for SARS-CoV-2 testing, these pose a high risk of exposing healthcare workers to large numbers of potentially infected individuals, in addition to causing patient discomfort. An alternative in the form of saliva specimens as a non-invasive method of sample collection has been proposed to address these concerns (To <italic>et al.</italic>
<xref ref-type="bibr" rid="CR98">2020</xref>).</p>
        <p id="Par6">In order to enhance the sensitivity and fidelity of RT-PCR assays, a worthwhile strategy is to evaluate the potential of various viral components as probe targets and compare the relative performance of each. For instance, an early RT-PCR-based detection assay used probes against the ORF1b and N region of the viral genome (Chu <italic>et al.</italic>
<xref ref-type="bibr" rid="CR22">2020</xref>). Subsequently, another study developed three novel assays aimed at the viral spike protein (S), nucleocapsid (N), and RNA-dependant RNA polymerase (RdRp)/Helicase (Hel) genes, out of which, the RdRp/Hel-based assay demonstrated no cross-reactivity with common respiratory pathogens as well as the lowest detection limit <italic>in vitro</italic> (Chan <italic>et al.</italic>
<xref ref-type="bibr" rid="CR17">2020</xref>). Exploring such novel targets may help develop superior assays, which can improve the sensitivity and accuracy of detection. Furthermore, a comparative analysis by Nalla <italic>et al.</italic> evaluated seven different assay kits and reported the E-gene primer/probe set (as described by Corman <italic>et al.</italic> (<xref ref-type="bibr" rid="CR23">2020</xref>)) and the N2 set (developed by the Division of Viral Diseases, Center for Disease Control and Prevention) as the most sensitive assays available. The importance of such independent assessments of reported/published studies needs to be underscored in healthcare crisis scenarios such as the present one, wherein resources are limited and must be judiciously allocated.</p>
      </sec>
      <sec id="Sec4">
        <title>Chest CT scans</title>
        <p id="Par7">A few studies have also pointed out the liabilities of RT-PCR-based techniques. While some publications and <italic>in vitro</italic> assays may report excellent parameters of performance, clinical testing and feedback raise several red flags. A most elementary instance of this was reported in a case wherein two patients who were SARS-CoV-2 infected returned negative RT-PCR results, leading the authors to suggest chest CT scans as an essential part of clinical diagnosis (Li <italic>et al.</italic>
<xref ref-type="bibr" rid="CR58">2020a</xref>). Similar issues with a high false-negative rate of RT-PCR testing on patients over the course of disease progression and treatment have been reported separately as well (Li <italic>et al.</italic>
<xref ref-type="bibr" rid="CR62">2020e</xref>). Such observations have promoted recommendations to include clinical parameters such as CT scan diagnosis as factors to be considered in addition to the aforementioned assays while making decisions on patient discharge, evaluation of recovery/response to treatment protocols. A retrospective study reached similar conclusions in favor of CT scans, ascribing a 97.2% sensitivity to CT, as compared to 83.3% using RT-PCR (Long <italic>et al.</italic>
<xref ref-type="bibr" rid="CR66">2020a</xref>).</p>
        <p id="Par8">At this juncture, we would like to emphasize a few recent studies which have underscored the potential of chest CT scans as a viable diagnostic technique. Work by Cao <italic>et al.</italic> and Dai <italic>et al.</italic> seeks to formulate a standard set of characteristic features indicative of a SARS-CoV-2 infection. The former, a systematic review and meta-analysis of infected patients, establishes the most common clinical symptoms as fever, cough, chest distress, fatigue, and dyspnea, along with major imaging features as ground-glass opacities and bilateral pneumonia (Cao <italic>et al.</italic>
<xref ref-type="bibr" rid="CR15">2020a</xref>). The latter provides a more comprehensive treatment in which over two hundred patients were studied to report bilateral multiple lung lobes in both the periphery and lower portion of the lungs as being present in over 94.98% of the cases (Dai <italic>et al.</italic>
<xref ref-type="bibr" rid="CR25">2020</xref>). Additionally, ground-glass opacities and vascular enhancement were identified as characteristic signatures, as well as fibrosis, air, trapping, and interlobular septal thickening. It is worthwhile to note that highly concordant observations have been made across different patient cohorts, and the general agreement between these is an indicator of the proposed technique&#x2019;s versatility and broad-spectrum applicability. A more extensive and detailed elucidation of the same may be found in the recent review by Hani <italic>et al.</italic> (Hani <italic>et al.</italic>
<xref ref-type="bibr" rid="CR42">2020</xref>). Furthermore, time-point-based CT scan data may be an invaluable tool to assess disease progression, treatment response, development of complications, and understanding the pathophysiology of the disease, as has been stressed by Bernheim <italic>et al.</italic> (<xref ref-type="bibr" rid="CR8">2020</xref>). Additionally, an artificial intelligence (AI)-based platform has also been devised which utilizes a neural network to evaluate X-ray images and automatically detects SARS-CoV-2-infected positive specimens with an accuracy of 97.82% (Apostolopoulos and Bessiana <xref ref-type="bibr" rid="CR3">2020</xref>). Harnessing advances in computer science for medical diagnostics may serve as an essential tool to standardize and speed up the testing process. Similar applications of machine learning and AI to aid in the pandemic control efforts will be further elaborated in Sect.&#xA0;<xref rid="Sec14" ref-type="sec">4</xref>.</p>
      </sec>
      <sec id="Sec5">
        <title>Antibody-based techniques</title>
        <p id="Par9">The evident advantage of antibodies over nucleic acids amplification is higher specificity, accuracy, as well as rapid testing times since it does not require time-consuming amplification steps, nor involves cumbersome extraction/purification processes. A recent report has also highlighted that antibody titers may be a more reliable indicator of SARS-CoV-2 infections, especially for asymptomatic and suspected carriers who return negative RT-PCR results (Long <italic>et al.</italic>
<xref ref-type="bibr" rid="CR67">2020b</xref>).</p>
        <p id="Par10">The classic Enzyme-linked Immunosorbent Assay (ELISA) may be readily adapted to serve as a SARS-CoV-2 detection test. Accordingly, this has been employed against the recombinant viral nucleocapsid proteins and the recombinant viral spike proteins, which were used to detect the IgM and IgG antibody levels (Liu <italic>et al.</italic>
<xref ref-type="bibr" rid="CR64">2020</xref>). This study established that spike protein-based assay would be more sensitive for detecting IgM. Along similar lines, the comparative performance of ELISA-based and Gold-immunochromatographic Assay (GICA)-based methods have also been evaluated (Xiang <italic>et al.</italic>
<xref ref-type="bibr" rid="CR105">2020</xref>). The rapid testing times and high sensitivity observed posit serological assays as superior alternatives to RT-PCR on account of ease of sample collection (blood, which poses minimal risk to healthcare staff compared to swab samples) and low false-negative rates. In this regard, an efficient point-of-care device for diagnostic testing which combined the IgG-IgM testing platform with a testing time of fifteen minutes was recently reported (Li <italic>et al.</italic>
<xref ref-type="bibr" rid="CR63">2020f</xref>). While the repurposing of cross-reactive antibodies from highly similar species like the SARS-CoV is a viable idea, an interesting report notes some pitfalls (Tian <italic>et al.</italic>
<xref ref-type="bibr" rid="CR97">2020</xref>). Despite the relative identity between the SARS-CoV and the SARS-CoV-2, the authors point out that highly potent receptor binding site-targeting SARS-CoV neutralizing antibodies (like the CR3014 and m396) fail to engage the SARS-CoV-2 spike protein. This indicates that effective management of novel pathogens may necessitate the development of novel antibodies and those homology-based strategies to repurpose existing therapeutics should be rigorously vetted.</p>
        <p id="Par11">However, an over-reliance on antibody-based approaches is impractical. Designing nucleic acid probes is a far more straightforward process, and one much more rapidly deployable. Also, the detection of antibodies may be difficult in the early stages of infection, until a significant titer of IgG/IgM has accumulated in circulation. This may contribute towards significant false-negative rates during large-scale screenings, especially when periodic sampling and extended observation of test subjects may not be feasible. Hence, despite the salient advantages of antibody-based techniques as discussed above, several assay kits and field-testing protocols have remained in the domain of PCR amplification-based methods. Accordingly, our object of focus for the next section will be one such recently evolved technology, loop-mediated isothermal amplification (LAMP).</p>
      </sec>
      <sec id="Sec6">
        <title>RT-LAMP</title>
        <p id="Par12">LAMP-based protocols enable the efficient amplification of nucleic acids at a single point temperature. This feature makes it a strong contender for direct field applications, since incorporating the thermal cycling steps in PCR assays has traditionally been a significant limitation for point-of-care devices. LAMP&#x2019;s inherent advantages are not limited to isothermal operability alone. This robust technique works efficiently even with crude sample preparations, compared to traditional PCR methods, and also offers a very high amplification efficiency since it is not limited by a doubling-per-cycle threshold (Becherer <italic>et al.</italic>
<xref ref-type="bibr" rid="CR6">2020</xref>).</p>
        <p id="Par13">We wish to highlight two particular tests, both of which report colorimetric detection capability &#x2013; a major boon for point-of-care devices. A team led by Di Liu and Jing Yuan reported RT-LAMP assays for SARS-CoV-2 detection, with ORF1ab and S genes as the primer-probe targets (Yan <italic>et al.</italic>
<xref ref-type="bibr" rid="CR106">2020</xref>). The work claims complete detection within 60 min, using a colorimetric detection system that employs fluorescent calcein, where a color change from orange to green indicates positive reactions (visually detectable by the naked eye). Another effort by Renfei Lu <italic>et al.</italic> involving primers targeted at the RdRp utilizes cresol red (a pH-sensitive indicator dye) for the assay readout (Lu <italic>et al.</italic>
<xref ref-type="bibr" rid="CR68">2020</xref>). Since a proceeding amplification can progressively change the buffer pH from alkaline to acidic, a color change from burgundy to orange/yellow signals a positive reaction. These innovations in assay readout methodology imply a significant advancement since they make it possible to have even untrained healthcare workers administer, conduct, and interpret diagnostic tests.</p>
        <p id="Par14">A noteworthy instance of adapting RT-LAMP for a truly bedside point-of-care application is the innovative closed-tube test developed by Song and colleagues (El-Tholoth <italic>et al.</italic>
<xref ref-type="bibr" rid="CR29">2020</xref>). Combining straightforward sample collection with single or two-step RT-LAMP amplification protocols, along with a visual detection system based on LCV (leucocrystalviolet &#x2013; an intercalating agent which colorimetrically detects double-stranded LAMP amplicons), this device is a readily deployable and highly portable testing method that promises to be a cheap and reliable alternative suitable for all testing environments.</p>
      </sec>
      <sec id="Sec7">
        <title>Emerging techniques: reactive polymers and CRISPR/Cas-based systems</title>
        <p id="Par15">This subsection is devoted to a couple of non-conventional detection methods, which may well serve as a versatile platform in the future. The first is a reactive polymer-grafter device which utilizes antibodies to detect dsRNA (Ku <italic>et al.</italic>
<xref ref-type="bibr" rid="CR54">2020</xref>). A suitable polymer-coated surface-reactive poly(pentafluorophenyl acetate) in this case is used to immobilize J2 antibodies on the surface. Following the preparation of the platform, it may be directly applied to detect dsRNA as the J2 antibodies may bind dsRNA molecules specifically. The principal advantage, in this case, is that the antibody binding is sequence-independent; hence the platform may serve as a universal virus detection unit. However, it may be noted that such one-size-fits-all approaches suffer from an inherent lack of specificity. In this case, the sequence-independent nature of detection suggests a high possibility of false positives. Such a scenario would necessitate secondary tests using established protocols for reliable confirmations of diagnosis, thereby positing the J antibodies-based technique as a potential preliminary screening step, rather than as a standalone entity.</p>
        <p id="Par16">The second major innovation involves the use of CRISPR-Cas-based techniques for the detection of viral nucleic acids. Recently, such CRISPR-based detection systems, notably SHERLOCK and DETECTR, were reported as emerging diagnostic tools. The fundamental principle involves the activation of a suitable Cas variant (Cas13 for SHERLOCK, Cas12a for DETECTR) by binding of the appropriate target sequence (ssRNA or mRNA for Cas13 and dsDNA for Cas12a), which enables the Cas variants to promiscuously cleave and degrade surrounding ssRNA and ssDNA, respectively. The ssRNA/ssDNA meant for the latter reaction may be coupled with a quenchable fluorophore, which produces a quantifiable signal upon being released by cleavage. Hence, the detection of the exact target sequence is indicated by an assay readout in the form of a fluorescence signal. This system allows for rapid and accurate detection of viral RNA samples since amplification of these (along with suitable modifications as per the system used) can then allow for precise targeting and detection by the Cas-based assay described above. This remarkable ability has been recently demonstrated by using the DETECTR system as a diagnostic tool for SARS-CoV-2 infections in a rapid lateral flow assay incorporating RT-LAMP using nasal swab samples (Broughton <italic>et al.</italic>
<xref ref-type="bibr" rid="CR12">2020</xref>). Additionally, a series of reports may be found on the Broad Institute&#x2019;s website (<ext-link ext-link-type="uri" xlink:href="https://www.broadinstitute.org/news/enabling-coronavirus-detection-using-crispr-cas13-open-access-sherlock-research-protocols-and">https://www.broadinstitute.org/news/enabling-coronavirus-detection-using-crispr-cas13-open-access-sherlock-research-protocols-and</ext-link>), wherein a team comprising of Feng Zhang, Omar Abudayyeh, and Jonathan Gootenberg aim to develop paper-based platforms for rapid and straightforward SARS-CoV-2 detection (B Institute <xref ref-type="bibr" rid="CR45">2020</xref>).</p>
      </sec>
    </sec>
    <sec id="Sec8">
      <title>Treatment strategies for SARS-CoV-2 infections</title>
      <p id="Par17">In this section, we endeavor to review some of the established and emerging treatment paradigms which are being currently employed or recommended on the basis of published literature and empirical evidence from clinical case studies. The major ones have been pictorially represented in figure&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>.<fig id="Fig2"><label>Figure&#xA0;2</label><caption><p>Some established and emerging treatment paradigms being currently employed or recommended on the basis of published literature and empirical evidence from clinical case studies.</p></caption><graphic xlink:href="12038_2020_114_Fig2_HTML" id="MO2"/></fig></p>
      <sec id="Sec9">
        <title>Drugs-based conventional approaches</title>
        <p id="Par18">Amongst drug-based treatment strategies, the broad-spectrum antiviral chloroquine and its derivative hydroxychloroquine have received much attention. As early as February 2020, both remdesivir and chloroquine were identified as potential inhibitors of the SARS-CoV-2 <italic>in vitro</italic> (Wang <italic>et al.</italic>
<xref ref-type="bibr" rid="CR101">2020b</xref>). Remdesivir, a potential candidate against Ebola, SARS-CoV, and MERS-CoV, is an adenosine analog that inhibits viral replication. On the other hand, chloroquine targets endosomal fusion by elevating the endosomal pH, alongside interfering with the glycosylation of ACE2. The rationale for using chloroquine is further buttressed by a variety of possible antiviral effector functions (Devaux <italic>et al.</italic>
<xref ref-type="bibr" rid="CR27">2020</xref>). Experimental evidence for a putative mechanism was provided by structural data and molecular modeling approaches, where a conserved ganglioside binding domain at the N terminus of the viral S protein was identified as the target for chloroquine and hydroxychloroquine. This inhibition of viral attachment and entry appears to explain chloroquine and its derivative hydroxychloroquine&#x2019;s apparent efficacy against SARS-CoV-2 infections (Fantini <italic>et al.</italic>
<xref ref-type="bibr" rid="CR31">2020</xref>). However, it is important to recognize that evidence for the clinical benefits of these much-touted drugs is contentious at best and unreliable at worst. While hydroxychloroquine and azithromycin were earlier claimed as potentially effective drugs against SARS-CoV-2 infections, the reporting study has since come under criticism for the lack of a control group and incomplete descriptors of actual clinical outcomes and patient inclusion criteria (Gautret <italic>et al.</italic>
<xref ref-type="bibr" rid="CR35">2020</xref>). A separate randomized trial enrolling 62 patients did, however, report a statistically significant positive effect of hydroxychloroquine treatment in alleviating patient symptoms (Chen <italic>et al.</italic>
<xref ref-type="bibr" rid="CR20">2020c</xref>). These claims are offset by three additional reports, none of which conclude any significant benefit from this treatment method (Borba <italic>et al.</italic>
<xref ref-type="bibr" rid="CR11">2020</xref>; Magagnoli <italic>et al.</italic>
<xref ref-type="bibr" rid="CR73">2020</xref>; Mahevas <italic>et al.</italic>
<xref ref-type="bibr" rid="CR75">2020</xref>). An emerging class of candidate drugs are corticosteroids, which have recently generated great interest in the context of COVID-19 treatment approaches. While early skepticism did reign over corticosteroids usage, considering its propensity to elicit adverse reactions in severely ill patients, evidence from recent clinical trials and meta-analyses have hinted at significant benefits from this drug for the management of critically ill patients. This has led to a growing advocacy of corticosteroids as a leading candidate in the global effort against COVID-19 (Halpin <italic>et al.</italic>
<xref ref-type="bibr" rid="CR41">2020</xref>; Ma <italic>et al.</italic>
<xref ref-type="bibr" rid="CR72">2020b</xref>; Sanders <italic>et al.</italic>
<xref ref-type="bibr" rid="CR92">2020</xref>; Singh <italic>et al.</italic>
<xref ref-type="bibr" rid="CR94">2020</xref>; Yang <italic>et al.</italic>
<xref ref-type="bibr" rid="CR108">2020b</xref>; Ye <italic>et al.</italic>
<xref ref-type="bibr" rid="CR109">2020</xref>; Zha <italic>et al.</italic>
<xref ref-type="bibr" rid="CR110">2020</xref>).</p>
        <p id="Par19">Emerging technologies powered by AI offer systematic and highly modular solutions for urgent drug discovery and identification requirements. A study published in The Lancet (Richardson <italic>et al.</italic>
<xref ref-type="bibr" rid="CR88">2020</xref>) employed Benevolent AI, a platform for AI-guided drug discovery and clinical development, to offer suggestions for drugs targeted explicitly at SARS-CoV-2. Using a systematic knowledge graph, the platform was able to identify baricitinib, a Janus kinase inhibitor that binds the AAK1 (AP2-associated protein kinase 1, a regulator of endocytosis). Section&#xA0;<xref rid="Sec14" ref-type="sec">4</xref> will deal with this domain in greater detail.</p>
      </sec>
      <sec id="Sec10">
        <title>Docking simulations and molecular dynamics-based approaches</title>
        <p id="Par20">Powerful computational resources can greatly enhance our ability to rapidly screen for drugs and inhibitory agents against emerging pathogens. The SARS-CoV-2 protease has been a popular target for such docking simulations and molecular dynamics-based studies (Liu and Wang <xref ref-type="bibr" rid="CR65">2020</xref>), in part due to the recent availability of its structure. A broad screening effort of over 1.3 billion compounds from the ZINC15 database used an upgraded docking protocol (termed DeepDocking) to identify over a thousand such potential inhibitors of the SARS-CoV-2 protease (Ton <italic>et al.</italic>
<xref ref-type="bibr" rid="CR99">2020</xref>). A more systematic approach along similar lines screened 687 million compounds via docking, followed by molecular dynamics simulations to evaluate ligand-binding energies, stability, toxicity assessment, as well as off-target binding (Fischer <italic>et al.</italic>
<xref ref-type="bibr" rid="CR32">2020</xref>). Alongside such screening efforts for existing molecules, the identification of promising lead compounds that could serve as scaffolds for further modification is an essential step to enable the development of novel drugs. This requirement was addressed by a recent in-silico study, which provided a clustered report of twenty short-listed compounds into three groups, each of which could serve as leads for the development of SARS-CoV-2 inhibiting drugs (Ortega <italic>et al.</italic>
<xref ref-type="bibr" rid="CR86">2020</xref>).</p>
        <p id="Par21">While the ability of advanced computational facilities to virtually screen multitudinous drugs and compounds &#x2013; numbering anywhere from a few thousand to even a billion &#x2013; might be unmatched by traditional methods, the importance of physical assay-based screens is indispensable. The recent report of a large-scale (12,000+ compounds) repositioning survey of FDA-approved and under-trial drugs in the context of SARS-CoV-2-targeted antivirals attests to this (Riva <italic>et al.</italic>
<xref ref-type="bibr" rid="CR90">2020</xref>). Following an initial selection based on inhibition of cytopathic effects, an orthogonal validation assay was used to delineate the compounds which specifically inhibited viral replication. This study also provided classification and categorization of target annotations and drug target genes for the short-listed drugs. The identification of these specific domains can help similar such efforts in the future to be more focussed on specific drug types and targets that have been identified to exert the most promising antiviral effect on SARS-CoV-2. Another notable effort combined virtual screening methods with high-throughput assays to enable the rapid identification of promising drug candidates (Jin <italic>et al.</italic>
<xref ref-type="bibr" rid="CR49">2020</xref>). Using a FRET-based assay to assess the enzymatic activity of SARS-CoV-2 protease, over 10,000 compounds were screened for inhibitory effects on the enzyme. Additionally, the authors extensively analyzed a compound termed N3, initially developed using computer-aided drug design as an inhibitor of multiple coronavirus proteases. Following molecular docking, kinetic analysis of the protease, and determination of its crystal structure with the SARS-CoV-2 protease, the inhibitory effects of N3 were ascertained. The comprehensive approach adopted by this study is an exemplar model for similar investigations. The obvious merits of virtual screening methods notwithstanding, strong emphasis needs to be laid on developing high-throughput biochemical and cellular assays for experimental validation of pharmacologically active compounds. The importance of this cannot be overstated, as such empirical evidence helps establish a reliable standard for ascertaining the actual merits of proposed therapeutic approaches, which may, at least at the current stage of research, only be supplemented by computational studies.</p>
      </sec>
      <sec id="Sec11">
        <title>Plasma therapy</title>
        <p id="Par22">Alongside treatment with drugs, convalescent plasma (CP) therapy is being advocated as a clinically effective practice. The procedure involves using blood plasma obtained from recovered patients as an adaptive immune therapy for critical cases. The underlying principle at work is that the donor plasma contains a high titer of antibodies that are effective against the pathogen, hence provides an immunity boost to the recipient. CP has been advocated as an alternative therapy for SARS-CoV-2 infections (Chen <italic>et al.</italic>
<xref ref-type="bibr" rid="CR18">2020a</xref>) and therapeutic plasma exchange has been recommended as a suitable strategy to deal with the often associated acute respiratory distress syndrome (ARDS) (Keith <italic>et al.</italic>
<xref ref-type="bibr" rid="CR52">2020</xref>). An initial four-patient sample established that CP could have therapeutic benefits for critically ill patients (Zhang <italic>et al.</italic>
<xref ref-type="bibr" rid="CR111">2020a</xref>). While all four patients showed a progression towards negative RT-PCR results, the authors of the study stress that it would be difficult to rule out confounding factors as well as the effects of additional supportive care and treatments such as antiviral drugs and intravenous immunoglobulin. A similar study involving a ten-patient cohort demonstrated that CP dosages could either increase or maintain the existing levels of neutralizing antibodies in the recipients (Duan <italic>et al.</italic>
<xref ref-type="bibr" rid="CR28">2020</xref>). Additionally, the clinical symptoms were also observed to improve progressively, leading up to the absence of viremia. The study highlights two other salient outcomes &#x2013; one, that CP appeared to be tolerated well by the recipients without adverse reactions, and two, that transfusion of CP alleviated inflammation. It is important to note, however, that these studies need to be further supplemented by rigorous and controlled clinical trials to discount both the effects of external factors, as well as establish proper protocols for CP therapy concerning the dosage, duration, and other appropriate parameters.</p>
      </sec>
      <sec id="Sec12">
        <title>Managing cytokine storm responses</title>
        <p id="Par23">Among the several complications associated with SARS-CoV-2 infections, cytokine storm responses, which are a by-product of immune hyperactivation and loss of regulatory control over pro-inflammatory cytokines, pose a major risk for patient survival and may lead to rapid deterioration of patient health. The stimulation of CD-4+ T-cells to differentiate into Th1 helper cells along with IL-6, interferon-gamma, and GM-CSF (granulocyte-macrophage colony-stimulating factor) production, amongst other proinflammatory cytokines, are considered as the steps leading up to a cytokine storm-like condition. The persistently high levels of certain cytokines like IP-10, MCP-3, and IL-1ra may be characteristic of such an onset, and these may be developed as screening parameters to ascertain the same (Yang <italic>et al.</italic>
<xref ref-type="bibr" rid="CR107">2020a</xref>).</p>
        <p id="Par24">Extensive efforts to safely manage this condition have been undertaken. For instance, the use of an IL-6 receptor antagonist drug such as tocilizumab has been suggested, since the IL-6 has been identified as a key driver of cytokine storm response (Zhang <italic>et al.</italic>
<xref ref-type="bibr" rid="CR112">2020b</xref>). Writing in The Lancet, Mehta <italic>et al.</italic> also recommend similar IL-6 targeted strategies (Mehta <italic>et al.</italic>
<xref ref-type="bibr" rid="CR77">2020</xref>). While a previous study had failed to establish a significant connection between the administration of corticosteroids and improved treatment outcomes (Zha <italic>et al.</italic>
<xref ref-type="bibr" rid="CR110">2020</xref>), Mehta <italic>et al.</italic> recommend consideration of such a course of treatment to tackle hyperinflammation. However, there is no concrete evidence to support corticosteroid-based treatment as being of overall therapeutic value, in addition to the associated risks of lung injury (Russell <italic>et al.</italic>
<xref ref-type="bibr" rid="CR91">2020</xref>). A detailed review also suggests several strategies by which cytokine storm responses may be dealt with, including the use of the above-cited IL-6R agonist tocilizumab. Glycyrrhetinic acid, another IL-6 and STAT3 signaling inhibitor has been suggested as a potential candidate. Additionally, mesenchymal stem cell infusions have been highlighted due to the immunomodulatory and anti-inflammatory potential of these cells (Cheng <italic>et al.</italic>
<xref ref-type="bibr" rid="CR21">2020</xref>). An alternate approach to managing cytokine storm response has been suggested in the form of artificial blood purification systems. Essentially, this involves using an external filtration-cum-treatment setup to modulate the various factors and chemokines responsible for orchestrating the proinflammatory response. This may be achieved by the use of scavenging inflammatory mediators and plasma exchange. At the same time, continuous venovenous hemofiltration units may be employed, as demonstrated for the successful containment of cytokine storm responses in critically afflicted H7N9 influenza patients (Zhang <italic>et al.</italic>
<xref ref-type="bibr" rid="CR114">2020d</xref>). The merits of blood purification therapy for alleviating similar symptoms in SARS-CoV-2 infected patients have also been demonstrated by a recent study from Wuhan involving three patients (Ma <italic>et al.</italic>
<xref ref-type="bibr" rid="CR71">2020a</xref>).</p>
      </sec>
      <sec id="Sec13">
        <title>Other emerging treatment strategies</title>
        <p id="Par25">Strategies aimed at halting viral entry are not limited to drug-based approaches alone, as peptide inhibitors can play a vital role in achieving similar effects. To this end, the team led by Shibo Jiang and Lu Lu has built upon previous work that generated fusion inhibitors against the SARS-CoV spike protein&#x2019;s HR1 region to design HR2P as a fusion inhibitor against SARS-CoV-2, as well as EK1 (a pan-coronavirus fusion inhibitor). In a follow-up study, the team generated a series of EK1-derived lipopeptides to determine the ones exhibiting the most potent inhibition of fusion (variant identified as EK1C4). Suitable formulations of such peptide preparations, as suggested by the authors, may be a valuable treatment resource for SARS-CoV-2 infections (Xia <italic>et al.</italic>
<xref ref-type="bibr" rid="CR103">2020a</xref>; Xia <italic>et al.</italic>
<xref ref-type="bibr" rid="CR104">2020b</xref>).</p>
        <p id="Par26">The value of mesenchymal stem cell transplants in improving patient health for SARS-CoV-2 infections was demonstrated in a clinical study involving seven patients (Leng <italic>et al.</italic>
<xref ref-type="bibr" rid="CR57">2020</xref>). Several outcomes were characteristic of the suggestions made by Cheng <italic>et al.</italic> as mentioned earlier, including immunomodulatory effects, an attenuating effect on proinflammatory cytokines, and elevated IL-10 levels. An interesting observation made by the authors of the clinical study was that such mesenchymal stem cells lacked both ACE2 and TMPRSS2 gene expression, which could effectively render them immune to SARS-CoV-2 infection. The possible benefits of cell therapy-based therapeutic approaches may be immense and have been explored at length in a recent review (Khoury <italic>et al.</italic>
<xref ref-type="bibr" rid="CR53">2020</xref>).</p>
        <p id="Par27">The potential of melatonin as an adjuvant in clinical treatment on account of its immune-enhancing, anti-inflammatory, and anti-oxidative effects has been extolled at length in a recent review (Zhang <italic>et al.</italic>
<xref ref-type="bibr" rid="CR113">2020c</xref>). Another study focused on the antagonists of the lipid-dependant attachment process of viral particles to host cells (Baglivo <italic>et al.</italic>
<xref ref-type="bibr" rid="CR4">2020</xref>). Given that SARS-CoV-2 utilizes structures such as lipid rafts to mediate its entry process, the authors recommend exploring the possibilities of employing substances like cyclodextrin and sterols to interfere with such viral attachment and entry-enabling mechanisms. Along similar lines of conjecturing prospective therapeutic candidates, EZH2-mediated H3K27me3 at ACE2 promoter regions has been demonstrated to inhibit the expression of ACE2 receptors in mammalian cell lines, as indicated by data from RNA-Seq and CHIP-Seq experiments (Li <italic>et al.</italic>
<xref ref-type="bibr" rid="CR61">2020d</xref>).</p>
        <p id="Par28">A major cause of patient mortality in severe SARS-CoV-2 infections is the ARDS as well as coagulopathy. Fibrinolytic therapy to target the fibrin deposition in the pulmonary vasculature (a potential contributor towards ARDS) has been shown to improve survival, along with administration of tissue plasminogen activators (which converts plasminogen to plasmin, that can further breakdown blood clots). This strategy has been shown to improve conditions in a three patient study, and further clinical trials to ascertain its applicability as a standard clinical practice for critically ill SARS-CoV-2 infected patients with ARDS have been recommended (Wang <italic>et al.</italic>
<xref ref-type="bibr" rid="CR100">2020a</xref>).</p>
        <p id="Par29">The development of effective prophylactic agents is an essential component of a comprehensive approach towards tackling a global pandemic of this scale and severity. The importance of administering prophylaxis to frontline healthcare workers, screening personnel, and researchers, among others, cannot be overstressed, as the safety and continued productivity (which necessitates sound health) of these key players is paramount to maintain any sustained effort at containing the pandemic and providing healthcare and treatment of adequate quality to affected patients. In this regard, a concise review of established protocols and proposed strategies currently under scrutiny has been recently published in the form of correspondence (Agrawal <italic>et al.</italic>
<xref ref-type="bibr" rid="CR1">2020</xref>).</p>
        <p id="Par30">Considering the rapidly evolving status of COVID-19 treatment protocols, it is of utmost importance to critically evaluate the most up-to-date evidence available while designing guidelines for clinical practice. Of equal pertinence are social awareness campaigns and the regular dissemination of accurate information regarding clinically proven treatment protocols. This assumes greater importance in light of a growing inclination towards scientifically unsubstantiated claims based on anecdotal/circumstantial evidence or misrepresented facts placed out of context. We further present a brief, non-exhaustive listing (table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>) of leading therapeutic agents frequently associated with COVID-19 treatment, as well as the current opinion of the scientific community regarding each of these, based on the evidence from reported/ongoing clinical trials.<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Leading therapeutic agents against COVID-19, evaluated and described across common parameters</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Drug</th><th align="left">Parameters</th><th align="left">Details</th></tr></thead><tbody><tr><td align="left" rowspan="5">Azithromycin</td><td align="left">Status/Remarks</td><td align="left">No improvement on clinical outcomes, but no significant increase in detrimental side-effects either</td></tr><tr><td align="left">Drug type/Original purpose</td><td align="left">Antibiotic</td></tr><tr><td align="left">Mode of Administration</td><td align="left">Oral/Intravenous</td></tr><tr><td align="left">Mechanism of Action</td><td align="left">Inhibits mRNA translation by binding to 50s subunit of bacterial ribosome</td></tr><tr><td align="left">References</td><td align="left">Furtado <italic>et al.</italic> (<xref ref-type="bibr" rid="CR34">2020</xref>), Oldenburg and Doan (<xref ref-type="bibr" rid="CR81">2020</xref>)</td></tr><tr><td align="left" rowspan="5">Baricitinib</td><td align="left">Status/Remarks</td><td align="left">Improvement in patient status observed, no adverse side-effects reported. Currently in phase III clinical trials conducted by Eli Lilly and Co</td></tr><tr><td align="left">Drug type/Original purpose</td><td align="left">For rheumatoid arthritis treatment</td></tr><tr><td align="left">Mode of Administration</td><td align="left">Oral</td></tr><tr><td align="left">Mechanism of Action</td><td align="left">Janus kinase inhibitor. Shows anti-inflammatory activity</td></tr><tr><td align="left">References</td><td align="left">Cantini <italic>et al.</italic> (<xref ref-type="bibr" rid="CR14">2020</xref>)</td></tr><tr><td align="left" rowspan="5">CD24Fc</td><td align="left">Status/Remarks</td><td align="left">In phase III clinical trials. Preliminary results suggest effective management of COVID-associated symptoms</td></tr><tr><td align="left">Drug type/Original purpose</td><td align="left">nonpolymorphic regions of CD24 attached to the Fc region of human IgG1</td></tr><tr><td align="left">Mode of Administration</td><td align="left">Intravenous</td></tr><tr><td align="left">Mechanism of Action</td><td align="left">Immunomodulator, tempers inflammatory responses</td></tr><tr><td align="left">References</td><td align="left">OncoImmune (<xref ref-type="bibr" rid="CR82">2020</xref>)</td></tr><tr><td align="left" rowspan="5">Colchicine</td><td align="left">Status/Remarks</td><td align="left">Has been hypothesized to address inflamatory responses in COVID-19 infection, but concerns regarding adverse side-effects have been raised. Currently under clinical trial</td></tr><tr><td align="left">Drug type/Original purpose</td><td align="left">Anti-gout agent</td></tr><tr><td align="left">Mode of Administration</td><td align="left">Oral</td></tr><tr><td align="left">Mechanism of Action</td><td align="left">Inhibits microtubule polymerization, proinflammatory responses, neutrophil migration, and mitosis</td></tr><tr><td align="left">References</td><td align="left">Cumhur Cure <italic>et al.</italic> (<xref ref-type="bibr" rid="CR24">2020</xref>), Dalili (<xref ref-type="bibr" rid="CR26">2020</xref>)</td></tr><tr><td align="left" rowspan="5">Dexamethasone</td><td align="left">Status/Remarks</td><td align="left">Shown to lower mortality rate in a recent trial, currently being provisionally approved for patient treatment in certain regions. May be effective in critically ill patients</td></tr><tr><td align="left">Drug type/Original purpose</td><td align="left">Corticosteroid</td></tr><tr><td align="left">Mode of Administration</td><td align="left">Oral/Intravenous/Intramuscular</td></tr><tr><td align="left">Mechanism of Action</td><td align="left">Immunosuppresant. Shows anti-inflammatory effects</td></tr><tr><td align="left">References</td><td align="left">Horby <italic>et al.</italic> (<xref ref-type="bibr" rid="CR44">2020</xref>)</td></tr><tr><td align="left" rowspan="5">EIDD-2801</td><td align="left">Status/Remarks</td><td align="left">Potent antiviral activity observed in mouse models and primary human cells. Currently under phase 2 clinical trial</td></tr><tr><td align="left">Drug type/Original purpose</td><td align="left">Antiviral drug. Nucleoside derivative N4-hydroxycytidine</td></tr><tr><td align="left">Mode of Administration</td><td align="left">Oral</td></tr><tr><td align="left">Mechanism of Action</td><td align="left">Interferes with viral replication by introducing mutations</td></tr><tr><td align="left">References</td><td align="left">Ridgeback Biotherapeutics (<xref ref-type="bibr" rid="CR89">2020</xref>), Sheahan <italic>et al.</italic> (<xref ref-type="bibr" rid="CR93">2020</xref>)</td></tr><tr><td align="left" rowspan="5">Favipiravir</td><td align="left">Status/Remarks</td><td align="left">Clinical studies show faster viral clearence and improvement in chest imaging. A recent clinical trial from India by Glenmark showed faster and more effective recovery rate</td></tr><tr><td align="left">Drug type/Original purpose</td><td align="left">Pyrazinecarboxamide&#xA0;derivative</td></tr><tr><td align="left">Mode of Administration</td><td align="left">Oral/Intravenous</td></tr><tr><td align="left">Mechanism of Action</td><td align="left">Inhibits the viral RNA-dependent RNA polymerase</td></tr><tr><td align="left">References</td><td align="left">Glenmark (<xref ref-type="bibr" rid="CR37">2020</xref>), Irvani (<xref ref-type="bibr" rid="CR46">2020</xref>)</td></tr><tr><td align="left" rowspan="5">Hydroxychloroquine</td><td align="left">Status/Remarks</td><td align="left">Discontinued as a recommended drug for treatment. Clinical studies show no significant benefit for patients. Adverse cardiovascular effects have been reported. However, the study by Mehra <italic>et al.</italic>, claiming no significant benefits of HCQ administration, has since been withdrawn</td></tr><tr><td align="left">Drug type/Original purpose</td><td align="left">Chloroquine derivative. Antimalarial drug</td></tr><tr><td align="left">Mode of Administration</td><td align="left">Oral</td></tr><tr><td align="left">Mechanism of Action</td><td align="left">Increases lysosomal pH. Also dampens inflammatory response</td></tr><tr><td align="left">References</td><td align="left">Chen <italic>et al.</italic> (<xref ref-type="bibr" rid="CR20">2020c</xref>), Gautret <italic>et al.</italic> (<xref ref-type="bibr" rid="CR35">2020</xref>), Li <italic>et al.</italic> (<xref ref-type="bibr" rid="CR58">2020a</xref>, <xref ref-type="bibr" rid="CR59">b</xref>, <xref ref-type="bibr" rid="CR60">c</xref>, <xref ref-type="bibr" rid="CR61">d</xref>, <xref ref-type="bibr" rid="CR62">e</xref>, <xref ref-type="bibr" rid="CR63">f</xref>), Mahevas <italic>et al.</italic> (<xref ref-type="bibr" rid="CR75">2020</xref>), WHO (<xref ref-type="bibr" rid="CR85">2020b</xref>)</td></tr><tr><td align="left" rowspan="5">Ivermectin</td><td align="left">Status/Remarks</td><td align="left">Emerging candidate against COVID-19. Initial concerns were raised over its high effective dosage concentration by Caly <italic>et al.</italic>, but this is being explored as a safer and more effective alternative to HCQ</td></tr><tr><td align="left">Drug type/Original purpose</td><td align="left">Avermectin derivative</td></tr><tr><td align="left">Mode of Administration</td><td align="left">Oral/topical</td></tr><tr><td align="left">Mechanism of Action</td><td align="left">Targets ligand-gated ion channels of invertebrate neural cells</td></tr><tr><td align="left">References</td><td align="left">Caly <italic>et al.</italic> (<xref ref-type="bibr" rid="CR13">2020</xref>), Gupta <italic>et al.</italic> (<xref ref-type="bibr" rid="CR40">2020</xref>), Heidary and Gharebaghi (<xref ref-type="bibr" rid="CR43">2020</xref>)</td></tr><tr><td align="left" rowspan="5">Lopinavir&#x2013;ritonavir</td><td align="left">Status/Remarks</td><td align="left">Clinical studies have demonstrated no significant benefits of lipinavir-ritonavir in COVID-19 affected patients</td></tr><tr><td align="left">Drug type/Original purpose</td><td align="left">Antiretroviral drug</td></tr><tr><td align="left">Mode of Administration</td><td align="left">Oral</td></tr><tr><td align="left">Mechanism of Action</td><td align="left">HIV protease inhibitor</td></tr><tr><td align="left">References</td><td align="left">Cao <italic>et al.</italic> (<xref ref-type="bibr" rid="CR16">2020b</xref>), WHO (<xref ref-type="bibr" rid="CR85">2020b</xref>)</td></tr><tr><td align="left" rowspan="5">Remdesivir</td><td align="left">Status/Remarks</td><td align="left">Significant benefits from administration of this drug are doubtful. Clinical studies have reported a marginal improvement in critically ill patients</td></tr><tr><td align="left">Drug type/Original purpose</td><td align="left">Nucleoside analog</td></tr><tr><td align="left">Mode of Administration</td><td align="left">Intravenous</td></tr><tr><td align="left">Mechanism of Action</td><td align="left">Inhibits the viral RNA-dependent RNA polymerase</td></tr><tr><td align="left">References</td><td align="left">Grein <italic>et al.</italic> (<xref ref-type="bibr" rid="CR38">2020</xref>), Wang <italic>et al.</italic> (<xref ref-type="bibr" rid="CR100">2020a</xref>, <xref ref-type="bibr" rid="CR101">b</xref>)</td></tr><tr><td align="left" rowspan="5">Tocilizumab</td><td align="left">Status/Remarks</td><td align="left">Studies appear to recommend this drug for critically ill patients, especially for the alleviation of COVID-19-associated pneumonia and cytokine storm management</td></tr><tr><td align="left">Drug type/Original purpose</td><td align="left">Humanized monoclonal antibody against IL-6 receptor</td></tr><tr><td align="left">Mode of Administration</td><td align="left">Intravenous</td></tr><tr><td align="left">Mechanism of Action</td><td align="left">Immunosuppressant</td></tr><tr><td align="left">References</td><td align="left">Biran <italic>et al.</italic> (<xref ref-type="bibr" rid="CR9">2020</xref>), Guaraldi <italic>et al.</italic> (<xref ref-type="bibr" rid="CR39">2020</xref>), Luo <italic>et al.</italic> (<xref ref-type="bibr" rid="CR70">2020</xref>), Zhang <italic>et al.</italic> (<xref ref-type="bibr" rid="CR112">2020b</xref>)</td></tr></tbody></table></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec14">
      <title>Emerging technologies for biomedical research: artificial intelligence and machine learning</title>
      <p id="Par31">The fields of Artificial Intelligence (AI) and Machine Learning (ML) have undergone tremendous growth in scope and popularity in the recent past, establishing them as important paradigms for future innovation. More importantly, the development of modules suitable for biomedical applications has transformed AI and ML into attractive tools for the current global effort to tackle the SARS-CoV-2 pandemic.</p>
      <p id="Par32">With regard to infectious diseases, AI-based platforms may be employed to monitor outbreak and clustering trends, as well as evaluate the impact of containment programs and carry out risk assessment with minimal human intervention. The AI-based service BlueDot deserves a noteworthy mention of having raised one of the earliest alarms on SARS-CoV-2&#x2019;s potential for broad global spread (Bogoch <italic>et al.</italic>
<xref ref-type="bibr" rid="CR10">2020</xref>). Additionally, these hold immense promise for dynamic situational monitoring of patients in real-time, enabling critical evaluation and optimization of trial treatment protocols in a much more efficient manner. ML-based solutions can be expected to consistently enhance and refine such designs over time, provided they are trained on a readily updated and expertly-curated dataset. This represents an important caveat, as the efficacy and accuracy of ML-based pattern prediction and recognition may be maintained only if the training dataset is free of biases and a diverse range of scenarios are well-represented (Fitzpatrick <italic>et al.</italic>
<xref ref-type="bibr" rid="CR33">2020</xref>). We had previously referred to the work by Apostolopoulos and Bessiana, which could screen for SARS-CoV-2 infections using X-ray images. This has been supplemented by a neural network-based platform using X-ray images, with a maximum prediction accuracy of 98% (Narin <italic>et al.</italic>
<xref ref-type="bibr" rid="CR80">2020</xref>). Furthermore, an automated AI-based protocol to identify SARS-CoV-2 infections and distinguish these from other lung diseases or community-acquired pneumonia has been recently formulated (Li <italic>et al.</italic>
<xref ref-type="bibr" rid="CR58">2020a</xref>, <xref ref-type="bibr" rid="CR59">b</xref>, <xref ref-type="bibr" rid="CR60">c</xref>, <xref ref-type="bibr" rid="CR61">d</xref>, <xref ref-type="bibr" rid="CR62">e</xref>, <xref ref-type="bibr" rid="CR63">f</xref>). It must be noted that both these models were trained on datasets consisting of actual patient X-ray images, which is in line with a point we have reiterated above &#x2013; that training datasets should necessarily be accurate, well-represented, and as free of biases as possible. An exciting new development reported by the Broad Institute&#x2019;s Sabeti lab concerns an ML-based platform for automated Cas13-based SHERLOCK assay design (Metsky <italic>et al.</italic>
<xref ref-type="bibr" rid="CR78">2020</xref>). Such an advance represents a potential breakthrough, as highly optimized and expanded open-access platforms of this nature can aid researchers the world over in rapidly designing standardized tests for novel and emerging pathogens using just the knowledge about their genomic sequence. This can help accelerate the deployment of rapid responses to outbreaks and thereby greatly enhance early screening and containment efforts. Understandably, a confident reliance on such automated processes may only be possible once multiple field applications have validated the same and demonstrated similar, if not superior, performance in comparison with existing assay design pipelines.</p>
      <p id="Par33">Section&#xA0;<xref rid="Sec9" ref-type="sec">3.1</xref> of this review highlights the study which determined baricitinib as a potential drug against SARS-CoV-2 (Richardson <italic>et al.</italic>
<xref ref-type="bibr" rid="CR88">2020</xref>). Writing in The Lancet, the same team extended this workflow to develop more comprehensive treatment strategies aimed at shortlisting drugs that offered both antiviral as well as anti-inflammatory effects (Stebbing <italic>et al.</italic>
<xref ref-type="bibr" rid="CR95">2020</xref>). The highly modular nature of AI-based knowledge graphs, an example of which has been shown in figure&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>, posit these as versatile tools for efforts aimed at rapid drug prediction from extensive libraries. A similar report was published which used a drug repositioning framework employing ML and statistical analysis. The results were validated by testing its predictions for MERS-COV and SARS-COV, which were shown to be in line with the experimentally observed results (Ge <italic>et al.</italic>
<xref ref-type="bibr" rid="CR36">2020</xref>). A reverse vaccinology study employing Vaxign-ML (a machine learning-based application) was recently carried out (Ong <italic>et al.</italic>
<xref ref-type="bibr" rid="CR83">2020</xref>). The basic workflow involves a bioinformatic analysis of the genome/proteome, based upon which suitable targets are scored. Given the number of existing and reported studies targeting the viral spike protein (which also received the highest score using Vaxign-ML), the authors of this study decided to focus on the nsp3 which was ascribed the second-highest score by the aforementioned algorithm. It appears that vaccine candidate identification efforts stand to benefit from such ML-driven analysis, which may have an inherent edge in unearthing unconventional and generally non-obvious targets offering similar or superior outcomes as compared to those determined using traditional workflows or established tenets.<fig id="Fig3"><label>Figure&#xA0;3</label><caption><p>An example illustrating the highly modular nature of AI-based knowledge graphs.</p></caption><graphic xlink:href="12038_2020_114_Fig3_HTML" id="MO3"/></fig></p>
    </sec>
    <sec id="Sec15">
      <title>Vaccine development for SARS-CoV-2</title>
      <p id="Par34">Considering the highly contagious nature of the SARS-CoV-2 infection, the only long-term sustainable solution is the development of robust vaccination protocols. In this brief section, we wish to draw the reader&#x2019;s attention to some innovative, cutting-edge approaches towards determining potential vaccine candidates.</p>
      <p id="Par35">An approach based on comparing the human and viral proteomes to search for pentapeptide sequences unique to the SARS-CoV-2 was proposed by Guglielmo Lucchese, as these would be expected to have high immunogenicity as well as specificity (Lucchese <xref ref-type="bibr" rid="CR69">2020</xref>). Immunoinformatics-guided investigations may also play a significant role in the identification of suitable target epitopes, as shown by two recent papers (Ahmed <italic>et al.</italic>
<xref ref-type="bibr" rid="CR2">2020</xref>; Baruah and Bose <xref ref-type="bibr" rid="CR5">2020</xref>). Baruah and Bose screened the SARS-CoV-2&#x2019;s surface glycoprotein for CTL and B-cell epitopes, further supplemented by molecular dynamics simulations to adjudge the interactions of the former with MHC Class I types majorly represented in the Chinese population (Baruah and Bose <xref ref-type="bibr" rid="CR5">2020</xref>). The work by Ahmed <italic>et al.</italic> incorporated insights from the study of immunogenic SARS-CoV proteins and B/T-cell epitopes derived from the same to obtain a set of such epitopes for the SARS-CoV-2, which have also been verified to be invariable amongst the published SARS-CoV-2 genomes, thereby making these attractive targets (Ahmed <italic>et al.</italic>
<xref ref-type="bibr" rid="CR2">2020</xref>). Another notable effort undertook an in-silico approach aimed at designing a multi-epitope vaccine candidate by predicting B/T-cell epitopes based on analysis of the viral nucleocapsid, ORF3a, and membrane protein (Enayatkhani <italic>et al.</italic>
<xref ref-type="bibr" rid="CR30">2020</xref>). It is conceivable that a comprehensive screen of epitopes identified in the above-cited (and other related) literature in suitable animal models may yield lead candidates for vaccine trials.</p>
      <p id="Par36">Data generated by previous studies on the SARS-CoV significantly facilitates current vaccine development efforts against the SARS-CoV-2. For instance, an analysis of the antigenic and glycosylation variation between SARS CoV and SARS-CoV-2 revealed that while several novel glycosylation sites were observed in the receptor-binding domain of SARS-CoV-2, the structure of the glycoprotein showed no significant divergence (Kumar <italic>et al.</italic>
<xref ref-type="bibr" rid="CR55">2020</xref>). Additionally, despite the antigenic variability between both the strains, certain CTL epitopes were found to be conserved, suggesting that existing peptide-based vaccine candidates against the SARS-CoV could be repurposed for testing against SARS-CoV-2. This observation is supplemented by a recently published report, wherein Conformational-Epitope BLAST (which identifies antigenic similarity of a new pathogen to existing ones) was used to identify cross-reactive epitopes in the ACE2 receptor binding region of SARS-CoV-2&#x2019;s S protein (Qiu <italic>et al.</italic>
<xref ref-type="bibr" rid="CR87">2020</xref>). Along similar lines, polyclonal antibodies against the SARS-CoV receptor-binding domain have been shown to cross-react with SARS-CoV-2 receptor-binding domain (RBD), thereby inhibiting SARS-CoV-2&#x2019;s entry into cells (Tai <italic>et al.</italic>
<xref ref-type="bibr" rid="CR96">2020</xref>). A largely concordant line of reasoning has also advocated the consideration of the RBD219-N1 (a yeast-expressed potential vaccine candidate against SARS-CoV) as a heterologous vaccine against the SARS-CoV-2 (Chen <italic>et al.</italic>
<xref ref-type="bibr" rid="CR19">2020b</xref>). These examples serve to highlight that alongside initiatives to develop novel vaccine candidates, repurposing efforts could help provide immediate solutions to address the urgent needs imposed by the ongoing pandemic situation.</p>
      <p id="Par37">A cell-based antigen delivery system against the SARS-CoV-2 has also been proposed recently using decoy cells displaying viral spike protein (Ji <italic>et al.</italic>
<xref ref-type="bibr" rid="CR48">2020</xref>). The report provides evidence from the literature to support and justify the approach, in particular, citing the example of GM-CSF expressing irradiated cells being well tolerated in clinical trials against cancer. However, no records of assays or in-vivo animal model studies have been provided at the moment; hence it is premature to comment on the suitability of this concept in the context of SARS-CoV-2 infections.</p>
      <p id="Par38">The recent review by Iwasaki and Yang raises important caveats regarding vaccine development efforts, in particular, the phenomenon of antibody-dependant enhancement (ADE). ADE occurs when therapeutically administered antibodies can exacerbate the existing pathology by enabling infection of immune cells by the invading virus, promoting inflammation, downregulation of anti-inflammatory factors like IL-10, and aberrant activation of the immune system leading up to tissue injury. The dangers associated with hyper-inflammation and immune dysregulation in the context of SARS-CoV-2 infections have been elucidated at length in Sect.&#xA0;<xref rid="Sec12" ref-type="sec">3.4</xref>. The authors outline several possible contributing factors towards ADE, including antibody specificity, choice of target epitope, affinity, subtype (IgM or IgG), dosage, and patient status. Such concerns underscore the need for well-rounded vaccine development protocols and extensive preclinical evaluations in order to optimize the choice of adjuvants, mode of administration, and other relevant parameters as enlisted above. A more thorough elaboration may be found in the publication referenced (Iwasaki and Yang <xref ref-type="bibr" rid="CR47">2020</xref>).</p>
      <p id="Par39">The World Health Organization (WHO) is currently maintaining publicly accessible, comprehensive, and authoritative databases (<ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</ext-link>) listing all the vaccines under clinical or preclinical evaluation (WHO <xref ref-type="bibr" rid="CR84">2020a</xref>). At the time of writing, 33 vaccine candidates are under clinical trial, which have been summarized in table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>. Additionally, the WHO&#x2019;s COVID-19 modeling <italic>ad hoc</italic> expert working group (<ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/covid-19-animal-models---summary-of-progress-made-by-the-who-covid-19-modelling-(march-04-june-2020)">https://www.who.int/publications/m/item/covid-19-animal-models---summary-of-progress-made-by-the-who-covid-19-modelling-(march-04-june-2020)</ext-link>) has also reported (based on the available results from studies across the world) that Rhesus macaques and ferrets appear to be the most suitable large animal models for studying SARS-CoV-2 infections to date (WHO <xref ref-type="bibr" rid="CR102">2020</xref>). Such public information initiatives are of immense benefit to encourage collaboration, avoid unnecessary and wasteful duplication of effort, and disseminate valuable data rapidly across the research community. We would also like to direct the interested reader to refer to an excellent summary of the SARS-CoV-2 vaccine landscape by Nature Reviews Drug Discovery and authors affiliated with the Coalition for Epidemic Preparedness Innovations (CEPI) (Le <italic>et al.</italic>
<xref ref-type="bibr" rid="CR56">2020</xref>).<table-wrap id="Tab2"><label>Table&#xA0;2</label><caption><p>Vaccines being developed against COVID-19 currently in clinical trial stages</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">COVID-19 vaccine developer/manufacturer</th><th align="left">Vaccine platform</th><th align="left">Phase</th></tr></thead><tbody><tr><td align="left">Inovio Pharmaceuticals/ International Vaccine Institute</td><td align="left">DNA</td><td align="left">1/2</td></tr><tr><td align="left">Osaka University/ AnGes/ Takara Bio</td><td align="left">DNA</td><td align="left">1/2</td></tr><tr><td align="left">Cadila Healthcare Limited</td><td align="left">DNA</td><td align="left">1/2</td></tr><tr><td align="left">Genexine Consortium</td><td align="left">DNA</td><td align="left">1/2</td></tr><tr><td align="left">Sinovac</td><td align="left">Inactivated</td><td align="left">3</td></tr><tr><td align="left">Wuhan Institute of Biological Products/Sinopharm</td><td align="left">Inactivated</td><td align="left">3</td></tr><tr><td align="left">Beijing Institute of Biological Products/Sinopharm</td><td align="left">Inactivated</td><td align="left">3</td></tr><tr><td align="left">Institute of Medical Biology, Chinese Academy of Medical Sciences</td><td align="left">Inactivated</td><td align="left">1/2</td></tr><tr><td align="left">Research Institute for Biological Safety Problems, Rep of Kazakhstan</td><td align="left">Inactivated</td><td align="left">1/2</td></tr><tr><td align="left">Bharat Biotech</td><td align="left">Inactivated</td><td align="left">1/2</td></tr><tr><td align="left">University of Oxford/AstraZeneca</td><td align="left">Non-Replicating Viral Vector</td><td align="left">3</td></tr><tr><td align="left">CanSino Biological Inc./Beijing Institute of Biotechnology</td><td align="left">Non-Replicating Viral Vector</td><td align="left">3</td></tr><tr><td align="left">Gamaleya Research Institute</td><td align="left">Non-Replicating Viral Vector</td><td align="left">3</td></tr><tr><td align="left">Janssen Pharmaceutical Companies</td><td align="left">Non-Replicating Viral Vector</td><td align="left">3</td></tr><tr><td align="left">ReiThera/LEUKOCARE/Univercells</td><td align="left">Non-Replicating Viral Vector</td><td align="left">1</td></tr><tr><td align="left">Anhui Zhifei Longcom Biopharmaceutical/Institute of Microbiology, Chinese Academy of Sciences</td><td align="left">Protein Subunit</td><td align="left">2</td></tr><tr><td align="left">Novavax</td><td align="left">Protein Subunit</td><td align="left">1/2</td></tr><tr><td align="left">Kentucky Bioprocessing, Inc</td><td align="left">Protein Subunit</td><td align="left">1/2</td></tr><tr><td align="left">Clover Biopharmaceuticals Inc./GSK/Dynavax</td><td align="left">Protein Subunit</td><td align="left">1</td></tr><tr><td align="left">Vaxine Pty Ltd/Medytox</td><td align="left">Protein Subunit</td><td align="left">1</td></tr><tr><td align="left">University of Queensland/CSL/Seqirus</td><td align="left">Protein Subunit</td><td align="left">1</td></tr><tr><td align="left">Medigen Vaccine Biologics Corporation/NIAID/Dynavax</td><td align="left">Protein Subunit</td><td align="left">1</td></tr><tr><td align="left">Instituto Finlay de Vacunas, Cuba</td><td align="left">Protein Subunit</td><td align="left">1</td></tr><tr><td align="left">FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo</td><td align="left">Protein Subunit</td><td align="left">1</td></tr><tr><td align="left">West China Hospital, Sichuan University</td><td align="left">Protein Subunit</td><td align="left">1</td></tr><tr><td align="left">Institute Pasteur/Themis/Univ. of Pittsburg CVR/Merck Sharp &amp; Dohme</td><td align="left">Replicating Viral Vector</td><td align="left">1</td></tr><tr><td align="left">Moderna/NIAID</td><td align="left">RNA</td><td align="left">3</td></tr><tr><td align="left">BioNTech/Fosun Pharma/Pfizer</td><td align="left">RNA</td><td align="left">3</td></tr><tr><td align="left">Curevac</td><td align="left">RNA</td><td align="left">2</td></tr><tr><td align="left">Arcturus/Duke-NUS</td><td align="left">RNA</td><td align="left">1/2</td></tr><tr><td align="left">Imperial College London</td><td align="left">RNA</td><td align="left">1</td></tr><tr><td align="left">People&#x2019;s Liberation Army (PLA) Academy of Military Sciences/Walvax Biotech.</td><td align="left">RNA</td><td align="left">1</td></tr><tr><td align="left">Medicago Inc.</td><td align="left">VLP</td><td align="left">1</td></tr></tbody></table></table-wrap></p>
    </sec>
    <sec id="Sec16">
      <title>Conclusion</title>
      <p id="Par40">As the current progress of the SARS-CoV-2 outbreak has made obvious, clinical management of these infections has been under multiple pressures ranging from high false-negative rates of diagnosis, contentious results on the efficacy of proposed drugs, and the threat of severely detrimental symptoms like ARDS and cytokine storm responses. The development of accessible point-of-care diagnostic devices tailor-made for low-resource settings continues to be a pressing requirement. This may be achieved by cell lysis-free workflows, increasingly sensitive and robust bioassays, improved sample collection and processing methods which minimize risks to healthcare workers, and ready-to-use kits not requiring technical expertise, among other possible innovations. In this regard, RT-LAMP and CRISPR/Cas-based methods like SHERLOCK and DETECTR are notable advancements that could be explored as promising alternatives. With regard to portable diagnostic devices, few technologies hold as much promise as paper-based microfluidics. The applicability of this has already been demonstrated in the context of the Ebola and Zika outbreaks (Kaarj <italic>et al.</italic>
<xref ref-type="bibr" rid="CR50">2018</xref>; Magro <italic>et al.</italic>
<xref ref-type="bibr" rid="CR74">2017</xref>). While a comprehensive overview of the microfluidics domain is beyond the scope of this work, considering the immense potential of this technology we would like to direct the interested reader to refer to a dedicated review of paper-based microfluidic platforms for nucleic acid detection (Kaur and Toley <xref ref-type="bibr" rid="CR51">2018</xref>).</p>
      <p id="Par41">Advocating accelerated vaccine development efforts might prove to be a risky gamble, on account of the associated safety caveats which have been underscored in the preceding sections. Instead, an emphasis on designing and adopting reliable biophysical assays for comprehensive, yet rapid preclinical evaluation may be beneficial in reducing the historically high attrition rate among candidates under clinical trials. This holds especially true for studies proposing novel therapeutic agents as well, for which emerging techniques like the CETSA (cellular thermal shift assay) may help deter the occurrence of misleading false positives (Martinez Molina <italic>et al.</italic>
<xref ref-type="bibr" rid="CR76">2013</xref>). Furthermore, as regards the application of AI/ML-based platforms in biomedical research and diagnostics, a confluence of cross-domain expertise is crucial to ensure the development of reliable models and workflows which faithfully capture real-world dynamics. As instances of governments and healthcare agencies employing AI-based containment and prevention strategies increase, it is important that critical studies be undertaken to ascertain the true benefits and outcomes of such technological integration, rather than a reliance on anecdotal evidence alone.</p>
      <p id="Par42">Throughout our discussion, certain points have been recurrent &#x2013; the advantages of leveraging existing knowledge on closely related species like the SARS CoV, the potent efficacy of seemingly disparate techniques when applied in tandem, and the importance of collaborative efforts coupled with rapid, timely dissemination of results which may inform ongoing efforts. Requirements key to enabling these include the availability of genomic sequences, structural data, and expertly curated databases. The push towards developing modular assay workflows (with elements of automation involved) may well be a defining paradigm of future responses to such scenarios. The advent of <italic>in silico</italic> epitope screening, algorithmic vaccine and inhibitor design, and preliminary evaluation of drug libraries by molecular docking has the potential to greatly facilitate wet-lab-based and clinical investigations while expediting results. However, we reiterate our concerns over adequate quality testing and rigorous experimental validation before adopting such approaches as an established norm. Skepticism must also be extended in light of a growing tendency to extrapolate trends observed from <italic>in vitro</italic> setups and unsuitable animal models to recommend clinical guidelines. We conclude our narrative on the hopeful note that the topical coverage should have appealed to both experts in virology and biomedical engineers, as well as recent entrants in these research domains. The purpose of this effort would be best served if the diverse studies described herein motivate and help lay the foundation for ambitious multidisciplinary undertakings aimed at the advancement of public health.</p>
    </sec>
  </body>
  <back>
    <fn-group>
      <fn>
        <p>This article is part of the Topical Collection: COVID-19: Disease Biology &amp; Intervention.</p>
      </fn>
      <fn>
        <p>Corresponding editor: K<sc>undan</sc> S<sc>engupta</sc></p>
      </fn>
    </fn-group>
    <ack>
      <title>Acknowledgements</title>
      <p>The authors thank Hitaishi Desai for helping with illustrations and designs for the figure panels, and Dr. Ankit Kumar Sahu and Minita Desai for proofreading and editing of the final draft. AC thanks India Alliance, IISER Bhopal and DBT for supporting various research programs in the lab.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Agrawal</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Goel</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Gupta</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Emerging prophylaxis strategies against COVID-19</article-title>
          <source>Monaldi Arch. Chest Dis.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.4081/monaldi.2020.1289</pub-id>
          <pub-id pub-id-type="pmid">33305553</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ahmed</surname>
              <given-names>SF</given-names>
            </name>
            <name>
              <surname>Quadeer</surname>
              <given-names>AA</given-names>
            </name>
            <name>
              <surname>McKay</surname>
              <given-names>MR</given-names>
            </name>
          </person-group>
          <article-title>Preliminary Identification of Potential Vaccine Targets for the COVID-19 Coronavirus (SARS-CoV-2) Based on SARS-CoV Immunological Studies</article-title>
          <source>Viruses</source>
          <year>2020</year>
          <volume>12</volume>
          <fpage>254</fpage>
        </element-citation>
      </ref>
      <ref id="CR3">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Apostolopoulos</surname>
              <given-names>ID</given-names>
            </name>
            <name>
              <surname>Bessiana</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <source>Covid-19: Automatic detection from X-Ray images utilizing Transfer Learning with Convolutional Neural Networks</source>
          <year>2020</year>
          <publisher-loc>Phys</publisher-loc>
          <publisher-name>Eng. Sci. Med</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR4">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baglivo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Baronio</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Natalini</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Beccari</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Chiurazzi</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Natural small molecules as inhibitors of coronavirus lipid-dependent attachment to host cells: a possible strategy for reducing SARS-COV-2 infectivity?</article-title>
          <source>Acta Biomed.</source>
          <year>2020</year>
          <volume>91</volume>
          <fpage>161</fpage>
          <lpage>164</lpage>
          <pub-id pub-id-type="pmid">32191676</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baruah</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Bose</surname>
              <given-names>S</given-names>
            </name>
          </person-group>
          <article-title>Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV</article-title>
          <source>J. Med. Virol.</source>
          <year>2020</year>
          <volume>92</volume>
          <fpage>495</fpage>
          <lpage>500</lpage>
          <pub-id pub-id-type="pmid">32022276</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Becherer</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Borst</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Bakheit</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Frischmann</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zengerle</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Loop-mediated isothermal amplification (LAMP) &#x2013; review and classification of methods for sequence-specific detection</article-title>
          <source>Anal. Methods</source>
          <year>2020</year>
          <volume>12</volume>
          <fpage>717</fpage>
          <lpage>746</lpage>
        </element-citation>
      </ref>
      <ref id="CR7">
        <mixed-citation publication-type="other">Beltr&#xE1;n-Pavez C, M&#xE1;rquez CL, Mu&#xF1;oz G, Valiente-Echeverr&#xED;a F, Gaggero A <italic>et al.</italic> 2020 SARS-CoV-2 detection from nasopharyngeal swab samples without RNA extraction. <italic>bioRxiv</italic>10.1101/2020.03.28.013508</mixed-citation>
      </ref>
      <ref id="CR8">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bernheim</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Mei</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Fayad</surname>
              <given-names>ZA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Chest CT Findings in Coronavirus Disease-19 (COVID-19): Relationship to Duration of Infection</article-title>
          <source>Radiology</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1148/radiol.2020200463</pub-id>
          <pub-id pub-id-type="pmid">32407255</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Biran</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Ip</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ahn</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Go</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study</article-title>
          <source>Lancet Rheumatol</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/S2665-9913(20)30277-0</pub-id>
          <pub-id pub-id-type="pmid">32838323</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bogoch</surname>
              <given-names>II</given-names>
            </name>
            <name>
              <surname>Watts</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Thomas-Bachli</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Huber</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Kraemer</surname>
              <given-names>MUG</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel</article-title>
          <source>J. Travel Med.</source>
          <year>2020</year>
          <volume>27</volume>
          <fpage>taaa008</fpage>
          <pub-id pub-id-type="pmid">31943059</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <mixed-citation publication-type="other">Borba MGS, Val FdA, Sampaio VS, Alexandre MA <italic>et al.</italic> 2020 Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study). <italic>medRxiv</italic>10.1101/2020.04.07.20056424</mixed-citation>
      </ref>
      <ref id="CR12">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Broughton</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Fasching</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>Servellita</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>CRISPR&#x2013;Cas12-based detection of SARS-CoV-2</article-title>
          <source>Nat. Biotechnol.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1038/s41587-020-0513-4</pub-id>
          <pub-id pub-id-type="pmid">32300245</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Caly</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Druce</surname>
              <given-names>JD</given-names>
            </name>
            <name>
              <surname>Catton</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Jans</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Wagstaff</surname>
              <given-names>KM</given-names>
            </name>
          </person-group>
          <article-title>The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro</article-title>
          <source>Antiviral Res.</source>
          <year>2020</year>
          <volume>178</volume>
          <fpage>104787</fpage>
          <pub-id pub-id-type="pmid">32251768</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cantini</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Niccoli</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Matarrese</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Nicastri</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Stobbione</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Baricitinib therapy in COVID-19: A pilot study on safety and clinical impact</article-title>
          <source>J. Infect.</source>
          <year>2020</year>
          <volume>81</volume>
          <fpage>318</fpage>
          <lpage>356</lpage>
          <pub-id pub-id-type="pmid">32333918</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cao</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wen</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19</article-title>
          <source>N. Engl. J. Med.</source>
          <year>2020</year>
          <volume>382</volume>
          <fpage>1787</fpage>
          <lpage>1799</lpage>
          <pub-id pub-id-type="pmid">32187464</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cao</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Xiong</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Cai</surname>
              <given-names>K</given-names>
            </name>
          </person-group>
          <article-title>Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis</article-title>
          <source>J. Med. Virol.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1002/jmv.25822</pub-id>
          <pub-id pub-id-type="pmid">33325107</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chan</surname>
              <given-names>JF-W</given-names>
            </name>
            <name>
              <surname>Yip</surname>
              <given-names>CC-Y</given-names>
            </name>
            <name>
              <surname>To</surname>
              <given-names>KK-W</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>TH-C</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>SC-Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-polymerase chain reaction assay validated in vitro and with clinical specimens</article-title>
          <source>J. Clin. Microbiol.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1128/JCM.00310-20</pub-id>
          <pub-id pub-id-type="pmid">33067272</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Xiong</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Bao</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Shi</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>Convalescent plasma as a potential therapy for COVID-19</article-title>
          <source>Lancet Infect. Dis.</source>
          <year>2020</year>
          <volume>20</volume>
          <fpage>398</fpage>
          <lpage>400</lpage>
          <pub-id pub-id-type="pmid">32113510</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chen</surname>
              <given-names>W-H</given-names>
            </name>
            <name>
              <surname>Hotez</surname>
              <given-names>PJ</given-names>
            </name>
            <name>
              <surname>Bottazzi</surname>
              <given-names>ME</given-names>
            </name>
          </person-group>
          <article-title>Potential for developing a SARS-CoV receptor-binding domain (RBD) recombinant protein as a heterologous human vaccine against coronavirus infectious disease (COVID)-19</article-title>
          <source>Hum. Vaccin. Immunother.</source>
          <year>2020</year>
          <volume>0</volume>
          <fpage>1</fpage>
          <lpage>4</lpage>
        </element-citation>
      </ref>
      <ref id="CR20">
        <mixed-citation publication-type="other">Chen Z, Hu J, Zhang Z, Jiang S, Han S <italic>et al.</italic> 2020 Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. <italic>medRxiv</italic>10.1101/2020.03.22.20040758</mixed-citation>
      </ref>
      <ref id="CR21">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cheng</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Xiaorong</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zhenyu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Weifeng</surname>
              <given-names>H</given-names>
            </name>
          </person-group>
          <article-title>Advances in the research of cytokine storm mechanism induced by Corona Virus Disease 2019 and the corresponding immunotherapies</article-title>
          <source>Zhonghua Shao Shang Za Zhi</source>
          <year>2020</year>
          <volume>36</volume>
          <fpage>E005</fpage>
        </element-citation>
      </ref>
      <ref id="CR22">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Chu</surname>
              <given-names>DKW</given-names>
            </name>
            <name>
              <surname>Pan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>SMS</given-names>
            </name>
            <name>
              <surname>Hui</surname>
              <given-names>KPY</given-names>
            </name>
            <name>
              <surname>Krishnan</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Molecular Diagnosis of a Novel Coronavirus (2019-nCoV) Causing an Outbreak of Pneumonia</article-title>
          <source>Clin. Chem.</source>
          <year>2020</year>
          <volume>66</volume>
          <fpage>549</fpage>
          <lpage>555</lpage>
          <pub-id pub-id-type="pmid">32031583</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Corman</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Landt</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Kaiser</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Molenkamp</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Meijer</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR</source>
          <year>2020</year>
          <publisher-loc>Euro</publisher-loc>
          <publisher-name>Surveill</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR24">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cumhur Cure</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Kucuk</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Cure</surname>
              <given-names>E</given-names>
            </name>
          </person-group>
          <article-title>Colchicine may not be effective in COVID-19 infection; it may even be harmful?</article-title>
          <source>Clin. Rheumatol.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1007/s10067-020-05144-x</pub-id>
          <pub-id pub-id-type="pmid">32458242</pub-id>
        </element-citation>
      </ref>
      <ref id="CR25">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dai</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Xia</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shang</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>High-resolution Chest CT Features and Clinical Characteristics of Patients Infected with COVID-19 in Jiangsu, China</article-title>
          <source>Int. J. Infect. Dis.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/j.ijid.2020.04.003</pub-id>
          <pub-id pub-id-type="pmid">32920233</pub-id>
        </element-citation>
      </ref>
      <ref id="CR26">
        <mixed-citation publication-type="other">Dalili N 2020 Effects of Standard Protocol Therapy With or Without Colchicine in Covid-19 Infection: A Randomized Double Blind Clinical Trial. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04360980">https://clinicaltrials.gov/ct2/show/NCT04360980</ext-link></mixed-citation>
      </ref>
      <ref id="CR27">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Devaux</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Rolain</surname>
              <given-names>J-M</given-names>
            </name>
            <name>
              <surname>Colson</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Raoult</surname>
              <given-names>D</given-names>
            </name>
          </person-group>
          <article-title>New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?</article-title>
          <source>Int. J. Antimicrob. Agents</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105938</pub-id>
          <pub-id pub-id-type="pmid">32179150</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Duan</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>T</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</article-title>
          <source>Proc. Natl. Acad. Sci. U S A</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1073/pnas.2004168117</pub-id>
          <pub-id pub-id-type="pmid">33318207</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>El-Tholoth</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bau</surname>
              <given-names>HH</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>J</given-names>
            </name>
          </person-group>
          <article-title>A Single and Two-Stage, Closed-Tube, Molecular Test for the 2019 Novel Coronavirus (COVID-19) at Home, Clinic, and Points of Entry</article-title>
          <source>ChemRxiv</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.26434/chemrxiv.11860137.v1</pub-id>
          <pub-id pub-id-type="pmid">32511284</pub-id>
        </element-citation>
      </ref>
      <ref id="CR30">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Enayatkhani</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Hasaniazad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Faezi</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Guklani</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Davoodian</surname>
              <given-names>P</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Reverse vaccinology approach to design a novel multi-epitope vaccine candidate against COVID-19: an in silico study</article-title>
          <source>J. Biomol. Struct. Dyn.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1080/07391102.2020.1756411</pub-id>
          <pub-id pub-id-type="pmid">33351722</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fantini</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Di Scala</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Chahinian</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yahi</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection</article-title>
          <source>Int. J. Antimicrob. Agents</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105960</pub-id>
          <pub-id pub-id-type="pmid">32862840</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fischer</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Sellner</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Neranjan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lill</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Smie&#x161;ko</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Inhibitors for Novel Coronavirus Protease Identified by Virtual Screening of 687 Million Compounds</article-title>
          <source>ChemRxiv</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.26434/chemrxiv.11923239.v1</pub-id>
          <pub-id pub-id-type="pmid">33200116</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fitzpatrick</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Doherty</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Lacey</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <article-title>Using Artificial Intelligence in Infection Prevention</article-title>
          <source>Curr. Treat. Options Infect. Dis</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1007/s40506-020-00216-7</pub-id>
          <pub-id pub-id-type="pmid">32218708</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Furtado</surname>
              <given-names>RHM</given-names>
            </name>
            <name>
              <surname>Berwanger</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Fonseca</surname>
              <given-names>HA</given-names>
            </name>
            <name>
              <surname>Corr&#xEA;a</surname>
              <given-names>TD</given-names>
            </name>
            <name>
              <surname>Ferraz</surname>
              <given-names>LR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Azithromycin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial</article-title>
          <source>Lancet</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31862-6</pub-id>
          <pub-id pub-id-type="pmid">32896292</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gautret</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lagier</surname>
              <given-names>J-C</given-names>
            </name>
            <name>
              <surname>Parola</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Hoang</surname>
              <given-names>VT</given-names>
            </name>
            <name>
              <surname>Meddeb</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial</article-title>
          <source>Int. J. Antimicrob. Agents</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105949</pub-id>
          <pub-id pub-id-type="pmid">33189890</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ge</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Tian</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Wan</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A data-driven drug repositioning framework discovered a potential therapeutic agent targeting COVID-19</article-title>
          <source>Int. J. Antimicrob. Agents</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1101/2020.03.11.986836</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <mixed-citation publication-type="other">Glenmark 2020 Positive Ph III top-line results for favipiravir in COVID-19. <ext-link ext-link-type="uri" xlink:href="https://www.thepharmaletter.com/article/positive-ph-iii-top-line-results-for-favipiravir-in-covid-19">https://www.thepharmaletter.com/article/positive-ph-iii-top-line-results-for-favipiravir-in-covid-19</ext-link></mixed-citation>
      </ref>
      <ref id="CR38">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Grein</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Ohmagari</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Shin</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Diaz</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Asperges</surname>
              <given-names>E</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Compassionate Use of Remdesivir for Patients with Severe Covid-19</article-title>
          <source>N. Engl. J. Med.</source>
          <year>2020</year>
          <volume>382</volume>
          <fpage>2327</fpage>
          <lpage>2336</lpage>
          <pub-id pub-id-type="pmid">32275812</pub-id>
        </element-citation>
      </ref>
      <ref id="CR39">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Guaraldi</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Meschiari</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cozzi-Lepri</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Milic</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Tonelli</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tocilizumab in patients with severe COVID-19: a retrospective cohort study</article-title>
          <source>Lancet Rheumatol.</source>
          <year>2020</year>
          <volume>2</volume>
          <fpage>e474</fpage>
          <lpage>e484</lpage>
          <pub-id pub-id-type="pmid">32835257</pub-id>
        </element-citation>
      </ref>
      <ref id="CR40">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gupta</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Sahoo</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Ivermectin: potential candidate for the treatment of Covid 19</article-title>
          <source>Braz. J. Infect. Dis.</source>
          <year>2020</year>
          <volume>24</volume>
          <fpage>369</fpage>
          <lpage>371</lpage>
          <pub-id pub-id-type="pmid">32615072</pub-id>
        </element-citation>
      </ref>
      <ref id="CR41">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Halpin</surname>
              <given-names>DMG</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Hadfield</surname>
              <given-names>RM</given-names>
            </name>
          </person-group>
          <source>Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective</source>
          <year>2020</year>
          <publisher-loc>Eur</publisher-loc>
          <publisher-name>Respir. J</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR42">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Hani</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Trieu</surname>
              <given-names>NH</given-names>
            </name>
            <name>
              <surname>Saab</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Dangeard</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bennani</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <source>COVID-19 pneumonia: A review of typical CT findings and differential diagnosis</source>
          <year>2020</year>
          <publisher-loc>Diagn</publisher-loc>
          <publisher-name>Interv. Imaging</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR43">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Heidary</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Gharebaghi</surname>
              <given-names>R</given-names>
            </name>
          </person-group>
          <article-title>Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen</article-title>
          <source>J. Antibiot.</source>
          <year>2020</year>
          <volume>73</volume>
          <fpage>593</fpage>
          <lpage>602</lpage>
        </element-citation>
      </ref>
      <ref id="CR44">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Horby</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Lim</surname>
              <given-names>WS</given-names>
            </name>
            <name>
              <surname>Emberson</surname>
              <given-names>JR</given-names>
            </name>
            <name>
              <surname>Mafham</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>JL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Dexamethasone in Hospitalized Patients with Covid-19-Preliminary Report</article-title>
          <source>N. Engl. J. Med.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1056/NEJMoa2021436</pub-id>
          <pub-id pub-id-type="pmid">33031652</pub-id>
        </element-citation>
      </ref>
      <ref id="CR45">
        <mixed-citation publication-type="other">Institute B 2020 Enabling coronavirus detection using CRISPR-Cas13: Open-access SHERLOCK research protocols and design resources. <ext-link ext-link-type="uri" xlink:href="https://www.broadinstitute.org/news/enabling-coronavirus-detection-using-crispr-cas13-open-access-sherlock-research-protocols-and">https://www.broadinstitute.org/news/enabling-coronavirus-detection-using-crispr-cas13-open-access-sherlock-research-protocols-and</ext-link></mixed-citation>
      </ref>
      <ref id="CR46">
        <mixed-citation publication-type="other">Irvani SSN 2020 Efficacy and Safety of Favipiravir Compared to the Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized, Controlled, Double-Blind, Clinical Trial. In: clinicaltrials.gov</mixed-citation>
      </ref>
      <ref id="CR47">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Iwasaki</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>The potential danger of suboptimal antibody responses in COVID-19</article-title>
          <source>Nat. Rev. Immuno.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1038/s41577-020-0321-6</pub-id>
        </element-citation>
      </ref>
      <ref id="CR48">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ji</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ding</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Guo</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Brunswick</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Novel decoy cellular vaccine strategy utilizing transgenic antigen-expressing cells as immune presenter and adjuvant in vaccine prototype against SARS-CoV-2 virus</article-title>
          <source>Med. Drug Discov.</source>
          <year>2020</year>
          <volume>5</volume>
          <fpage>100026</fpage>
          <pub-id pub-id-type="pmid">32289117</pub-id>
        </element-citation>
      </ref>
      <ref id="CR49">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jin</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Structure of Mpro from COVID-19 virus and discovery of its inhibitors</article-title>
          <source>Nature</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1038/s41586-020-2223-y</pub-id>
          <pub-id pub-id-type="pmid">33299191</pub-id>
        </element-citation>
      </ref>
      <ref id="CR50">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaarj</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Akarapipad</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Yoon</surname>
              <given-names>J-Y</given-names>
            </name>
          </person-group>
          <article-title>Simpler, Faster, and Sensitive Zika Virus Assay Using Smartphone Detection of Loop-mediated Isothermal Amplification on Paper Microfluidic Chips</article-title>
          <source>Sci. Rep.</source>
          <year>2018</year>
          <volume>8</volume>
          <fpage>12438</fpage>
          <pub-id pub-id-type="pmid">30127503</pub-id>
        </element-citation>
      </ref>
      <ref id="CR51">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kaur</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Toley</surname>
              <given-names>BJ</given-names>
            </name>
          </person-group>
          <article-title>Paper-based nucleic acid amplification tests for point-of-care diagnostics</article-title>
          <source>Analyst</source>
          <year>2018</year>
          <volume>143</volume>
          <fpage>2213</fpage>
          <lpage>2234</lpage>
          <pub-id pub-id-type="pmid">29683153</pub-id>
        </element-citation>
      </ref>
      <ref id="CR52">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Keith</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Day</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Perkins</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Moyer</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Hewitt</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A novel treatment approach to the novel coronavirus: an argument for the use of therapeutic plasma exchange for fulminant COVID-19</article-title>
          <source>Crit. Care</source>
          <year>2020</year>
          <volume>24</volume>
          <fpage>128</fpage>
          <pub-id pub-id-type="pmid">32241301</pub-id>
        </element-citation>
      </ref>
      <ref id="CR53">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Khoury</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cuenca</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Cruz</surname>
              <given-names>FF</given-names>
            </name>
            <name>
              <surname>Figueroa</surname>
              <given-names>FE</given-names>
            </name>
            <name>
              <surname>Rocco</surname>
              <given-names>PRM</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Current Status of Cell-Based Therapies for Respiratory Virus Infections: Applicability to COVID-19</article-title>
          <source>Eur. Respir. J</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1183/13993003.00858-2020</pub-id>
          <pub-id pub-id-type="pmid">32265310</pub-id>
        </element-citation>
      </ref>
      <ref id="CR54">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ku</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>T-S</given-names>
            </name>
            <name>
              <surname>Kharbash</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Reactive Polymer Targeting dsRNA as Universal Virus Detection Platform with Enhanced Sensitivity</article-title>
          <source>Biomacromolecules</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1021/acs.biomac.0c00379</pub-id>
          <pub-id pub-id-type="pmid">32233463</pub-id>
        </element-citation>
      </ref>
      <ref id="CR55">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kumar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Maurya</surname>
              <given-names>VK</given-names>
            </name>
            <name>
              <surname>Prasad</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Bhatt</surname>
              <given-names>MLB</given-names>
            </name>
            <name>
              <surname>Saxena</surname>
              <given-names>SK</given-names>
            </name>
          </person-group>
          <article-title>Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV)</article-title>
          <source>Virusdisease</source>
          <year>2020</year>
          <volume>31</volume>
          <fpage>13</fpage>
          <lpage>21</lpage>
          <pub-id pub-id-type="pmid">32206694</pub-id>
        </element-citation>
      </ref>
      <ref id="CR56">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Le</surname>
              <given-names>TT</given-names>
            </name>
            <name>
              <surname>Andreadakis</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Kumar</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Rom&#xE1;n</surname>
              <given-names>RG</given-names>
            </name>
            <name>
              <surname>Tollefsen</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <source>The COVID-19 vaccine development landscape</source>
          <year>2020</year>
          <publisher-loc>Nat</publisher-loc>
          <publisher-name>Rev. Drug Discov</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR57">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leng</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Hou</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Feng</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia</article-title>
          <source>Aging Dis.</source>
          <year>2020</year>
          <volume>11</volume>
          <fpage>216</fpage>
          <pub-id pub-id-type="pmid">32257537</pub-id>
        </element-citation>
      </ref>
      <ref id="CR58">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>False-Negative Results of Real-Time Reverse-Transcriptase Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2: Role of Deep-Learning-Based CT Diagnosis and Insights from Two Cases</article-title>
          <source>Korean J. Radiol.</source>
          <year>2020</year>
          <volume>21</volume>
          <fpage>505</fpage>
          <lpage>508</lpage>
          <pub-id pub-id-type="pmid">32174053</pub-id>
        </element-citation>
      </ref>
      <ref id="CR59">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Qin</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Artificial Intelligence Distinguishes COVID-19 from Community Acquired Pneumonia on Chest CT</article-title>
          <source>Radiology</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1148/radiol.2020200905</pub-id>
          <pub-id pub-id-type="pmid">33330848</pub-id>
        </element-citation>
      </ref>
      <ref id="CR60">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Agostinis</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Rabson</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Melino</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Is hydroxychloroquine beneficial for COVID-19 patients?</article-title>
          <source>Cell Death Dis.</source>
          <year>2020</year>
          <volume>11</volume>
          <fpage>1</fpage>
          <lpage>6</lpage>
          <pub-id pub-id-type="pmid">31911576</pub-id>
        </element-citation>
      </ref>
      <ref id="CR61">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>L</given-names>
            </name>
          </person-group>
          <article-title>EZH2-mediated H3K27me3 inhibits ACE2 expression</article-title>
          <source>Biochem. Biophys. Res. Commun.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/j.bbrc.2020.04.010</pub-id>
          <pub-id pub-id-type="pmid">33387886</pub-id>
        </element-citation>
      </ref>
      <ref id="CR62">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yao</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Song</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19</article-title>
          <source>J. Med. Virol.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1002/jmv.25786</pub-id>
          <pub-id pub-id-type="pmid">33325107</pub-id>
        </element-citation>
      </ref>
      <ref id="CR63">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Li</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Yi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Luo</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Xiong</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis</article-title>
          <source>J. Med. Virol.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1002/jmv.25727</pub-id>
          <pub-id pub-id-type="pmid">33325107</pub-id>
        </element-citation>
      </ref>
      <ref id="CR64">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Kou</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Zheng</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Ding</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Evaluation of Nucleocapsid and Spike Protein-based ELISAs for detecting antibodies against SARS-CoV-2</article-title>
          <source>J. Clin. Microbiol.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1128/JCM.00461-20</pub-id>
          <pub-id pub-id-type="pmid">33328177</pub-id>
        </element-citation>
      </ref>
      <ref id="CR65">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Liu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X-J</given-names>
            </name>
          </person-group>
          <article-title>Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines</article-title>
          <source>J. Genet. Genomics.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/j.jgg.2020.02.001</pub-id>
          <pub-id pub-id-type="pmid">33573880</pub-id>
        </element-citation>
      </ref>
      <ref id="CR66">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Long</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Fan</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT?</article-title>
          <source>Eur. J. Radiol.</source>
          <year>2020</year>
          <volume>126</volume>
          <fpage>108961</fpage>
          <pub-id pub-id-type="pmid">32229322</pub-id>
        </element-citation>
      </ref>
      <ref id="CR67">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Long</surname>
              <given-names>Q-X</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>B-Z</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>H-J</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>G-C</given-names>
            </name>
            <name>
              <surname>Deng</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Antibody responses to SARS-CoV-2 in patients with COVID-19</article-title>
          <source>Nat. Med.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1038/s41591-020-0897-1</pub-id>
          <pub-id pub-id-type="pmid">33020648</pub-id>
        </element-citation>
      </ref>
      <ref id="CR68">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lu</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Wan</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zuo</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Development of a Novel Reverse Transcription Loop-Mediated Isothermal Amplification Method for Rapid Detection of SARS-CoV-2</article-title>
          <source>Virol. Sin.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1007/s12250-020-00218-1</pub-id>
          <pub-id pub-id-type="pmid">33351168</pub-id>
        </element-citation>
      </ref>
      <ref id="CR69">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Lucchese</surname>
              <given-names>G</given-names>
            </name>
          </person-group>
          <source>Epitopes for a 2019-nCoV vaccine</source>
          <year>2020</year>
          <publisher-loc>Cell Mol</publisher-loc>
          <publisher-name>Immunol</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR70">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Luo</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tocilizumab treatment in COVID-19: A single center experience</article-title>
          <source>J. Med. Viro.</source>
          <year>2020</year>
          <volume>92</volume>
          <fpage>814</fpage>
          <lpage>818</lpage>
        </element-citation>
      </ref>
      <ref id="CR71">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Xia</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>X</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19</article-title>
          <source>Clin. Immunol.</source>
          <year>2020</year>
          <volume>214</volume>
          <fpage>108408</fpage>
          <pub-id pub-id-type="pmid">32247038</pub-id>
        </element-citation>
      </ref>
      <ref id="CR72">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ma</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zeng</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zhan</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Zeng</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Corticosteroid Use in the Treatment of COVID-19: A Multicenter Retrospective Study in Hunan</article-title>
          <source>China. Front. Pharmacol.</source>
          <year>2020</year>
          <volume>11</volume>
          <fpage>1198</fpage>
          <pub-id pub-id-type="pmid">32903363</pub-id>
        </element-citation>
      </ref>
      <ref id="CR73">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Magagnoli</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Narendran</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pereira</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cummings</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hardin</surname>
              <given-names>JW</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19</article-title>
          <source>medRxiv</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1101/2020.04.16.20065920</pub-id>
          <pub-id pub-id-type="pmid">32511622</pub-id>
        </element-citation>
      </ref>
      <ref id="CR74">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Magro</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Jacquelin</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Escadafal</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Garneret</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kwasiborski</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Paper-based RNA detection and multiplexed analysis for Ebola virus diagnostics</article-title>
          <source>Sci. Rep.</source>
          <year>2017</year>
          <volume>7</volume>
          <fpage>1347</fpage>
          <pub-id pub-id-type="pmid">28465576</pub-id>
        </element-citation>
      </ref>
      <ref id="CR75">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mahevas</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tran</surname>
              <given-names>V-T</given-names>
            </name>
            <name>
              <surname>Roumier</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Chabrol</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Paule</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial</article-title>
          <source>medRxiv</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1101/2020.04.10.20060699</pub-id>
        </element-citation>
      </ref>
      <ref id="CR76">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Martinez Molina</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Jafari</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Ignatushchenko</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Seki</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Larsson</surname>
              <given-names>EA</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay</article-title>
          <source>Science</source>
          <year>2013</year>
          <volume>341</volume>
          <fpage>84</fpage>
          <lpage>87</lpage>
          <pub-id pub-id-type="pmid">23828940</pub-id>
        </element-citation>
      </ref>
      <ref id="CR77">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mehta</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>McAuley</surname>
              <given-names>DF</given-names>
            </name>
            <name>
              <surname>Brown</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Sanchez</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Tattersall</surname>
              <given-names>RS</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>COVID-19: consider cytokine storm syndromes and immunosuppression</article-title>
          <source>Lancet</source>
          <year>2020</year>
          <volume>395</volume>
          <fpage>1033</fpage>
          <lpage>1034</lpage>
          <pub-id pub-id-type="pmid">32192578</pub-id>
        </element-citation>
      </ref>
      <ref id="CR78">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Metsky</surname>
              <given-names>HC</given-names>
            </name>
            <name>
              <surname>Freije</surname>
              <given-names>CA</given-names>
            </name>
            <name>
              <surname>Kosoko-Thoroddsen</surname>
              <given-names>T-SF</given-names>
            </name>
            <name>
              <surname>Sabeti</surname>
              <given-names>PC</given-names>
            </name>
            <name>
              <surname>Myhrvold</surname>
              <given-names>C</given-names>
            </name>
          </person-group>
          <article-title>CRISPR-based COVID-19 surveillance using a genomically-comprehensive machine learning approach</article-title>
          <source>bioRxiv</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1101/2020.02.26.967026</pub-id>
        </element-citation>
      </ref>
      <ref id="CR79">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Nalla</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Casto</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>M-LW</given-names>
            </name>
            <name>
              <surname>Perchetti</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Sampoleo</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Comparative Performance of SARS-CoV-2 Detection Assays using Seven Different Primer/Probe Sets and One Assay Kit</article-title>
          <source>J. Clin. Microbiol.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1128/JCM.00557-20</pub-id>
          <pub-id pub-id-type="pmid">32269100</pub-id>
        </element-citation>
      </ref>
      <ref id="CR80">
        <mixed-citation publication-type="other">Narin A, Kaya C and Pamuk Z 2020 Automatic Detection of Coronavirus Disease (COVID-19) Using X-ray Images and Deep Convolutional Neural Networks. arXiv <ext-link ext-link-type="uri" xlink:href="http://arxiv.org/abs/2003.10849">arXiv:2003.10849</ext-link></mixed-citation>
      </ref>
      <ref id="CR81">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oldenburg</surname>
              <given-names>CE</given-names>
            </name>
            <name>
              <surname>Doan</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Azithromycin for severe COVID-19</article-title>
          <source>Lancet</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(20)31863-8</pub-id>
          <pub-id pub-id-type="pmid">33189186</pub-id>
        </element-citation>
      </ref>
      <ref id="CR82">
        <mixed-citation publication-type="other">OncoImmune I 2020 A Randomized, Double-blind, Placebo-controlled, Multi-site, Phase III Study to Evaluate the Safety and Efficacy of CD24Fc in COVID-19 Treatment. <ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04317040">https://clinicaltrials.gov/ct2/show/NCT04317040</ext-link></mixed-citation>
      </ref>
      <ref id="CR83">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ong</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>MU</given-names>
            </name>
            <name>
              <surname>Huffman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>Y</given-names>
            </name>
          </person-group>
          <article-title>COVID-19 coronavirus vaccine design using reverse vaccinology and machine learning</article-title>
          <source>bioRxiv</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1101/2020.03.20.000141</pub-id>
          <pub-id pub-id-type="pmid">33052349</pub-id>
        </element-citation>
      </ref>
      <ref id="CR84">
        <mixed-citation publication-type="other">Organization WH 2020a DRAFT landscape of COVID-19 candidate vaccines. <italic>WHO</italic><ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</ext-link></mixed-citation>
      </ref>
      <ref id="CR85">
        <mixed-citation publication-type="other">Organization WH 2020b WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19. <italic>Geneva, Switzerland: WHO.</italic><ext-link ext-link-type="uri" xlink:href="https://www.who.int/news/item/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19">https://www.who.int/news/item/04-07-2020-who-discontinues-hydroxychloroquine-and-lopinavir-ritonavir-treatment-arms-for-covid-19</ext-link></mixed-citation>
      </ref>
      <ref id="CR86">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ortega</surname>
              <given-names>JT</given-names>
            </name>
            <name>
              <surname>Serrano</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Pujol</surname>
              <given-names>FH</given-names>
            </name>
            <name>
              <surname>Rangel</surname>
              <given-names>HR</given-names>
            </name>
          </person-group>
          <article-title>Unrevealing sequence and structural features of novel coronavirus using in silico approaches: The main protease as molecular target</article-title>
          <source>EXCLI J.</source>
          <year>2020</year>
          <volume>19</volume>
          <fpage>400</fpage>
          <lpage>409</lpage>
          <pub-id pub-id-type="pmid">32210741</pub-id>
        </element-citation>
      </ref>
      <ref id="CR87">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Qiu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Mao</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Qiu</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Identification of potential cross-protective epitope between a new type of coronavirus (2019-nCoV) and severe acute respiratory syndrome virus</article-title>
          <source>J. Genet. Genomics</source>
          <year>2020</year>
          <volume>47</volume>
          <fpage>115</fpage>
          <lpage>117</lpage>
          <pub-id pub-id-type="pmid">32171450</pub-id>
        </element-citation>
      </ref>
      <ref id="CR88">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Richardson</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Griffin</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Tucker</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Smith</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Oechsle</surname>
              <given-names>O</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</article-title>
          <source>Lancet</source>
          <year>2020</year>
          <volume>395</volume>
          <fpage>e30</fpage>
          <lpage>e31</lpage>
          <pub-id pub-id-type="pmid">32032529</pub-id>
        </element-citation>
      </ref>
      <ref id="CR89">
        <mixed-citation publication-type="other">Ridgeback Biotherapeutics L 2020 The Safety of EIDD-2801 and Its Effect on Viral Shedding of SARS-CoV-2. <ext-link ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT04405739">https://www.clinicaltrials.gov/ct2/show/NCT04405739</ext-link></mixed-citation>
      </ref>
      <ref id="CR90">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Riva</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Yin</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Martin-Sancho</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Matsunaga</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A Large-scale Drug Repositioning Survey for SARS-CoV-2 Antivirals</article-title>
          <source>bioRxiv</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1101/2020.04.16.044016</pub-id>
          <pub-id pub-id-type="pmid">32511357</pub-id>
        </element-citation>
      </ref>
      <ref id="CR91">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Russell</surname>
              <given-names>CD</given-names>
            </name>
            <name>
              <surname>Millar</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Baillie</surname>
              <given-names>JK</given-names>
            </name>
          </person-group>
          <article-title>Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury</article-title>
          <source>Lancet</source>
          <year>2020</year>
          <volume>395</volume>
          <fpage>473</fpage>
          <lpage>475</lpage>
          <pub-id pub-id-type="pmid">32043983</pub-id>
        </element-citation>
      </ref>
      <ref id="CR92">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sanders</surname>
              <given-names>JM</given-names>
            </name>
            <name>
              <surname>Monogue</surname>
              <given-names>ML</given-names>
            </name>
            <name>
              <surname>Jodlowski</surname>
              <given-names>TZ</given-names>
            </name>
            <name>
              <surname>Cutrell</surname>
              <given-names>JB</given-names>
            </name>
          </person-group>
          <article-title>Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review</article-title>
          <source>JAMA</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1001/jama.2020.6019</pub-id>
          <pub-id pub-id-type="pmid">33165621</pub-id>
        </element-citation>
      </ref>
      <ref id="CR93">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sheahan</surname>
              <given-names>TP</given-names>
            </name>
            <name>
              <surname>Sims</surname>
              <given-names>AC</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Graham</surname>
              <given-names>RL</given-names>
            </name>
            <name>
              <surname>Pruijssers</surname>
              <given-names>AJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>An orally bioavailable broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and multiple coronaviruses in mice</article-title>
          <source>Sci. Transl. Med.</source>
          <year>2020</year>
          <volume>12</volume>
          <fpage>eabb5883</fpage>
          <pub-id pub-id-type="pmid">32253226</pub-id>
        </element-citation>
      </ref>
      <ref id="CR94">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Singh</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Majumdar</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Singh</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Misra</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Role of corticosteroid in the management of COVID-19: A systemic review and a Clinician&#x2019;s perspective</article-title>
          <source>Diabetes Metab. Syndr.</source>
          <year>2020</year>
          <volume>14</volume>
          <fpage>971</fpage>
          <lpage>978</lpage>
          <pub-id pub-id-type="pmid">32610262</pub-id>
        </element-citation>
      </ref>
      <ref id="CR95">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Stebbing</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Phelan</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Griffin</surname>
              <given-names>I</given-names>
            </name>
            <name>
              <surname>Tucker</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Oechsle</surname>
              <given-names>O</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>COVID-19: combining antiviral and anti-inflammatory treatments</article-title>
          <source>Lancet Infect. Dis.</source>
          <year>2020</year>
          <volume>20</volume>
          <fpage>400</fpage>
          <lpage>402</lpage>
          <pub-id pub-id-type="pmid">32113509</pub-id>
        </element-citation>
      </ref>
      <ref id="CR96">
        <element-citation publication-type="book">
          <person-group person-group-type="author">
            <name>
              <surname>Tai</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>He</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Pu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Voronin</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <source>Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine</source>
          <year>2020</year>
          <publisher-loc>Cell Mol</publisher-loc>
          <publisher-name>Immunol</publisher-name>
        </element-citation>
      </ref>
      <ref id="CR97">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tian</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Xia</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Lu</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody</article-title>
          <source>Emerg. Microbes. Infect.</source>
          <year>2020</year>
          <volume>9</volume>
          <fpage>382</fpage>
          <lpage>385</lpage>
          <pub-id pub-id-type="pmid">32065055</pub-id>
        </element-citation>
      </ref>
      <ref id="CR98">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>To</surname>
              <given-names>KK-W</given-names>
            </name>
            <name>
              <surname>Tsang</surname>
              <given-names>OT-Y</given-names>
            </name>
            <name>
              <surname>Yip</surname>
              <given-names>CC-Y</given-names>
            </name>
            <name>
              <surname>Chan</surname>
              <given-names>K-H</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>T-C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Consistent Detection of 2019 Novel Coronavirus in Saliva</article-title>
          <source>Clin. Infect. Dis.</source>
          <year>2020</year>
          <volume>71</volume>
          <fpage>841</fpage>
          <lpage>843</lpage>
          <pub-id pub-id-type="pmid">32047895</pub-id>
        </element-citation>
      </ref>
      <ref id="CR99">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ton</surname>
              <given-names>A-T</given-names>
            </name>
            <name>
              <surname>Gentile</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Hsing</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Ban</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Cherkasov</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds</article-title>
          <source>ChemRxiv</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.26434/chemrxiv.11860077.v1</pub-id>
        </element-citation>
      </ref>
      <ref id="CR100">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Hajizadeh</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>EE</given-names>
            </name>
            <name>
              <surname>McIntyre</surname>
              <given-names>RC</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>PK</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tissue Plasminogen Activator (tPA) Treatment for COVID-19 Associated Acute Respiratory Distress Syndrome (ARDS): A Case Series</article-title>
          <source>J. Thromb. Haemost.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1111/jth.14828</pub-id>
          <pub-id pub-id-type="pmid">33433069</pub-id>
        </element-citation>
      </ref>
      <ref id="CR101">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Cao</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Zhang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro</article-title>
          <source>Cell Res.</source>
          <year>2020</year>
          <volume>30</volume>
          <fpage>269</fpage>
          <lpage>271</lpage>
          <pub-id pub-id-type="pmid">32020029</pub-id>
        </element-citation>
      </ref>
      <ref id="CR102">
        <mixed-citation publication-type="other">WHO 2020 WHO R&amp;D Blueprint COVID-19 Animal Models. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/publications/m/item/covid-19-animal-models---summary-of-progress-made-by-the-who-covid-19-modelling-(march-04-june-2020)">https://www.who.int/publications/m/item/covid-19-animal-models---summary-of-progress-made-by-the-who-covid-19-modelling-(march-04-june-2020)</ext-link></mixed-citation>
      </ref>
      <ref id="CR103">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xia</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Lan</surname>
              <given-names>Q</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion</article-title>
          <source>Cell Res.</source>
          <year>2020</year>
          <volume>30</volume>
          <fpage>343</fpage>
          <lpage>355</lpage>
          <pub-id pub-id-type="pmid">32231345</pub-id>
        </element-citation>
      </ref>
      <ref id="CR104">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xia</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Lan</surname>
              <given-names>Q</given-names>
            </name>
            <name>
              <surname>Xu</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein</article-title>
          <source>Cell Mol. Immunol.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1038/s41423-020-0374-2</pub-id>
          <pub-id pub-id-type="pmid">33097834</pub-id>
        </element-citation>
      </ref>
      <ref id="CR105">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Xiang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yan</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Lin</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Evaluation of Enzyme-Linked Immunoassay and Colloidal Gold- Immunochromatographic Assay Kit for Detection of Novel Coronavirus (SARS-Cov-2) Causing an Outbreak of Pneumonia (COVID-19)</article-title>
          <source>medRxiv</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1101/2020.02.27.20028787</pub-id>
          <pub-id pub-id-type="pmid">33106820</pub-id>
        </element-citation>
      </ref>
      <ref id="CR106">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yan</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cui</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Du</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>L</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse transcription loop-mediated isothermal amplification assay</article-title>
          <source>Clin. Microbiol. Infect.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/j.cmi.2020.04.001</pub-id>
          <pub-id pub-id-type="pmid">33160036</pub-id>
        </element-citation>
      </ref>
      <ref id="CR107">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Shen</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yuan</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Yang</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Exuberant elevation of IP-10, MCP-3 and IL-1ra during SARS-CoV-2 infection is associated with disease severity and fatal outcome</article-title>
          <source>medRxiv</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1101/2020.03.02.20029975</pub-id>
          <pub-id pub-id-type="pmid">7781329</pub-id>
        </element-citation>
      </ref>
      <ref id="CR108">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yang</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Zhou</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>Q</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The effect of corticosteroid treatment on patients with coronavirus infection: a systematic review and meta-analysis</article-title>
          <source>J. Infect.</source>
          <year>2020</year>
          <volume>81</volume>
          <fpage>e13</fpage>
          <lpage>e20</lpage>
          <pub-id pub-id-type="pmid">32283144</pub-id>
        </element-citation>
      </ref>
      <ref id="CR109">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ye</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Colunga-Lozano</surname>
              <given-names>LE</given-names>
            </name>
            <name>
              <surname>Prasad</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tangamornsuksan</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Efficacy and safety of corticosteroids in COVID-19 based on evidence for COVID-19, other coronavirus infections, influenza, community-acquired pneumonia and acute respiratory distress syndrome: a systematic review and meta-analysis</article-title>
          <source>CMAJ</source>
          <year>2020</year>
          <volume>192</volume>
          <fpage>E756</fpage>
          <lpage>E767</lpage>
          <pub-id pub-id-type="pmid">32409522</pub-id>
        </element-citation>
      </ref>
      <ref id="CR110">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zha</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Pan</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tefsen</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)</article-title>
          <source>Med. J. Aust.</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.5694/mja2.50577</pub-id>
          <pub-id pub-id-type="pmid">32266987</pub-id>
        </element-citation>
      </ref>
      <ref id="CR111">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Liu</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Tan</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Dong</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Treatment With Convalescent Plasma for Critically Ill Patients With SARS-CoV-2 Infection</article-title>
          <source>CHEST</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/j.chest.2020.03.039</pub-id>
          <pub-id pub-id-type="pmid">33217413</pub-id>
        </element-citation>
      </ref>
      <ref id="CR112">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>Li</surname>
              <given-names>J-W</given-names>
            </name>
            <name>
              <surname>Zhao</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>G-Q</given-names>
            </name>
          </person-group>
          <article-title>The cytokine release syndrome (CRS) of severe COVID-19 and Interleukin-6 receptor (IL-6R) antagonist Tocilizumab may be the key to reduce the mortality</article-title>
          <source>Int. J. Antimicrob. Agents</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/j.ijantimicag.2020.105954</pub-id>
          <pub-id pub-id-type="pmid">33352235</pub-id>
        </element-citation>
      </ref>
      <ref id="CR113">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wang</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Ni</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Di</surname>
              <given-names>X</given-names>
            </name>
            <name>
              <surname>Ma</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>COVID-19: Melatonin as a potential adjuvant treatment</article-title>
          <source>Life Sci.</source>
          <year>2020</year>
          <volume>250</volume>
          <fpage>117583</fpage>
          <pub-id pub-id-type="pmid">32217117</pub-id>
        </element-citation>
      </ref>
      <ref id="CR114">
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Yu</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Tang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Zhu</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Jin</surname>
              <given-names>Y</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>A promising anti-cytokine-storm targeted therapy for COVID-19: The artificial-liver blood-purification system</article-title>
          <source>Engineering (Beijing)</source>
          <year>2020</year>
          <pub-id pub-id-type="doi">10.1016/j.eng.2020.03.006</pub-id>
          <pub-id pub-id-type="pmid">33449771</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" id="jmv26398" xml:lang="en" article-type="research-article">
  <?properties open_access?>
  <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
    <restricted-by>pmc</restricted-by>
  </processing-meta>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">J Med Virol</journal-id>
      <journal-id journal-id-type="iso-abbrev">J Med Virol</journal-id>
      <journal-id journal-id-type="doi">10.1002/(ISSN)1096-9071</journal-id>
      <journal-id journal-id-type="publisher-id">JMV</journal-id>
      <journal-title-group>
        <journal-title>Journal of Medical Virology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0146-6615</issn>
      <issn pub-type="epub">1096-9071</issn>
      <publisher>
        <publisher-name>John Wiley and Sons Inc.</publisher-name>
        <publisher-loc>Hoboken</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">32761898</article-id>
      <article-id pub-id-type="pmc">7436402</article-id>
      <article-id pub-id-type="doi">10.1002/jmv.26398</article-id>
      <article-id pub-id-type="publisher-id">JMV26398</article-id>
      <article-categories>
        <subj-group subj-group-type="overline">
          <subject>Research Article</subject>
        </subj-group>
        <subj-group subj-group-type="heading">
          <subject>Research Articles</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>A systematic review and meta&#x2010;analysis of children with coronavirus disease 2019 (COVID&#x2010;19)</article-title>
        <alt-title alt-title-type="left-running-head">CUI <sc>et al.</sc>
</alt-title>
      </title-group>
      <contrib-group>
        <contrib id="jmv26398-cr-0001" contrib-type="author">
          <name>
            <surname>Cui</surname>
            <given-names>Xiaojian</given-names>
          </name>
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0003-0204-7534</contrib-id>
          <xref rid="jmv26398-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jmv26398-cr-0002" contrib-type="author">
          <name>
            <surname>Zhao</surname>
            <given-names>Zhihu</given-names>
          </name>
          <xref rid="jmv26398-aff-0002" ref-type="aff">
<sup>2</sup>
</xref>
        </contrib>
        <contrib id="jmv26398-cr-0003" contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Tongqiang</given-names>
          </name>
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-6945-1868</contrib-id>
          <xref rid="jmv26398-aff-0003" ref-type="aff">
<sup>3</sup>
</xref>
          <xref rid="jmv26398-aff-0004" ref-type="aff">
<sup>4</sup>
</xref>
        </contrib>
        <contrib id="jmv26398-cr-0004" contrib-type="author">
          <name>
            <surname>Guo</surname>
            <given-names>Wei</given-names>
          </name>
          <xref rid="jmv26398-aff-0003" ref-type="aff">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="jmv26398-cr-0005" contrib-type="author">
          <name>
            <surname>Guo</surname>
            <given-names>Wenwei</given-names>
          </name>
          <xref rid="jmv26398-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jmv26398-cr-0006" contrib-type="author">
          <name>
            <surname>Zheng</surname>
            <given-names>Jiafeng</given-names>
          </name>
          <xref rid="jmv26398-aff-0003" ref-type="aff">
<sup>3</sup>
</xref>
        </contrib>
        <contrib id="jmv26398-cr-0007" contrib-type="author">
          <name>
            <surname>Zhang</surname>
            <given-names>Jiayi</given-names>
          </name>
          <xref rid="jmv26398-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jmv26398-cr-0008" contrib-type="author">
          <name>
            <surname>Dong</surname>
            <given-names>Cuicui</given-names>
          </name>
          <xref rid="jmv26398-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jmv26398-cr-0009" contrib-type="author">
          <name>
            <surname>Na</surname>
            <given-names>Ren</given-names>
          </name>
          <xref rid="jmv26398-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jmv26398-cr-0010" contrib-type="author">
          <name>
            <surname>Zheng</surname>
            <given-names>Lisheng</given-names>
          </name>
          <xref rid="jmv26398-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jmv26398-cr-0011" contrib-type="author">
          <name>
            <surname>Li</surname>
            <given-names>Wenliang</given-names>
          </name>
          <xref rid="jmv26398-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jmv26398-cr-0012" contrib-type="author">
          <name>
            <surname>Liu</surname>
            <given-names>Zihui</given-names>
          </name>
          <xref rid="jmv26398-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jmv26398-cr-0013" contrib-type="author">
          <name>
            <surname>Ma</surname>
            <given-names>Jia</given-names>
          </name>
          <xref rid="jmv26398-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
        </contrib>
        <contrib id="jmv26398-cr-0014" contrib-type="author">
          <name>
            <surname>Wang</surname>
            <given-names>Jinhu</given-names>
          </name>
          <xref rid="jmv26398-aff-0005" ref-type="aff">
<sup>5</sup>
</xref>
        </contrib>
        <contrib id="jmv26398-cr-0015" contrib-type="author">
          <name>
            <surname>He</surname>
            <given-names>Sijia</given-names>
          </name>
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1932-1141</contrib-id>
          <xref rid="jmv26398-aff-0006" ref-type="aff">
<sup>6</sup>
</xref>
        </contrib>
        <contrib id="jmv26398-cr-0016" contrib-type="author" corresp="yes">
          <name>
            <surname>Xu</surname>
            <given-names>Yongsheng</given-names>
          </name>
          <xref rid="jmv26398-aff-0003" ref-type="aff">
<sup>3</sup>
</xref>
          <address>
            <email>xxyyss@126.com</email>
          </address>
        </contrib>
        <contrib id="jmv26398-cr-0017" contrib-type="author" corresp="yes">
          <name>
            <surname>Si</surname>
            <given-names>Ping</given-names>
          </name>
          <xref rid="jmv26398-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
          <address>
            <email>kangsiping@live.cn</email>
          </address>
        </contrib>
        <contrib id="jmv26398-cr-0018" contrib-type="author" corresp="yes">
          <name>
            <surname>Shen</surname>
            <given-names>Yongming</given-names>
          </name>
          <xref rid="jmv26398-aff-0001" ref-type="aff">
<sup>1</sup>
</xref>
          <address>
            <email>shenymtj@sina.com</email>
          </address>
        </contrib>
        <contrib id="jmv26398-cr-0019" contrib-type="author" corresp="yes">
          <name>
            <surname>Cai</surname>
            <given-names>Chunquan</given-names>
          </name>
          <xref rid="jmv26398-aff-0007" ref-type="aff">
<sup>7</sup>
</xref>
          <xref rid="jmv26398-aff-0008" ref-type="aff">
<sup>8</sup>
</xref>
          <xref rid="jmv26398-aff-0009" ref-type="aff">
<sup>9</sup>
</xref>
          <address>
            <email>15122656313@126.com</email>
          </address>
        </contrib>
      </contrib-group>
      <aff id="jmv26398-aff-0001">
<label>
<sup>1</sup>
</label>
<named-content content-type="organisation-division">Department of Clinical Lab</named-content>
<institution>Tianjin Children's Hospital (Children's Hospital of Tianjin University)</institution>
<city>Tianjin</city>
<country country="CN">PR China</country>
</aff>
      <aff id="jmv26398-aff-0002">
<label>
<sup>2</sup>
</label>
<named-content content-type="organisation-division">Department of Orthopaedic</named-content>
<institution>Tianjin Hospital</institution>
<city>Tianjin</city>
<country country="CN">PR China</country>
</aff>
      <aff id="jmv26398-aff-0003">
<label>
<sup>3</sup>
</label>
<named-content content-type="organisation-division">Department of Respiratory</named-content>
<institution>Tianjin Children's Hospital (Children's Hospital of Tianjin University)</institution>
<city>Tianjin</city>
<country country="CN">PR China</country>
</aff>
      <aff id="jmv26398-aff-0004">
<label>
<sup>4</sup>
</label>
<named-content content-type="organisation-division">Department of Pediatrics</named-content>
<institution>Graduate School of Tianjin Medical University</institution>
<city>Tianjin</city>
<country country="CN">PR China</country>
</aff>
      <aff id="jmv26398-aff-0005">
<label>
<sup>5</sup>
</label>
<named-content content-type="organisation-division">Department of Neonatal Surgery</named-content>
<institution>Tianjin Children's Hospital (Children's Hospital of Tianjin University)</institution>
<city>Tianjin</city>
<country country="CN">PR China</country>
</aff>
      <aff id="jmv26398-aff-0006">
<label>
<sup>6</sup>
</label>
<named-content content-type="organisation-division">Department of National Center for Biodefense and Infectious Diseases, School of Systems Biology</named-content>
<institution>George Mason University</institution>
<city>Manassas</city>
<named-content content-type="country-part">Virginia</named-content>
</aff>
      <aff id="jmv26398-aff-0007">
<label>
<sup>7</sup>
</label>
<named-content content-type="organisation-division">Department of Neurosurgery</named-content>
<institution>Tianjin Children's Hospital (Children's Hospital of Tianjin University)</institution>
<city>Tianjin</city>
<country country="CN">PR China</country>
</aff>
      <aff id="jmv26398-aff-0008">
<label>
<sup>8</sup>
</label>
<named-content content-type="organisation-division">Institute of Pediatrics</named-content>
<institution>Tianjin Children's Hospital (Children's Hospital of Tianjin University)</institution>
<city>Tianjin</city>
<country country="CN">PR China</country>
</aff>
      <aff id="jmv26398-aff-0009">
<label>
<sup>9</sup>
</label>
<institution>Tianjin Key Laboratory of Birth Defects for Prevention and Treatment</institution>
<city>Tianjin</city>
<country country="CN">PR China</country>
</aff>
      <author-notes>
        <corresp id="correspondenceTo">
<label>*</label>
<bold>Correspondence</bold> Yongming Shen and Ping Si, Department of Clinical Lab, Tianjin Children's Hospital, No. 238 Longyan Road, Beichen District, 300134, Tianjin, PR China.<break/>
Email: <email>shenymtj@sina.com</email> (YS) and <email>kangsiping@live.cn</email> (PS)<break/>
Yongsheng Xu, Department of Respiratory, Tianjin Children's Hospital, No. 238 Longyan Road, Beichen District, 300134, Tianjin, PR China.<break/>
Email: <email>xxyyss@126.com</email>
<break/>
Chunquan Cai, Department of Neurosurgery, Tianjin Children's Hospital, No. 238 Longyan Road, Beichen District, 300134, Tianjin, PR China.<break/>
Email: <email>15122656313@126.com</email>
<break/>
</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>28</day>
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>2</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>28</day>
        <month>9</month>
        <year>2020</year>
      </pub-date>
      <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
      <volume>93</volume>
      <issue seq="940">2</issue>
      <issue-id pub-id-type="doi">10.1002/jmv.v93.2</issue-id>
      <issue-title>Special Issue on New coronavirus (2019&#x2010;nCoV or SARS&#x2010;CoV&#x2010;2) and the outbreak of the respiratory illness (COVID&#x2010;19): Part&#x2010;IX</issue-title>
      <fpage>1057</fpage>
      <lpage>1069</lpage>
      <history>
<date date-type="received"><day>18</day><month>6</month><year>2020</year></date>
<date date-type="accepted"><day>30</day><month>7</month><year>2020</year></date>
</history>
      <permissions>
        <!--&#x000a9; 2020 Wiley Periodicals LLC-->
        <copyright-statement content-type="article-copyright">&#xA9; 2020 Wiley Periodicals LLC</copyright-statement>
        <license>
          <license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p>
        </license>
      </permissions>
      <self-uri content-type="pdf" xlink:href="file:JMV-93-1057.pdf"/>
      <abstract>
        <title>Abstract</title>
        <p>To provide a comprehensive and systematic analysis of demographic characteristics, clinical symptoms, laboratory findings, and imaging features of coronavirus disease 2019 (COVID&#x2010;19) in pediatric patients.&#xA0;A meta&#x2010;analysis was carried out to identify studies on COVID&#x2010;19 from 25 December 2019 to 30 April 2020. A total of 48 studies with 5829 pediatric patients were included. Children of all ages were at risk for COVID&#x2010;19. The main illness classification ranged as: 20% (95% confidence interval [CI]: 14%&#x2010;26%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;91.4%) asymptomatic, 33% (95% CI: 23%&#x2010;43%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;95.6%) mild and 51% (95% CI: 42%&#x2010;61%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;93.4%) moderate. The typical clinical manifestations were fever 51% (95% CI: 45%&#x2010;57%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;78.9%) and cough 41% (95% CI: 35%&#x2010;47%, <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;81.0%). The common laboratory findings were normal white blood cell 69% (95% CI: 64%&#x2010;75%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;58.5%), lymphopenia 16% (95% CI: 11%&#x2010;21%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;76.9%) and elevated creatine&#x2010;kinase MB 37% (95% CI: 25%&#x2010;48%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;59.0%). The frequent imaging features were normal images 41% (95% CI: 30%&#x2010;52%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;93.4%) and ground&#x2010;glass opacity 36% (95% CI: 25%&#x2010;47%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;92.9%). Among children under 1 year old, critical cases account for 14% (95% CI: 13%&#x2010;34%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;37.3%) that should be of concern. In addition, vomiting occurred in 33% (95% CI: 18%&#x2010;67%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%) cases that may also need attention.&#xA0;Pediatric patients with COVID&#x2010;19 may experience milder illness with atypical clinical manifestations and rare lymphopenia. High incidence of critical illness and vomiting symptoms reward attention in children under 1 year old.</p>
      </abstract>
      <abstract abstract-type="highlights">
        <title>Highlights</title>
        <p>
<list list-type="bullet"><list-item><p>To provide a comprehensive characterization of coronavirus disease 2019 (COVID&#x2010;19) in pediatric patients.</p></list-item><list-item><p>The majority of pediatric cases with COVID&#x2010;19 have milder illness with atypical clinical manifestations and rare lymphopenia.</p></list-item><list-item><p>It is worth noting that the high incidence of critical illness and vomiting in children under 1 year old.</p></list-item><list-item><p>Our evidence&#x2010;based data will help formulate strategies for early clinical identification and epidemic control of COVID&#x2010;19 in children.</p></list-item></list>
</p>
      </abstract>
      <kwd-group>
        <kwd id="jmv26398-kwd-0001">2019&#x2010;nCoV</kwd>
        <kwd id="jmv26398-kwd-0002">children</kwd>
        <kwd id="jmv26398-kwd-0003">coronavirus</kwd>
        <kwd id="jmv26398-kwd-0004">COVID&#x2010;19</kwd>
        <kwd id="jmv26398-kwd-0005">meta&#x2010;analysis</kwd>
        <kwd id="jmv26398-kwd-0006">SARS&#x2010;CoV&#x2010;2</kwd>
      </kwd-group>
      <funding-group>
        <award-group id="funding-0001">
          <funding-source>The Key Project of Tianjin Health Care Professionals</funding-source>
          <award-id>16KG166</award-id>
        </award-group>
        <award-group id="funding-0002">
          <funding-source>The Program of Tianjin Science and Technology Plan</funding-source>
          <award-id>18ZXDBSY00170</award-id>
        </award-group>
        <award-group id="funding-0003">
          <funding-source>
            <institution-wrap>
              <institution>National Natural Science Foundation of China
</institution>
              <institution-id institution-id-type="doi">10.13039/501100001809</institution-id>
            </institution-wrap>
          </funding-source>
          <award-id>81771589</award-id>
        </award-group>
      </funding-group>
      <counts>
        <fig-count count="6"/>
        <table-count count="2"/>
        <page-count count="13"/>
        <word-count count="7240"/>
      </counts>
      <custom-meta-group>
        <custom-meta>
          <meta-name>source-schema-version-number</meta-name>
          <meta-value>2.0</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>cover-date</meta-name>
          <meta-value>February 2021</meta-value>
        </custom-meta>
        <custom-meta>
          <meta-name>details-of-publishers-convertor</meta-name>
          <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.1.7 mode:remove_FC converted:06.07.2022</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
    <notes>
      <p content-type="self-citation">
<mixed-citation publication-type="journal" id="jmv26398-cit-0070">
<string-name>
<surname>Cui</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>A systematic review and meta&#x2010;analysis of children with coronavirus disease 2019 (COVID&#x2010;19)</article-title>. <source>J Med Virol</source>. <year>2021</year>;<volume>93</volume>:<fpage>1057</fpage>&#x2013;<lpage>1069</lpage>. <pub-id pub-id-type="doi">10.1002/jmv.26398</pub-id>
<pub-id pub-id-type="pmid">32761898</pub-id></mixed-citation>
</p>
      <fn-group>
        <fn id="jmv26398-note-0001">
          <p>Xiaojian Cui, Zhihu Zhao, Tongqiang Zhang, and Wei Guo contributed equally to this work.</p>
        </fn>
      </fn-group>
    </notes>
  </front>
  <body>
    <sec id="jmv26398-sec-0010">
      <label>1</label>
      <title>INTRODUCTION</title>
      <p>An outbreak of the coronavirus disease 2019 (COVID&#x2010;19) is spreading rapidly around the world, which is caused by severe acute respiratory syndrome coronavirus&#x2010;2 (SARS&#x2010;CoV&#x2010;2) infection. As of 26 July 2020, the COVID&#x2010;19 pandemic has resulted in approximately 15&#x2009;785&#x2009;641 confirmed cases, including 640&#x2009;016 deaths worldwide.<xref rid="jmv26398-bib-0001" ref-type="bibr">
<sup>1</sup>
</xref> In the early stage, the majority of cases were concentrated in middle&#x2010;aged and old people. Under the ongoing pandemic situation, children cases are showing an increasing trend in many countries of the world: In China, a large cohort study on the epidemiological characteristics of children with COVID&#x2010;19 included 2135 cases<xref rid="jmv26398-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>; In the United States, it was reported that 74 children were admitted to pediatric intensive care units in 19 states; On a global scale, it was estimated 176&#x2009;190 children infected with SARS&#x2010;CoV&#x2010;2 by 6 April 2020.<xref rid="jmv26398-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref> One meta&#x2010;analysis found that fever and cough occurred in adults up to 92.8% and 63.4%, respectively.<xref rid="jmv26398-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> Another study showed lymphopenia occurred in 57.4% of an adult patient with COVID&#x2010;19.<xref rid="jmv26398-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> Although some previous studies have demonstrated that SARS&#x2010;CoV&#x2010;2 infection affects adults and children differently,<xref rid="jmv26398-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="jmv26398-bib-0007" ref-type="bibr">
<sup>7</sup>
</xref>, <xref rid="jmv26398-bib-0008" ref-type="bibr">
<sup>8</sup>
</xref> the data of a systematic meta&#x2010;analysis on characteristics of children with COVID&#x2010;19 are still lacking. Thus, in our research, we reviewed and analyzed the studies and reported cases from 25 December 2019 to 30 April 2020 to provide evidence&#x2010;based data involving clinical manifestations of COVID&#x2010;19 in pediatric patients. It will help to formulate policies on controlling SARS&#x2010;CoV&#x2010;2 transmission among children for pediatricians and public health specialists.</p>
    </sec>
    <sec sec-type="methods" id="jmv26398-sec-0020">
      <label>2</label>
      <title>METHODS</title>
      <p>This study was conducted following the Preferred Reporting Items for Systematic Reviews and Meta&#x2010;Analyses (PRISMA) statement and was registered in PROSPERO as CRD42020191099.</p>
      <sec id="jmv26398-sec-0030">
        <label>2.1</label>
        <title>Search strategies</title>
        <p>To identify studies pertaining clinical, laboratory, and imaging features in children with COVID&#x2010;19, we systematically searched from PubMed, Web of Science, Chinese Wanfang and China National Knowledge Infrastructure databases for relevant articles published through 30 April 2020. Moreover, additional records identified from World Health Organization (WHO)/Center for Disease Control reports, medRxiv, bioRxiv, SSRN, and Google Scholar. We also reviewed the references of all identified articles to identify additional studies. Search terms were as follows: novel coronavirus, nCoV, SARS2 vaccine, Wuhan coronavirus vaccine, 2019 novel coronavirus, novel coronavirus 2019, 2019&#x2010;nCoV, COVID&#x2010;19, Wuhan coronavirus, Wuhan pneumonia and SARS&#x2010;CoV&#x2010;2. These terms were used in combination with &#x201C;AND&#x201D; or &#x201C;OR.&#x201D; The literature review was performed independently by two investigators (XJC and TQZ), with a third reviewer (YMS) resolving any disputes as needed.</p>
      </sec>
      <sec id="jmv26398-sec-0040">
        <label>2.2</label>
        <title>Inclusion criteria</title>
        <p>We included published papers (cohort studies, case series, and case reports) that given available data about the demographic information, clinical, laboratory, and image features in children with COVID&#x2010;19. Pediatric population was defined as under 18 years old. SARS&#x2010;CoV&#x2010;2 nucleic acid was teased by RT&#x2010;PCR in accordance with the WHO guideline.<xref rid="jmv26398-bib-0009" ref-type="bibr">
<sup>9</sup>
</xref> The level of laboratory test items was determined according to the following standards: normal white blood cell: 5.5 to 12.0&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L, leukocytosis: more than 12.0&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L, leukopenia: less than 5.5&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L, lymphopenia: less than 1.2&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L, high PCT: more than 0.046&#x2009;ng/mL, high CRP: more than 10&#x2009;mg/L, high LDH: more than 300&#x2009;U/L, high ALT: more than 45&#x2009;U/L, high AST: more than 50&#x2009;U/L, high Creatinine: more than 62&#x2009;&#x3BC;mol/L, high blood urea nitrogen: more than 7.1&#x2009;mmol/L, high CK: more than 170&#x2009;U/L, high CK&#x2010;MB: more than 25&#x2009;U/L, high D&#x2010;dimer: more than 0.55&#x2009;mg/L. We excluded studies that did not report original data or clear diagnostic criteria, and no relevant outcome.</p>
      </sec>
      <sec id="jmv26398-sec-0050">
        <label>2.3</label>
        <title>Data collection</title>
        <p>Two authors (XJC and TQZ) independently extracted relevant information, including first author, publication year, sex (male, %), country, number of COVID&#x2010;19 patients, age distribution (ratio of &lt;1, 1&#x2010;5, 6&#x2010;10, 11&#x2010;15, and &gt;15 years) and contact history. The severity of COVID&#x2010;19 was defined according to the clinical characteristics, laboratory testing, and chest imaging, including asymptomatic infection, mild, moderate, severe and critical cases.<xref rid="jmv26398-bib-0010" ref-type="bibr">
<sup>10</sup>
</xref> The diagnostic criteria were as follows: Asymptomatic infection: The child had no clinical symptoms or signs, chest imaging was normal, and only 2019&#x2010;nCoV nucleic acid test was positive; mild: the acute upper respiratory tract infection was the main manifestations and some children may only have digestive symptoms. Some children may have no fever. Physical examination shows no auscultatory abnormalities; Moderate: with pneumonia, most of children have fever and cough, which are dry cough at first and then phlegm cough. Some of them may have wheezing, but without obvious hypoxia such as shortness of breath, sputum or dry snoring and/or wet snoring can be heard in the lungs. Some children only found lung lesions on chest computed tomography (CT) without any clinical symptoms and signs, which is called subclinical type; Severe: Early onset of respiratory symptoms such as fever and cough, some can be accompanied by gastrointestinal symptoms, disease progression often occurs in about 1 week, with hypoxia performance, and dyspnea occurs, oxygen saturation is less than 0.92; critical: children may rapidly progress to acute respiratory distress syndrome or respiratory failure. They may also develop shock, coagulation dysfunction or other multiple organ dysfunction, which may endanger their lives. Moreover, we extracted clinical performance data including fever, cough, sore throat, tachycardia, rhinorrhea, nasal congestion, tachypnea, diarrhea, vomiting, myalgia or fatigue, hypoxemia, and chest pain. Clinical laboratory results were extracted based on blood routine tests, liver function tests, renal function measurement, cardiac function, inflammatory factors and D&#x2010;dimer. Distributions for all imaging: normal, ground&#x2010;glass opacity (GGO), local patchy shadowing, bilateral patchy shadowing, white lung change and pleural effusion.</p>
      </sec>
      <sec id="jmv26398-sec-0060">
        <label>2.4</label>
        <title>Quality assessment</title>
        <p>We used the quality assessment tool for case series studies published by the National Institutes of Health to assess the methodological quality of included studies.<xref rid="jmv26398-bib-0011" ref-type="bibr">
<sup>11</sup>
</xref> We scored 0 or 1 point for each item according to the criteria and added scores for all items to generate an overall quality score that ranged from 0 to 8. Based on the overall score, we classified studies as low (&#x2265;7), moderate (5&#x2010;6), or high risk of bias (&#x2264;4). Any disagreement was resolved through discussion by all investigators.</p>
      </sec>
      <sec id="jmv26398-sec-0070">
        <label>2.5</label>
        <title>Statistical analysis</title>
        <p>We performed data analysis using metan packages in STATA (version 12.0; Stata Corp, College Station, TX). Statistical heterogeneity between studies was evaluated with Cochran's <italic toggle="yes">Q</italic> test and the <italic toggle="yes">I</italic>
<sup>2</sup> statistic. The <italic toggle="yes">I</italic>
<sup>2</sup>&#x2010;value of less than 50% was equivalent to no heterogeneity, whereas values greater than 50% was equivalent to large heterogeneity among studies. Freeman&#x2010;Tukey double arcsine transformation was used to stabilize the variance of specific prevalence rates between the included studies.<xref rid="jmv26398-bib-0012" ref-type="bibr">
<sup>12</sup>
</xref> To account for the potential heterogeneity of studied population in each study reflected by different geographic locations, ethnicity, age group, and so forth, a random&#x2010;effect model using the DerSimonian and Laird method was used to aggregate effect sizes to estimate the overall pooled prevalence and corresponding 95% confidence intervals (CIs). To explore the reasons for heterogeneity, subgroup analyses were applied based on the study type (noncase reports vs case reports). The Begg's funnel plot was performed to evaluate the publication bias. <italic toggle="yes">P</italic> value of less than .05 was identified as statistically significant.</p>
      </sec>
    </sec>
    <sec sec-type="results" id="jmv26398-sec-0080">
      <label>3</label>
      <title>RESULTS</title>
      <sec id="jmv26398-sec-0090">
        <label>3.1</label>
        <title>Study selection, general characteristics, and quality assessment</title>
        <p>A total of 2048 relevant studies were collected from databases and other sources based on the search strategies. We used Endnote Software (Version X7; Thompson Reuters, CA) to remove 992 duplicate studies. According to the title and abstract, 1003 relevant studies were excluded, and then, five studies were removed by reading the full text. Finally, a total of 48 studies<xref rid="jmv26398-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>, <xref rid="jmv26398-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="jmv26398-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>, <xref rid="jmv26398-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="jmv26398-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>, <xref rid="jmv26398-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="jmv26398-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>, <xref rid="jmv26398-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>, <xref rid="jmv26398-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>, <xref rid="jmv26398-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>, <xref rid="jmv26398-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>, <xref rid="jmv26398-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>, <xref rid="jmv26398-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>, <xref rid="jmv26398-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>, <xref rid="jmv26398-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>, <xref rid="jmv26398-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>, <xref rid="jmv26398-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>, <xref rid="jmv26398-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="jmv26398-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>, <xref rid="jmv26398-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>, <xref rid="jmv26398-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>, <xref rid="jmv26398-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>, <xref rid="jmv26398-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>, <xref rid="jmv26398-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="jmv26398-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>, <xref rid="jmv26398-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>, <xref rid="jmv26398-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>, <xref rid="jmv26398-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>, <xref rid="jmv26398-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>, <xref rid="jmv26398-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>, <xref rid="jmv26398-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>, <xref rid="jmv26398-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>, <xref rid="jmv26398-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>, <xref rid="jmv26398-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>, <xref rid="jmv26398-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>, <xref rid="jmv26398-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>, <xref rid="jmv26398-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>, <xref rid="jmv26398-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref>, <xref rid="jmv26398-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref>, <xref rid="jmv26398-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>, <xref rid="jmv26398-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>, <xref rid="jmv26398-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref>, <xref rid="jmv26398-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref>, <xref rid="jmv26398-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref>, <xref rid="jmv26398-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref>, <xref rid="jmv26398-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref>, <xref rid="jmv26398-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref>, <xref rid="jmv26398-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref> were included in this meta&#x2010;analysis in according with the inclusion criteria. The PRISMA flow diagram of the included studies is listed in Figure&#xA0;<xref rid="jmv26398-fig-0001" ref-type="fig">1</xref>. The general characteristics of the included studies are shown in Table&#xA0;<xref rid="jmv26398-tbl-0001" ref-type="table">1</xref>. One study was from Singapore, one from Korea, one from Spain, one from America, and one from Iranian. The rest of the studies were all from China. The number of patients ranged from 1 to 2490, and male patients ranged from 0 to 1408. Twenty&#x2010;nine studies were case reports, sixteen studies were case series, and the rest three studies were cohort studies. Total scores of the included studies ranged from 3 to 8 and mean scores were 5.69. The percentage scores were used for ordinal categorization of the studies as low quality (&#x2264;4, 25%), medium quality (5&#x2010;6, 43.8%), and high quality (&#x2265;7, 31.2%). The detailed results on quality assessment are listed in the Supporting Information material 1 (Table S1).</p>
        <fig position="float" fig-type="Figure" id="jmv26398-fig-0001">
          <label>Figure 1</label>
          <caption>
            <p>Flow diagram for the included studies</p>
          </caption>
          <graphic xlink:href="JMV-93-1057-g006" position="anchor" id="jats-graphic-1"/>
        </fig>
        <table-wrap position="float" id="jmv26398-tbl-0001" content-type="Table">
          <label>Table 1</label>
          <caption>
            <p>Characteristics of included studies</p>
          </caption>
          <table frame="hsides" rules="groups">
            <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
            <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
            <thead valign="bottom">
              <tr style="border-bottom:solid 1px #000000" valign="bottom">
                <th valign="bottom" rowspan="1" colspan="1">Author</th>
                <th valign="bottom" rowspan="1" colspan="1">Journal</th>
                <th valign="bottom" rowspan="1" colspan="1">Case number (N)</th>
                <th valign="bottom" rowspan="1" colspan="1">Male (n)</th>
                <th valign="bottom" rowspan="1" colspan="1">Female (n)</th>
                <th valign="bottom" rowspan="1" colspan="1">Study location</th>
                <th valign="bottom" rowspan="1" colspan="1">Study design</th>
                <th valign="bottom" rowspan="1" colspan="1">Total score</th>
              </tr>
            </thead>
            <tbody valign="top">
              <tr>
                <td valign="top" rowspan="1" colspan="1">Bialek et al<xref rid="jmv26398-bib-0059" ref-type="bibr">
<sup>59</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">MMWR Morb Mortal Wkly Rep</td>
                <td valign="top" rowspan="1" colspan="1">2490</td>
                <td valign="top" rowspan="1" colspan="1">1408</td>
                <td valign="top" rowspan="1" colspan="1">1082</td>
                <td valign="top" rowspan="1" colspan="1">America</td>
                <td valign="top" rowspan="1" colspan="1">Case series</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Dong et al<xref rid="jmv26398-bib-0002" ref-type="bibr">
<sup>2</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Pediatrics</td>
                <td valign="top" rowspan="1" colspan="1">2143</td>
                <td valign="top" rowspan="1" colspan="1">1213</td>
                <td valign="top" rowspan="1" colspan="1">930</td>
                <td valign="top" rowspan="1" colspan="1">China</td>
                <td valign="top" rowspan="1" colspan="1">Case series</td>
                <td valign="top" rowspan="1" colspan="1">7</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Ma et al<xref rid="jmv26398-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Chin J Contemp Pediatr</td>
                <td valign="top" rowspan="1" colspan="1">115</td>
                <td valign="top" rowspan="1" colspan="1">73</td>
                <td valign="top" rowspan="1" colspan="1">42</td>
                <td valign="top" rowspan="1" colspan="1">Wuhan</td>
                <td valign="top" rowspan="1" colspan="1">Case series</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Wang et al<xref rid="jmv26398-bib-0014" ref-type="bibr">
<sup>14</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Chin J Pediatr</td>
                <td valign="top" rowspan="1" colspan="1">34</td>
                <td valign="top" rowspan="1" colspan="1">14</td>
                <td valign="top" rowspan="1" colspan="1">20</td>
                <td valign="top" rowspan="1" colspan="1">Shenzhen</td>
                <td valign="top" rowspan="1" colspan="1">Case series</td>
                <td valign="top" rowspan="1" colspan="1">5</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Wang et al<xref rid="jmv26398-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Chin J Pediatr</td>
                <td valign="top" rowspan="1" colspan="1">31</td>
                <td valign="top" rowspan="1" colspan="1">NA</td>
                <td valign="top" rowspan="1" colspan="1">NA</td>
                <td valign="top" rowspan="1" colspan="1">Six provinces in north China</td>
                <td valign="top" rowspan="1" colspan="1">Case series</td>
                <td valign="top" rowspan="1" colspan="1">7</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Cai et al<xref rid="jmv26398-bib-0016" ref-type="bibr">
<sup>16</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Clin Infect Dis</td>
                <td valign="top" rowspan="1" colspan="1">10</td>
                <td valign="top" rowspan="1" colspan="1">4</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
                <td valign="top" rowspan="1" colspan="1">Shanghai</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">4</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Feng et al<xref rid="jmv26398-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Chin J Pediatr</td>
                <td valign="top" rowspan="1" colspan="1">15</td>
                <td valign="top" rowspan="1" colspan="1">5</td>
                <td valign="top" rowspan="1" colspan="1">10</td>
                <td valign="top" rowspan="1" colspan="1">Shenzhen</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">7</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Su et al<xref rid="jmv26398-bib-0018" ref-type="bibr">
<sup>18</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Emerg Microbes Infect</td>
                <td valign="top" rowspan="1" colspan="1">9</td>
                <td valign="top" rowspan="1" colspan="1">3</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
                <td valign="top" rowspan="1" colspan="1">Jinan</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">7</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Zhou et al<xref rid="jmv26398-bib-0019" ref-type="bibr">
<sup>19</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Chin J Contemp Pediatr</td>
                <td valign="top" rowspan="1" colspan="1">9</td>
                <td valign="top" rowspan="1" colspan="1">4</td>
                <td valign="top" rowspan="1" colspan="1">5</td>
                <td valign="top" rowspan="1" colspan="1">Shenzhen</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Wei et al<xref rid="jmv26398-bib-0020" ref-type="bibr">
<sup>20</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">JAMA</td>
                <td valign="top" rowspan="1" colspan="1">9</td>
                <td valign="top" rowspan="1" colspan="1">2</td>
                <td valign="top" rowspan="1" colspan="1">7</td>
                <td valign="top" rowspan="1" colspan="1">Wuhan</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">5</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Liu et al<xref rid="jmv26398-bib-0021" ref-type="bibr">
<sup>21</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">NEJM</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
                <td valign="top" rowspan="1" colspan="1">2</td>
                <td valign="top" rowspan="1" colspan="1">4</td>
                <td valign="top" rowspan="1" colspan="1">Wuhan</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">7</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Cai et al<xref rid="jmv26398-bib-0022" ref-type="bibr">
<sup>22</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Chin J Pediatr</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">0</td>
                <td valign="top" rowspan="1" colspan="1">Shanghai</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">3</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Zhang et al<xref rid="jmv26398-bib-0023" ref-type="bibr">
<sup>23</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Chin J Pediatr</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">0</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">Hubei</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">3</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Ji et al<xref rid="jmv26398-bib-0024" ref-type="bibr">
<sup>24</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">World J Pediatr</td>
                <td valign="top" rowspan="1" colspan="1">2</td>
                <td valign="top" rowspan="1" colspan="1">2</td>
                <td valign="top" rowspan="1" colspan="1">0</td>
                <td valign="top" rowspan="1" colspan="1">Zhejiang</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">4</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Zhang et al<xref rid="jmv26398-bib-0025" ref-type="bibr">
<sup>25</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Chin J Contemp Pediatr</td>
                <td valign="top" rowspan="1" colspan="1">2</td>
                <td valign="top" rowspan="1" colspan="1">0</td>
                <td valign="top" rowspan="1" colspan="1">2</td>
                <td valign="top" rowspan="1" colspan="1">Hunan</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">3</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Wang et al<xref rid="jmv26398-bib-0026" ref-type="bibr">
<sup>26</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Chin J Contemp Pediatr</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">0</td>
                <td valign="top" rowspan="1" colspan="1">Wuhan</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">5</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Zhao et al<xref rid="jmv26398-bib-0027" ref-type="bibr">
<sup>27</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Zhejiang Medicine</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">0</td>
                <td valign="top" rowspan="1" colspan="1">Zhejiang</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">4</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Zeng et al<xref rid="jmv26398-bib-0028" ref-type="bibr">
<sup>28</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Chin J Pediatr</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">0</td>
                <td valign="top" rowspan="1" colspan="1">Wuhan</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">4</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Zhang et al<xref rid="jmv26398-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">J Med Virol</td>
                <td valign="top" rowspan="1" colspan="1">3</td>
                <td valign="top" rowspan="1" colspan="1">3</td>
                <td valign="top" rowspan="1" colspan="1">0</td>
                <td valign="top" rowspan="1" colspan="1">Tianjin</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">4</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Zeng et al<xref rid="jmv26398-bib-0030" ref-type="bibr">
<sup>30</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">JAMA Pediatrics</td>
                <td valign="top" rowspan="1" colspan="1">3</td>
                <td valign="top" rowspan="1" colspan="1">3</td>
                <td valign="top" rowspan="1" colspan="1">0</td>
                <td valign="top" rowspan="1" colspan="1">Wuhan</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">7</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Kam et al<xref rid="jmv26398-bib-0031" ref-type="bibr">
<sup>31</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Clin Infect Dis</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">0</td>
                <td valign="top" rowspan="1" colspan="1">Singapore</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">4</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Wu et al<xref rid="jmv26398-bib-0032" ref-type="bibr">
<sup>32</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Pediatrics</td>
                <td valign="top" rowspan="1" colspan="1">74</td>
                <td valign="top" rowspan="1" colspan="1">44</td>
                <td valign="top" rowspan="1" colspan="1">30</td>
                <td valign="top" rowspan="1" colspan="1">Shandong</td>
                <td valign="top" rowspan="1" colspan="1">Case series</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Xing et al<xref rid="jmv26398-bib-0033" ref-type="bibr">
<sup>33</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">J Mircobiol Immunol Infect</td>
                <td valign="top" rowspan="1" colspan="1">3</td>
                <td valign="top" rowspan="1" colspan="1">2</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">Shandong</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Park et al<xref rid="jmv26398-bib-0034" ref-type="bibr">
<sup>34</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">J Korean Med Sci</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">0</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">Korea</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">3</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Xia et al<xref rid="jmv26398-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Pediatr Pulmonol</td>
                <td valign="top" rowspan="1" colspan="1">20</td>
                <td valign="top" rowspan="1" colspan="1">13</td>
                <td valign="top" rowspan="1" colspan="1">7</td>
                <td valign="top" rowspan="1" colspan="1">Wuhan</td>
                <td valign="top" rowspan="1" colspan="1">Case series</td>
                <td valign="top" rowspan="1" colspan="1">5</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Tagarro et al<xref rid="jmv26398-bib-0036" ref-type="bibr">
<sup>36</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">JAMA Pediatr</td>
                <td valign="top" rowspan="1" colspan="1">41</td>
                <td valign="top" rowspan="1" colspan="1">18</td>
                <td valign="top" rowspan="1" colspan="1">23</td>
                <td valign="top" rowspan="1" colspan="1">Spain</td>
                <td valign="top" rowspan="1" colspan="1">Case series</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Zhu et al<xref rid="jmv26398-bib-0037" ref-type="bibr">
<sup>37</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Pediatr Pulmonol</td>
                <td valign="top" rowspan="1" colspan="1">10</td>
                <td valign="top" rowspan="1" colspan="1">5</td>
                <td valign="top" rowspan="1" colspan="1">5</td>
                <td valign="top" rowspan="1" colspan="1">Suzhou</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Qiu et al<xref rid="jmv26398-bib-0038" ref-type="bibr">
<sup>38</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Lancet Infect Dis</td>
                <td valign="top" rowspan="1" colspan="1">36</td>
                <td valign="top" rowspan="1" colspan="1">23</td>
                <td valign="top" rowspan="1" colspan="1">13</td>
                <td valign="top" rowspan="1" colspan="1">Zhejiang</td>
                <td valign="top" rowspan="1" colspan="1">Cohort study</td>
                <td valign="top" rowspan="1" colspan="1">7</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Yu et al<xref rid="jmv26398-bib-0039" ref-type="bibr">
<sup>39</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Pre&#x2010;print</td>
                <td valign="top" rowspan="1" colspan="1">82</td>
                <td valign="top" rowspan="1" colspan="1">51</td>
                <td valign="top" rowspan="1" colspan="1">31</td>
                <td valign="top" rowspan="1" colspan="1">Wuhan</td>
                <td valign="top" rowspan="1" colspan="1">Case series</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">liu et al<xref rid="jmv26398-bib-0040" ref-type="bibr">
<sup>40</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Chin J Nosocomiol</td>
                <td valign="top" rowspan="1" colspan="1">91</td>
                <td valign="top" rowspan="1" colspan="1">56</td>
                <td valign="top" rowspan="1" colspan="1">35</td>
                <td valign="top" rowspan="1" colspan="1">Wuhan</td>
                <td valign="top" rowspan="1" colspan="1">Case series</td>
                <td valign="top" rowspan="1" colspan="1">7</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Ma et al<xref rid="jmv26398-bib-0041" ref-type="bibr">
<sup>41</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">BMC Med</td>
                <td valign="top" rowspan="1" colspan="1">50</td>
                <td valign="top" rowspan="1" colspan="1">28</td>
                <td valign="top" rowspan="1" colspan="1">22</td>
                <td valign="top" rowspan="1" colspan="1">Wuhan</td>
                <td valign="top" rowspan="1" colspan="1">Cohort study</td>
                <td valign="top" rowspan="1" colspan="1">7</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Wang et al<xref rid="jmv26398-bib-0042" ref-type="bibr">
<sup>42</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Pre&#x2010;print</td>
                <td valign="top" rowspan="1" colspan="1">74</td>
                <td valign="top" rowspan="1" colspan="1">38</td>
                <td valign="top" rowspan="1" colspan="1">36</td>
                <td valign="top" rowspan="1" colspan="1">Wuhan</td>
                <td valign="top" rowspan="1" colspan="1">Case series</td>
                <td valign="top" rowspan="1" colspan="1">7</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Li et al<xref rid="jmv26398-bib-0043" ref-type="bibr">
<sup>43</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Radiol Practice</td>
                <td valign="top" rowspan="1" colspan="1">30</td>
                <td valign="top" rowspan="1" colspan="1">18</td>
                <td valign="top" rowspan="1" colspan="1">12</td>
                <td valign="top" rowspan="1" colspan="1">Wuhan</td>
                <td valign="top" rowspan="1" colspan="1">Case series</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Lu et al<xref rid="jmv26398-bib-0044" ref-type="bibr">
<sup>44</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Pediatr Infect Dis J</td>
                <td valign="top" rowspan="1" colspan="1">110</td>
                <td valign="top" rowspan="1" colspan="1">59</td>
                <td valign="top" rowspan="1" colspan="1">51</td>
                <td valign="top" rowspan="1" colspan="1">Wuhan</td>
                <td valign="top" rowspan="1" colspan="1">Cohort study</td>
                <td valign="top" rowspan="1" colspan="1">8</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Tang et al<xref rid="jmv26398-bib-0045" ref-type="bibr">
<sup>45</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Pre&#x2010;print</td>
                <td valign="top" rowspan="1" colspan="1">26</td>
                <td valign="top" rowspan="1" colspan="1">17</td>
                <td valign="top" rowspan="1" colspan="1">9</td>
                <td valign="top" rowspan="1" colspan="1">Shenzhen</td>
                <td valign="top" rowspan="1" colspan="1">Case series</td>
                <td valign="top" rowspan="1" colspan="1">7</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Zheng et al<xref rid="jmv26398-bib-0046" ref-type="bibr">
<sup>46</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Curr Med Sci</td>
                <td valign="top" rowspan="1" colspan="1">25</td>
                <td valign="top" rowspan="1" colspan="1">14</td>
                <td valign="top" rowspan="1" colspan="1">11</td>
                <td valign="top" rowspan="1" colspan="1">Wuhan</td>
                <td valign="top" rowspan="1" colspan="1">Case series</td>
                <td valign="top" rowspan="1" colspan="1">8</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Shen et al<xref rid="jmv26398-bib-0047" ref-type="bibr">
<sup>47</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Pediatr Pulmonol</td>
                <td valign="top" rowspan="1" colspan="1">9</td>
                <td valign="top" rowspan="1" colspan="1">3</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
                <td valign="top" rowspan="1" colspan="1">Huna</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Sun et al<xref rid="jmv26398-bib-0048" ref-type="bibr">
<sup>48</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">World J Pediatr</td>
                <td valign="top" rowspan="1" colspan="1">8</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
                <td valign="top" rowspan="1" colspan="1">2</td>
                <td valign="top" rowspan="1" colspan="1">Wuhan</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">5</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Golnar et al<xref rid="jmv26398-bib-0049" ref-type="bibr">
<sup>49</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">J Pediatr Rev</td>
                <td valign="top" rowspan="1" colspan="1">9</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
                <td valign="top" rowspan="1" colspan="1">3</td>
                <td valign="top" rowspan="1" colspan="1">Iranian</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">4</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Liu et al<xref rid="jmv26398-bib-0050" ref-type="bibr">
<sup>50</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">J Infect</td>
                <td valign="top" rowspan="1" colspan="1">4</td>
                <td valign="top" rowspan="1" colspan="1">2</td>
                <td valign="top" rowspan="1" colspan="1">2</td>
                <td valign="top" rowspan="1" colspan="1">Wuhan</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">7</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Wu et al<xref rid="jmv26398-bib-0051" ref-type="bibr">
<sup>51</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Chin J Contemp Pediatr</td>
                <td valign="top" rowspan="1" colspan="1">23</td>
                <td valign="top" rowspan="1" colspan="1">9</td>
                <td valign="top" rowspan="1" colspan="1">14</td>
                <td valign="top" rowspan="1" colspan="1">Jiangxi</td>
                <td valign="top" rowspan="1" colspan="1">Case series</td>
                <td valign="top" rowspan="1" colspan="1">8</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Tan et al<xref rid="jmv26398-bib-0052" ref-type="bibr">
<sup>52</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Chin J Contemp Pediatr</td>
                <td valign="top" rowspan="1" colspan="1">13</td>
                <td valign="top" rowspan="1" colspan="1">4</td>
                <td valign="top" rowspan="1" colspan="1">9</td>
                <td valign="top" rowspan="1" colspan="1">Changsha</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Yang et al<xref rid="jmv26398-bib-0053" ref-type="bibr">
<sup>53</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Journal of Shandong University (Health Sciences)</td>
                <td valign="top" rowspan="1" colspan="1">10</td>
                <td valign="top" rowspan="1" colspan="1">3</td>
                <td valign="top" rowspan="1" colspan="1">7</td>
                <td valign="top" rowspan="1" colspan="1">Shandong</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Zhang et al<xref rid="jmv26398-bib-0054" ref-type="bibr">
<sup>54</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Journal of Shandong University (Health Sciences)</td>
                <td valign="top" rowspan="1" colspan="1">10</td>
                <td valign="top" rowspan="1" colspan="1">3</td>
                <td valign="top" rowspan="1" colspan="1">7</td>
                <td valign="top" rowspan="1" colspan="1">Shandong</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Xu et al<xref rid="jmv26398-bib-0055" ref-type="bibr">
<sup>55</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Nat Med</td>
                <td valign="top" rowspan="1" colspan="1">10</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
                <td valign="top" rowspan="1" colspan="1">4</td>
                <td valign="top" rowspan="1" colspan="1">Guangzhou</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Zhang et al<xref rid="jmv26398-bib-0056" ref-type="bibr">
<sup>56</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">World Latest Medicine Information</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">0</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">Yunnan</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Chen et al<xref rid="jmv26398-bib-0057" ref-type="bibr">
<sup>57</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">Chin J Pediatr</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">1</td>
                <td valign="top" rowspan="1" colspan="1">0</td>
                <td valign="top" rowspan="1" colspan="1">Wuhan</td>
                <td valign="top" rowspan="1" colspan="1">Case report</td>
                <td valign="top" rowspan="1" colspan="1">4</td>
              </tr>
              <tr>
                <td valign="top" rowspan="1" colspan="1">Lu et al<xref rid="jmv26398-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref>
</td>
                <td valign="top" rowspan="1" colspan="1">NEJM</td>
                <td valign="top" rowspan="1" colspan="1">171</td>
                <td valign="top" rowspan="1" colspan="1">104</td>
                <td valign="top" rowspan="1" colspan="1">67</td>
                <td valign="top" rowspan="1" colspan="1">Wuhan</td>
                <td valign="top" rowspan="1" colspan="1">Case series</td>
                <td valign="top" rowspan="1" colspan="1">6</td>
              </tr>
            </tbody>
          </table>
          <permissions>
            <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
          </permissions>
        </table-wrap>
      </sec>
      <sec id="jmv26398-sec-0100">
        <label>3.2</label>
        <title>Characteristics of COVID&#x2010;19 in children</title>
        <sec id="jmv26398-sec-0110">
          <label>3.2.1</label>
          <title>Demographical characteristics</title>
          <p>Figure&#xA0;<xref rid="jmv26398-fig-0002" ref-type="fig">2</xref> presents a summary of the age distribution of all participants. Among all the children cases, 17% (95% CI: 15%&#x2010;18%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;48.6%) was under 1 year old at diagnosis, 24% (95% CI: 19%&#x2010;29%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;80.6%) 1 to 5 years old, 25% (95% CI: 19%&#x2010;31%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;88.7%) 6 to 10 years old, 20% (95% CI: 16%&#x2010;24%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;82.7%) 11 to 15 years old and 18% (95% CI: 8%&#x2010;28%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;96.7%) were 15 years old or more.</p>
          <fig position="float" fig-type="Figure" id="jmv26398-fig-0002">
            <label>Figure 2</label>
            <caption>
              <p>Summary results of the age distribution of all participants</p>
            </caption>
            <graphic xlink:href="JMV-93-1057-g005" position="anchor" id="jats-graphic-3"/>
          </fig>
          <p>Gender was shown as the proportion of males (M). Male gender of the children with COVID&#x2010;19 was 55% (95%CI: 53%&#x2010;58%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;33.4%; <italic toggle="yes">P</italic>&#x2009;=&#x2009;.030). The proportion of cases with known contact history was estimated at 72% (95% CI: 64%&#x2010;80%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;90.1%; <italic toggle="yes">P</italic>&#x2009;=&#x2009;.000).</p>
        </sec>
        <sec id="jmv26398-sec-0120">
          <label>3.2.2</label>
          <title>Illness severity</title>
          <p>Figure&#xA0;<xref rid="jmv26398-fig-0003" ref-type="fig">3</xref> presents a summary of the illness severity of all patients. Patients were divided into six groups as indicated based on disease severity from light to severe, mainly including: asymptomatic, mild, moderate, severe, critical, and death. Included patients were classified by their clinicians as asymptomatic 20% (95% CI: 14%&#x2010;26%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;91.4%), mildly 33% (95% CI: 23%&#x2010;43%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;95.6%), moderate 51% (95% CI: 42%&#x2010;61%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;93.4%), severely 7% (95% CI: 4%&#x2010;11%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;90.2%), critically 5% (95% CI: 2%&#x2010;9%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;84.5%), and death 0% (95% CI: 0%&#x2010;0%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;94.9%).</p>
          <fig position="float" fig-type="Figure" id="jmv26398-fig-0003">
            <label>Figure 3</label>
            <caption>
              <p>Summary results of illness severity in children with COVID&#x2010;19. The definition of illness severity was mentioned as follows: (A) without any clinical symptoms and signs. Chest imaging examination was normal, while the 2019&#x2010;nCoV nucleic acid test is positive. B, The main manifestations were acute upper respiratory tract infection and some children may have only digestive symptoms. Physical examination shows no auscultatory abnormalities. C, With pneumonia, some cases may have no clinical symptoms and signs, but chest CT shows lung lesions, which are subclinical. D, The disease usually progresses in about 1 week, and dyspnea occurs, oxygen saturation is less than 92%. E, Children can quickly progress to acute respiratory distress syndrome (ARDS) or respiratory failure, multiple organ dysfunction can be life&#x2010;threatening. COVID&#x2010;19, coronavirus disease 2019; CT, computed tomography</p>
            </caption>
            <graphic xlink:href="JMV-93-1057-g004" position="anchor" id="jats-graphic-5"/>
          </fig>
          <p>Among children under 1&#x2010;year old cases, asymptomatic 6% (95% CI: 5%&#x2010;13%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;24.3%), mildly 54% (95% CI: 49%&#x2010;59%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%), moderate 36% (95% CI: 27%&#x2010;45%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;4.0%), severely 7% (95% CI: 4%&#x2010;11%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;34.3%), and critically 14% (95% CI: 13%&#x2010;34%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;37.3%) (Table&#xA0;<xref rid="jmv26398-tbl-0002" ref-type="table">2</xref>).</p>
          <table-wrap position="float" id="jmv26398-tbl-0002" content-type="Table">
            <label>Table 2</label>
            <caption>
              <p>Comparison of meta&#x2010;analysis results among different ages patients with COVID&#x2010;19</p>
            </caption>
            <table frame="hsides" rules="groups">
              <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
              <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
              <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
              <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
              <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
              <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
              <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
              <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
              <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
              <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
              <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
              <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
              <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
              <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
              <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
              <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
              <col style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
              <thead valign="bottom">
                <tr valign="bottom">
                  <th style="border-bottom:solid 1px #000000" rowspan="3" valign="bottom" colspan="1">Study</th>
                  <th colspan="4" valign="bottom" rowspan="1">Present study</th>
                  <th colspan="4" valign="bottom" rowspan="1">Present study</th>
                  <th colspan="4" valign="bottom" rowspan="1">Rodriguez&#x2010;Morales AJ<xref rid="jmv26398-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>
</th>
                  <th colspan="4" valign="bottom" rowspan="1">Michael C Grant<xref rid="jmv26398-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref>
</th>
                </tr>
                <tr style="border-bottom:solid 1px #000000" valign="bottom">
                  <th colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">&lt;1 y</th>
                  <th colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">0&#x2010;18 y</th>
                  <th colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">&gt;18 y</th>
                  <th colspan="4" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">&gt;16 y</th>
                </tr>
                <tr valign="bottom" style="border-bottom:solid 1px #000000">
                  <th valign="bottom" rowspan="1" colspan="1">No. reports</th>
                  <th valign="bottom" rowspan="1" colspan="1">No. patients</th>
                  <th valign="bottom" rowspan="1" colspan="1">Prevalence (%)</th>
                  <th valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">I</italic>
<sup>2</sup> (%)</th>
                  <th valign="bottom" rowspan="1" colspan="1">No. reports</th>
                  <th valign="bottom" rowspan="1" colspan="1">No. patients</th>
                  <th valign="bottom" rowspan="1" colspan="1">Prevalence (%)</th>
                  <th valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">I</italic>
<sup>2</sup> (%)</th>
                  <th valign="bottom" rowspan="1" colspan="1">No. reports</th>
                  <th valign="bottom" rowspan="1" colspan="1">No. patients</th>
                  <th valign="bottom" rowspan="1" colspan="1">Prevalence (%)</th>
                  <th valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">I</italic>
<sup>2</sup> (%)</th>
                  <th valign="bottom" rowspan="1" colspan="1">No. reports</th>
                  <th valign="bottom" rowspan="1" colspan="1">No. patients</th>
                  <th valign="bottom" rowspan="1" colspan="1">Prevalence (%)</th>
                  <th valign="bottom" rowspan="1" colspan="1">
<italic toggle="yes">I</italic>
<sup>2</sup> (%)</th>
                </tr>
              </thead>
              <tbody valign="top">
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Male</td>
                  <td valign="top" rowspan="1" colspan="1">11</td>
                  <td valign="top" rowspan="1" colspan="1">27</td>
                  <td valign="top" rowspan="1" colspan="1">46 (22&#x2010;66)</td>
                  <td valign="top" rowspan="1" colspan="1">33.7</td>
                  <td valign="top" rowspan="1" colspan="1">36</td>
                  <td valign="top" rowspan="1" colspan="1">5838</td>
                  <td valign="top" rowspan="1" colspan="1">55 (53&#x2010;58)</td>
                  <td valign="top" rowspan="1" colspan="1">33.4</td>
                  <td valign="top" rowspan="1" colspan="1">22</td>
                  <td valign="top" rowspan="1" colspan="1">2874</td>
                  <td valign="top" rowspan="1" colspan="1">55.9 (51.6&#x2010;60.1)</td>
                  <td valign="top" rowspan="1" colspan="1">66.1</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Asymptomatic</td>
                  <td valign="top" rowspan="1" colspan="1">11</td>
                  <td valign="top" rowspan="1" colspan="1">433</td>
                  <td valign="top" rowspan="1" colspan="1">6 (5&#x2010;13)</td>
                  <td valign="top" rowspan="1" colspan="1">24.3</td>
                  <td valign="top" rowspan="1" colspan="1">42</td>
                  <td valign="top" rowspan="1" colspan="1">3287</td>
                  <td valign="top" rowspan="1" colspan="1">20 (14&#x2010;26)</td>
                  <td valign="top" rowspan="1" colspan="1">91.4</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Mild</td>
                  <td valign="top" rowspan="1" colspan="1">10</td>
                  <td valign="top" rowspan="1" colspan="1">395</td>
                  <td valign="top" rowspan="1" colspan="1">54 (49&#x2010;59)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">42</td>
                  <td valign="top" rowspan="1" colspan="1">3048</td>
                  <td valign="top" rowspan="1" colspan="1">33 (23&#x2010;43)</td>
                  <td valign="top" rowspan="1" colspan="1">95.6</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Moderate</td>
                  <td valign="top" rowspan="1" colspan="1">10</td>
                  <td valign="top" rowspan="1" colspan="1">395</td>
                  <td valign="top" rowspan="1" colspan="1">36 (27&#x2010;45)</td>
                  <td valign="top" rowspan="1" colspan="1">4</td>
                  <td valign="top" rowspan="1" colspan="1">40</td>
                  <td valign="top" rowspan="1" colspan="1">3046</td>
                  <td valign="top" rowspan="1" colspan="1">51 (42&#x2010;61)</td>
                  <td valign="top" rowspan="1" colspan="1">93.4</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Severe</td>
                  <td valign="top" rowspan="1" colspan="1">12</td>
                  <td valign="top" rowspan="1" colspan="1">499</td>
                  <td valign="top" rowspan="1" colspan="1">7 (4&#x2010;11)</td>
                  <td valign="top" rowspan="1" colspan="1">34.3</td>
                  <td valign="top" rowspan="1" colspan="1">41</td>
                  <td valign="top" rowspan="1" colspan="1">3775</td>
                  <td valign="top" rowspan="1" colspan="1">7 (4&#x2010;11)</td>
                  <td valign="top" rowspan="1" colspan="1">90.2</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Critical</td>
                  <td valign="top" rowspan="1" colspan="1">11</td>
                  <td valign="top" rowspan="1" colspan="1">404</td>
                  <td valign="top" rowspan="1" colspan="1">14 (13&#x2010;34)</td>
                  <td valign="top" rowspan="1" colspan="1">37.3</td>
                  <td valign="top" rowspan="1" colspan="1">42</td>
                  <td valign="top" rowspan="1" colspan="1">3121</td>
                  <td valign="top" rowspan="1" colspan="1">5 (2&#x2010;9)</td>
                  <td valign="top" rowspan="1" colspan="1">87.5</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Death</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">42</td>
                  <td valign="top" rowspan="1" colspan="1">5684</td>
                  <td valign="top" rowspan="1" colspan="1">0 (0&#x2010;0)</td>
                  <td valign="top" rowspan="1" colspan="1">94.9</td>
                  <td valign="top" rowspan="1" colspan="1">7</td>
                  <td valign="top" rowspan="1" colspan="1">632</td>
                  <td valign="top" rowspan="1" colspan="1">13.9 (6.2&#x2010;21.5)</td>
                  <td valign="top" rowspan="1" colspan="1">91.4</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Fever</td>
                  <td valign="top" rowspan="1" colspan="1">11</td>
                  <td valign="top" rowspan="1" colspan="1">24</td>
                  <td valign="top" rowspan="1" colspan="1">53 (30&#x2010;76)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">48</td>
                  <td valign="top" rowspan="1" colspan="1">1494</td>
                  <td valign="top" rowspan="1" colspan="1">51 (45&#x2010;57)</td>
                  <td valign="top" rowspan="1" colspan="1">78.9</td>
                  <td valign="top" rowspan="1" colspan="1">13</td>
                  <td valign="top" rowspan="1" colspan="1">735</td>
                  <td valign="top" rowspan="1" colspan="1">92.8 (89.4&#x2010;96.2)</td>
                  <td valign="top" rowspan="1" colspan="1">82.4</td>
                  <td valign="top" rowspan="1" colspan="1">138</td>
                  <td valign="top" rowspan="1" colspan="1">21701</td>
                  <td valign="top" rowspan="1" colspan="1">78 (75&#x2010;81)</td>
                  <td valign="top" rowspan="1" colspan="1">94</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Cough</td>
                  <td valign="top" rowspan="1" colspan="1">9</td>
                  <td valign="top" rowspan="1" colspan="1">19</td>
                  <td valign="top" rowspan="1" colspan="1">30 (2&#x2010;58)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">45</td>
                  <td valign="top" rowspan="1" colspan="1">1435</td>
                  <td valign="top" rowspan="1" colspan="1">41 (35&#x2010;47)</td>
                  <td valign="top" rowspan="1" colspan="1">81</td>
                  <td valign="top" rowspan="1" colspan="1">13</td>
                  <td valign="top" rowspan="1" colspan="1">735</td>
                  <td valign="top" rowspan="1" colspan="1">63.4 (48.0&#x2010;78.8)</td>
                  <td valign="top" rowspan="1" colspan="1">97.1</td>
                  <td valign="top" rowspan="1" colspan="1">138</td>
                  <td valign="top" rowspan="1" colspan="1">21682</td>
                  <td valign="top" rowspan="1" colspan="1">57 (54&#x2010;60)</td>
                  <td valign="top" rowspan="1" colspan="1">94</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Sore throat</td>
                  <td valign="top" rowspan="1" colspan="1">7</td>
                  <td valign="top" rowspan="1" colspan="1">10</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">38</td>
                  <td valign="top" rowspan="1" colspan="1">1040</td>
                  <td valign="top" rowspan="1" colspan="1">16 (7&#x2010;25)</td>
                  <td valign="top" rowspan="1" colspan="1">91.6</td>
                  <td valign="top" rowspan="1" colspan="1">5</td>
                  <td valign="top" rowspan="1" colspan="1">308</td>
                  <td valign="top" rowspan="1" colspan="1">11 (2.8&#x2010;19.2)</td>
                  <td valign="top" rowspan="1" colspan="1">85.4</td>
                  <td valign="top" rowspan="1" colspan="1">78</td>
                  <td valign="top" rowspan="1" colspan="1">11721</td>
                  <td valign="top" rowspan="1" colspan="1">12 (10&#x2010;14)</td>
                  <td valign="top" rowspan="1" colspan="1">88</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Tachycardia</td>
                  <td valign="top" rowspan="1" colspan="1">5</td>
                  <td valign="top" rowspan="1" colspan="1">7</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">35</td>
                  <td valign="top" rowspan="1" colspan="1">950</td>
                  <td valign="top" rowspan="1" colspan="1">12 (3&#x2010;21)</td>
                  <td valign="top" rowspan="1" colspan="1">93.9</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Rhinorrhea</td>
                  <td valign="top" rowspan="1" colspan="1">8</td>
                  <td valign="top" rowspan="1" colspan="1">17</td>
                  <td valign="top" rowspan="1" colspan="1">21 (5&#x2010;43)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">36</td>
                  <td valign="top" rowspan="1" colspan="1">990</td>
                  <td valign="top" rowspan="1" colspan="1">14 (8&#x2010;19)</td>
                  <td valign="top" rowspan="1" colspan="1">75.4</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">36</td>
                  <td valign="top" rowspan="1" colspan="1">10656</td>
                  <td valign="top" rowspan="1" colspan="1">8 (5&#x2010;12)</td>
                  <td valign="top" rowspan="1" colspan="1">97</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Nasal congestion</td>
                  <td valign="top" rowspan="1" colspan="1">6</td>
                  <td valign="top" rowspan="1" colspan="1">9</td>
                  <td valign="top" rowspan="1" colspan="1">50 (20&#x2010;99)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">33</td>
                  <td valign="top" rowspan="1" colspan="1">623</td>
                  <td valign="top" rowspan="1" colspan="1">17 (6&#x2010;27)</td>
                  <td valign="top" rowspan="1" colspan="1">87.2</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">10</td>
                  <td valign="top" rowspan="1" colspan="1">2584</td>
                  <td valign="top" rowspan="1" colspan="1">5 (3&#x2010;7)</td>
                  <td valign="top" rowspan="1" colspan="1">78</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Tachypnea</td>
                  <td valign="top" rowspan="1" colspan="1">6</td>
                  <td valign="top" rowspan="1" colspan="1">10</td>
                  <td valign="top" rowspan="1" colspan="1">33 (20&#x2010;57)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">29</td>
                  <td valign="top" rowspan="1" colspan="1">1034</td>
                  <td valign="top" rowspan="1" colspan="1">9 (4&#x2010;14)</td>
                  <td valign="top" rowspan="1" colspan="1">87.4</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Diarrhea</td>
                  <td valign="top" rowspan="1" colspan="1">7</td>
                  <td valign="top" rowspan="1" colspan="1">10</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">42</td>
                  <td valign="top" rowspan="1" colspan="1">1250</td>
                  <td valign="top" rowspan="1" colspan="1">8 (6&#x2010;11)</td>
                  <td valign="top" rowspan="1" colspan="1">47</td>
                  <td valign="top" rowspan="1" colspan="1">6</td>
                  <td valign="top" rowspan="1" colspan="1">457</td>
                  <td valign="top" rowspan="1" colspan="1">6.1 (2.4&#x2010;9.7)</td>
                  <td valign="top" rowspan="1" colspan="1">62.1</td>
                  <td valign="top" rowspan="1" colspan="1">93</td>
                  <td valign="top" rowspan="1" colspan="1">11707</td>
                  <td valign="top" rowspan="1" colspan="1">10 (8&#x2010;12)</td>
                  <td valign="top" rowspan="1" colspan="1">93</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Vomiting</td>
                  <td valign="top" rowspan="1" colspan="1">7</td>
                  <td valign="top" rowspan="1" colspan="1">12</td>
                  <td valign="top" rowspan="1" colspan="1">33 (18&#x2010;67)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">42</td>
                  <td valign="top" rowspan="1" colspan="1">1238</td>
                  <td valign="top" rowspan="1" colspan="1">7 (5&#x2010;10)</td>
                  <td valign="top" rowspan="1" colspan="1">50.4</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">26</td>
                  <td valign="top" rowspan="1" colspan="1">4959</td>
                  <td valign="top" rowspan="1" colspan="1">4 (2&#x2010;8)</td>
                  <td valign="top" rowspan="1" colspan="1">94</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Myalgia or Fatigue</td>
                  <td valign="top" rowspan="1" colspan="1">6</td>
                  <td valign="top" rowspan="1" colspan="1">9</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">42</td>
                  <td valign="top" rowspan="1" colspan="1">1253</td>
                  <td valign="top" rowspan="1" colspan="1">12 (7&#x2010;17)</td>
                  <td valign="top" rowspan="1" colspan="1">77.7</td>
                  <td valign="top" rowspan="1" colspan="1">11</td>
                  <td valign="top" rowspan="1" colspan="1">446</td>
                  <td valign="top" rowspan="1" colspan="1">29.4 (19.8&#x2010;39.0)</td>
                  <td valign="top" rowspan="1" colspan="1">80.7</td>
                  <td valign="top" rowspan="1" colspan="1">78</td>
                  <td valign="top" rowspan="1" colspan="1">13385</td>
                  <td valign="top" rowspan="1" colspan="1">31 (27&#x2010;35)</td>
                  <td valign="top" rowspan="1" colspan="1">95</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Hypoxemia</td>
                  <td valign="top" rowspan="1" colspan="1">5</td>
                  <td valign="top" rowspan="1" colspan="1">7</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">33</td>
                  <td valign="top" rowspan="1" colspan="1">623</td>
                  <td valign="top" rowspan="1" colspan="1">3 (1&#x2010;4)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">8</td>
                  <td valign="top" rowspan="1" colspan="1">656</td>
                  <td valign="top" rowspan="1" colspan="1">45.6 (10.9&#x2010;80.4)</td>
                  <td valign="top" rowspan="1" colspan="1">99.5</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Chest pain</td>
                  <td valign="top" rowspan="1" colspan="1">5</td>
                  <td valign="top" rowspan="1" colspan="1">7</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">34</td>
                  <td valign="top" rowspan="1" colspan="1">673</td>
                  <td valign="top" rowspan="1" colspan="1">3 (0&#x2010;5)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">30</td>
                  <td valign="top" rowspan="1" colspan="1">3510</td>
                  <td valign="top" rowspan="1" colspan="1">7 (4&#x2010;10)</td>
                  <td valign="top" rowspan="1" colspan="1">92</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Leukocytosis</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">38</td>
                  <td valign="top" rowspan="1" colspan="1">907</td>
                  <td valign="top" rowspan="1" colspan="1">10 (7&#x2010;14)</td>
                  <td valign="top" rowspan="1" colspan="1">63.1</td>
                  <td valign="top" rowspan="1" colspan="1">7</td>
                  <td valign="top" rowspan="1" colspan="1">487</td>
                  <td valign="top" rowspan="1" colspan="1">16.8 (5.5&#x2010;28.0)</td>
                  <td valign="top" rowspan="1" colspan="1">93.1</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Leukopenia</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">42</td>
                  <td valign="top" rowspan="1" colspan="1">978</td>
                  <td valign="top" rowspan="1" colspan="1">19 (14&#x2010;25)</td>
                  <td valign="top" rowspan="1" colspan="1">80.9</td>
                  <td valign="top" rowspan="1" colspan="1">8</td>
                  <td valign="top" rowspan="1" colspan="1">517</td>
                  <td valign="top" rowspan="1" colspan="1">18.7 (8.5&#x2010;28.8)</td>
                  <td valign="top" rowspan="1" colspan="1">94.5</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Lymphopenia</td>
                  <td valign="top" rowspan="1" colspan="1">5</td>
                  <td valign="top" rowspan="1" colspan="1">9</td>
                  <td valign="top" rowspan="1" colspan="1">33 (24&#x2010;47)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">39</td>
                  <td valign="top" rowspan="1" colspan="1">795</td>
                  <td valign="top" rowspan="1" colspan="1">16 (11&#x2010;21)</td>
                  <td valign="top" rowspan="1" colspan="1">76.9</td>
                  <td valign="top" rowspan="1" colspan="1">8</td>
                  <td valign="top" rowspan="1" colspan="1">511</td>
                  <td valign="top" rowspan="1" colspan="1">43.1 (18.9&#x2010;67.3)</td>
                  <td valign="top" rowspan="1" colspan="1">98</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">High PCT</td>
                  <td valign="top" rowspan="1" colspan="1">7</td>
                  <td valign="top" rowspan="1" colspan="1">10</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">29</td>
                  <td valign="top" rowspan="1" colspan="1">709</td>
                  <td valign="top" rowspan="1" colspan="1">36 (21&#x2010;51)</td>
                  <td valign="top" rowspan="1" colspan="1">97.0</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">High CRP</td>
                  <td valign="top" rowspan="1" colspan="1">9</td>
                  <td valign="top" rowspan="1" colspan="1">15</td>
                  <td valign="top" rowspan="1" colspan="1">42 (6&#x2010;78)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">32</td>
                  <td valign="top" rowspan="1" colspan="1">651</td>
                  <td valign="top" rowspan="1" colspan="1">19 (13&#x2010;26)</td>
                  <td valign="top" rowspan="1" colspan="1">79.3</td>
                  <td valign="top" rowspan="1" colspan="1">6</td>
                  <td valign="top" rowspan="1" colspan="1">332</td>
                  <td valign="top" rowspan="1" colspan="1">58.3 (21.8&#x2010;94.7)</td>
                  <td valign="top" rowspan="1" colspan="1">98.9</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">High LDH</td>
                  <td valign="top" rowspan="1" colspan="1">4</td>
                  <td valign="top" rowspan="1" colspan="1">7</td>
                  <td valign="top" rowspan="1" colspan="1">50 (15&#x2010;69)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">24</td>
                  <td valign="top" rowspan="1" colspan="1">301</td>
                  <td valign="top" rowspan="1" colspan="1">29 (20&#x2010;39)</td>
                  <td valign="top" rowspan="1" colspan="1">69.8</td>
                  <td valign="top" rowspan="1" colspan="1">5</td>
                  <td valign="top" rowspan="1" colspan="1">341</td>
                  <td valign="top" rowspan="1" colspan="1">57.0 (38.0&#x2010;76.0)</td>
                  <td valign="top" rowspan="1" colspan="1">92.6</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">High ALT</td>
                  <td valign="top" rowspan="1" colspan="1">7</td>
                  <td valign="top" rowspan="1" colspan="1">25</td>
                  <td valign="top" rowspan="1" colspan="1">47 (25&#x2010;69)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">32</td>
                  <td valign="top" rowspan="1" colspan="1">686</td>
                  <td valign="top" rowspan="1" colspan="1">11 (7&#x2010;15)</td>
                  <td valign="top" rowspan="1" colspan="1">38.5</td>
                  <td valign="top" rowspan="1" colspan="1">2</td>
                  <td valign="top" rowspan="1" colspan="1">128</td>
                  <td valign="top" rowspan="1" colspan="1">24.1 (13.5&#x2010;34.6)</td>
                  <td valign="top" rowspan="1" colspan="1">42.8</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">High AST</td>
                  <td valign="top" rowspan="1" colspan="1">7</td>
                  <td valign="top" rowspan="1" colspan="1">14</td>
                  <td valign="top" rowspan="1" colspan="1">33 (20&#x2010;67)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">28</td>
                  <td valign="top" rowspan="1" colspan="1">529</td>
                  <td valign="top" rowspan="1" colspan="1">18 (13&#x2010;23)</td>
                  <td valign="top" rowspan="1" colspan="1">48.6</td>
                  <td valign="top" rowspan="1" colspan="1">3</td>
                  <td valign="top" rowspan="1" colspan="1">169</td>
                  <td valign="top" rowspan="1" colspan="1">33.3 (26.3&#x2010;40.4)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">High Creatinine</td>
                  <td valign="top" rowspan="1" colspan="1">5</td>
                  <td valign="top" rowspan="1" colspan="1">20</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">3</td>
                  <td valign="top" rowspan="1" colspan="1">169</td>
                  <td valign="top" rowspan="1" colspan="1">4.5 (1.0&#x2010;8.0)</td>
                  <td valign="top" rowspan="1" colspan="1">10.2</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">High Blood urea nitrogen</td>
                  <td valign="top" rowspan="1" colspan="1">4</td>
                  <td valign="top" rowspan="1" colspan="1">18</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">High CK</td>
                  <td valign="top" rowspan="1" colspan="1">2</td>
                  <td valign="top" rowspan="1" colspan="1">3</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">17</td>
                  <td valign="top" rowspan="1" colspan="1">109</td>
                  <td valign="top" rowspan="1" colspan="1">9 (1&#x2010;17)</td>
                  <td valign="top" rowspan="1" colspan="1">33.2</td>
                  <td valign="top" rowspan="1" colspan="1">2</td>
                  <td valign="top" rowspan="1" colspan="1">140</td>
                  <td valign="top" rowspan="1" colspan="1">21.3 (3.2&#x2010;39.4)</td>
                  <td valign="top" rowspan="1" colspan="1">81.4</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">High CK&#x2010;MB</td>
                  <td valign="top" rowspan="1" colspan="1">4</td>
                  <td valign="top" rowspan="1" colspan="1">21</td>
                  <td valign="top" rowspan="1" colspan="1">88 (71&#x2010;94)</td>
                  <td valign="top" rowspan="1" colspan="1">8.5</td>
                  <td valign="top" rowspan="1" colspan="1">23</td>
                  <td valign="top" rowspan="1" colspan="1">228</td>
                  <td valign="top" rowspan="1" colspan="1">37 (25&#x2010;48)</td>
                  <td valign="top" rowspan="1" colspan="1">59.0</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">High D&#x2010;dimer</td>
                  <td valign="top" rowspan="1" colspan="1">4</td>
                  <td valign="top" rowspan="1" colspan="1">5</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">24</td>
                  <td valign="top" rowspan="1" colspan="1">194</td>
                  <td valign="top" rowspan="1" colspan="1">11 (8&#x2010;14)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Normal Imaging</td>
                  <td valign="top" rowspan="1" colspan="1">8</td>
                  <td valign="top" rowspan="1" colspan="1">13</td>
                  <td valign="top" rowspan="1" colspan="1">42 (6&#x2010;78)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">38</td>
                  <td valign="top" rowspan="1" colspan="1">902</td>
                  <td valign="top" rowspan="1" colspan="1">41 (30&#x2010;52)</td>
                  <td valign="top" rowspan="1" colspan="1">93.4</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Ground&#x2010;glass opacity</td>
                  <td valign="top" rowspan="1" colspan="1">8</td>
                  <td valign="top" rowspan="1" colspan="1">14</td>
                  <td valign="top" rowspan="1" colspan="1">50 (20&#x2010;80)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">39</td>
                  <td valign="top" rowspan="1" colspan="1">898</td>
                  <td valign="top" rowspan="1" colspan="1">36 (25&#x2010;47)</td>
                  <td valign="top" rowspan="1" colspan="1">92.9</td>
                  <td valign="top" rowspan="1" colspan="1">10</td>
                  <td valign="top" rowspan="1" colspan="1">584</td>
                  <td valign="top" rowspan="1" colspan="1">68.5 (51.8&#x2010;85.2)</td>
                  <td valign="top" rowspan="1" colspan="1">99.1</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Local patchy shadow</td>
                  <td valign="top" rowspan="1" colspan="1">7</td>
                  <td valign="top" rowspan="1" colspan="1">11</td>
                  <td valign="top" rowspan="1" colspan="1">42 (6&#x2010;78)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">35</td>
                  <td valign="top" rowspan="1" colspan="1">928</td>
                  <td valign="top" rowspan="1" colspan="1">26 (21&#x2010;32)</td>
                  <td valign="top" rowspan="1" colspan="1">58.2</td>
                  <td valign="top" rowspan="1" colspan="1">7</td>
                  <td valign="top" rowspan="1" colspan="1">316</td>
                  <td valign="top" rowspan="1" colspan="1">25 (5.2&#x2010;44.8)</td>
                  <td valign="top" rowspan="1" colspan="1">96.4</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Bilateral patchy shadow</td>
                  <td valign="top" rowspan="1" colspan="1">7</td>
                  <td valign="top" rowspan="1" colspan="1">11</td>
                  <td valign="top" rowspan="1" colspan="1">40 (13&#x2010;55)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">34</td>
                  <td valign="top" rowspan="1" colspan="1">814</td>
                  <td valign="top" rowspan="1" colspan="1">28 (21&#x2010;35)</td>
                  <td valign="top" rowspan="1" colspan="1">73.8</td>
                  <td valign="top" rowspan="1" colspan="1">7</td>
                  <td valign="top" rowspan="1" colspan="1">508</td>
                  <td valign="top" rowspan="1" colspan="1">70.7 (50.4&#x2010;91.0)</td>
                  <td valign="top" rowspan="1" colspan="1">98.7</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">White lung change</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">32</td>
                  <td valign="top" rowspan="1" colspan="1">653</td>
                  <td valign="top" rowspan="1" colspan="1">2 (0&#x2010;4)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
                <tr>
                  <td valign="top" rowspan="1" colspan="1">Pleural effusion</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">35</td>
                  <td valign="top" rowspan="1" colspan="1">769</td>
                  <td valign="top" rowspan="1" colspan="1">2 (0&#x2010;3)</td>
                  <td valign="top" rowspan="1" colspan="1">0</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                  <td valign="top" rowspan="1" colspan="1">NA</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="jmv26398-tbl2-note-0001">
                <p>Abbreviation: COVID&#x2010;19, coronavirus disease 2019.</p>
              </fn>
            </table-wrap-foot>
            <permissions>
              <copyright-holder>John Wiley &amp; Sons, Ltd.</copyright-holder>
            </permissions>
          </table-wrap>
        </sec>
        <sec id="jmv26398-sec-0130">
          <label>3.2.3</label>
          <title>Clinical presentation</title>
          <p>Figure&#xA0;<xref rid="jmv26398-fig-0004" ref-type="fig">4</xref> presents a summary of the clinical presentation of all children. The most common clinical manifestations were fever 51% (95% CI: 45%&#x2010;57%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;78.9%), cough 41% (95% CI: 35%&#x2010;47%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;81.0%), sore throat 16% (95% CI: 7%&#x2010;25%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;91.6%), tachycardia 12% (95% CI: 3%&#x2010;21%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;93.9%), rhinorrhea 14% (95% CI: 8%&#x2010;19%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;75.4%), nasal congestion 17% (95% CI: 6%&#x2010;27%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;87.2%), tachypnea 9% (95% CI: 4%&#x2010;14%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;87.4%), diarrhea 8% (95% CI: 6%&#x2010;11%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;47.0%), vomiting 7% (95% CI: 5%&#x2010;10%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;50.4%), myalgia or fatigue 12% (95% CI: 7%&#x2010;17%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;77.7%), hypoxemia 3% (95% CI: 1%&#x2010;4%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%) and chest pain 3% (95% CI: 0%&#x2010;5%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%).</p>
          <fig position="float" fig-type="Figure" id="jmv26398-fig-0004">
            <label>Figure 4</label>
            <caption>
              <p>Aggregated results of clinical presentation in children with COVID&#x2010;19. COVID&#x2010;19, coronavirus disease 2019</p>
            </caption>
            <graphic xlink:href="JMV-93-1057-g003" position="anchor" id="jats-graphic-7"/>
          </fig>
          <p>Among children under 1&#x2010;year old cases, fever 53% (95% CI: 30%&#x2010;76%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%), cough 30% (95% CI: 2%&#x2010;58%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%), rhinorrhea 21% (95% CI: 5%&#x2010;43%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%), nasal congestion 50% (95% CI: 20%&#x2010;99%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%), tachypnea 33% (95% CI: 20%&#x2010;57%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%) and vomiting 33% (95% CI: 18%&#x2010;67%, <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%) (Table&#xA0;<xref rid="jmv26398-tbl-0002" ref-type="table">2</xref>).</p>
        </sec>
        <sec id="jmv26398-sec-0140">
          <label>3.2.4</label>
          <title>Laboratory examination</title>
          <p>Laboratory examination results, which including blood routine test, liver function tests, renal function measurement, cardiac function, inflammatory factors, and D&#x2010;dimer, are shown in Figure&#xA0;<xref rid="jmv26398-fig-0005" ref-type="fig">5</xref>. With respect to laboratory findings, the proportion of normal white blood cells in COVID&#x2010;19 patients in children was 69% (95% CI: 64%&#x2010;75%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;58.5%). Leukocytosis (&gt;12&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L) was observed in 10% (95% CI: 7%&#x2010;14%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;63.1%) of patients, and 19% (95% CI: 14%&#x2010;25%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;80.9%) patient had leukopenia (&lt;5.5&#x2009;&#xD7;&#x2009;10<sup>9</sup>/L). The proportion of patients with lymphopenia was 16% (95% CI: 11%&#x2010;21%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;76.9%). The proportion of patients with high PCT 36% (95% CI: 21%&#x2010; 51%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;97.0%), CRP 19% (95% CI: 13%&#x2010;26%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;79.3%) and LDH 29% (95% CI: 20%&#x2010;39%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;69.8%), respectively. ALT and AST are indicative parameters for liver function, the high ALT and AST patients was 11% (95% CI: 7%&#x2010;15%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;38.5%) and 18% (95% CI: 13%&#x2010;23%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;48.6%), respectively. Creatine&#x2010;kinase (CK) and CK&#x2010;MB are indicative parameters for cardiac function, the high CK and CK&#x2010;MB was 9% (95% CI: 1%&#x2010;17%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;33.2%) and 37% (95% CI: 25%&#x2010;48%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;59.0%), respectively. We also evaluated the patients had elevated D&#x2010;dimer, result revealed that nearly 11% (95% CI: 8%&#x2010;14%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%).</p>
          <fig position="float" fig-type="Figure" id="jmv26398-fig-0005">
            <label>Figure 5</label>
            <caption>
              <p>Summary results of laboratory examination in children with COVID&#x2010;19. COVID&#x2010;19, coronavirus disease 2019</p>
            </caption>
            <graphic xlink:href="JMV-93-1057-g002" position="anchor" id="jats-graphic-9"/>
          </fig>
          <p>Among children under 1&#x2010;year old cases, the proportion of lymphopenia was 33% (95% CI: 24%&#x2010;47%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%). The ratio of elevated CRP and LDH were 42% (95% CI: 6%&#x2010;78%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%) and 50% (95% CI: 15%&#x2010;69%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%), respectively. The high ALT and AST patients were 47% (95% CI: 25%&#x2010;69%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%) and 33% (95% CI: 20%&#x2010;67%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%), respectively. The proportion of elevated CK&#x2010;MB was 88% (95% CI: 71%&#x2010;94%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;8.5%) (Table&#xA0;<xref rid="jmv26398-tbl-0002" ref-type="table">2</xref>).</p>
        </sec>
        <sec id="jmv26398-sec-0150">
          <label>3.2.5</label>
          <title>Imaging features</title>
          <p>Imaging features for patients were summarized in Figure&#xA0;<xref rid="jmv26398-fig-0006" ref-type="fig">6</xref>. All pediatric patients with normal imaging was 41% (95% CI: 30%&#x2010;52%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;93.4%), GGO 36% (95% CI: 25%&#x2010;47%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;92.9%), local patchy shadowing 26% (95% CI: 21%&#x2010;32%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;58.2%), bilateral patchy shadowing 28% (95% CI: 21%&#x2010;35%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;73.8%), white lung change was 2% (95% CI: 0%&#x2010;4%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%) and pleural effusion 2% (95% CI: 0%&#x2010;3%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%).</p>
          <fig position="float" fig-type="Figure" id="jmv26398-fig-0006">
            <label>Figure 6</label>
            <caption>
              <p>Pooled results of imaging features in children with COVID&#x2010;19. COVID&#x2010;19, coronavirus disease 2019</p>
            </caption>
            <graphic xlink:href="JMV-93-1057-g001" position="anchor" id="jats-graphic-11"/>
          </fig>
          <p>Among children under 1&#x2010;year old cases, the proportion of normal imaging was 42% (95% CI: 6%&#x2010;78%, <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%). The GGO accounted for 50% (95% CI: 20%&#x2010;80%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%) of lung abnormality. Local and bilateral patchy shadowing were 42% (95% CI: 6%&#x2010;78%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%) and 40% (95% CI: 13%&#x2010;55%; <italic toggle="yes">I</italic>
<sup>2</sup>&#x2009;=&#x2009;0.0%), respectively (Table&#xA0;<xref rid="jmv26398-tbl-0002" ref-type="table">2</xref>).</p>
        </sec>
        <sec id="jmv26398-sec-0160">
          <label>3.2.6</label>
          <title>Publication bias</title>
          <p>Publication bias was evaluated by Begg's test, which suggested that there was no notable evidence of publication bias except for 1 to 5 year (<italic toggle="yes">P</italic>&#x2009;=&#x2009;.004); asymptomatic (<italic toggle="yes">P</italic>&#x2009;=&#x2009;.000); critical (<italic toggle="yes">P</italic>&#x2009;=&#x2009;.008); diarrhea (<italic toggle="yes">P</italic>&#x2009;=&#x2009;.004); vomiting (<italic toggle="yes">P</italic>&#x2009;=&#x2009;.016); hypoxemia (<italic toggle="yes">P</italic>&#x2009;=&#x2009;.007); normal white blood cell (<italic toggle="yes">P</italic>&#x2009;=&#x2009;.002); leukocytosis (<italic toggle="yes">P</italic>&#x2009;=&#x2009;.002); leukopenia (<italic toggle="yes">P</italic>&#x2009;=&#x2009;.000); high CRP (<italic toggle="yes">P</italic>&#x2009;=&#x2009;.009) and pleural effusion (<italic toggle="yes">P</italic>&#x2009;=&#x2009;.001).</p>
        </sec>
        <sec id="jmv26398-sec-0170">
          <label>3.2.7</label>
          <title>Subgroup analysis</title>
          <p>Tables S2 to S6 present the results of subgroup analyses. Noncase reports included case series and cohort studies, case reports only referred to the study design of the case report. The findings were consistent in all subgroup analyses except for the 6 to 10 years, critical and tachycardia subgroups.</p>
        </sec>
      </sec>
    </sec>
    <sec sec-type="discussion" id="jmv26398-sec-0180">
      <label>4</label>
      <title>DISCUSSION</title>
      <p>We comprehensively examined the demographic, clinical characteristics, laboratory, and imaging features among pediatric patients with COVID&#x2010;19 and further made a meta&#x2010;analysis with literature studies. We also compared the characteristics of SARS&#x2010;CoV&#x2010;2 infection in children under 1 year old, children between 0 and 18 years old, as well as in adults (Table&#xA0;<xref rid="jmv26398-tbl-0002" ref-type="table">2</xref>). The main findings are as follows: first, SARS&#x2010;CoV&#x2010;2 was susceptible to all age groups of children, the most common clinical manifestations were fever and cough and the majority of them had experienced asymptomatic, mild and moderate illness; second, children were more likely to have normal leukocyte counts, whereas lymphocytosis occurred infrequently; Third, the incidence of critical illness and vomiting symptoms was high in children under 1 year old.</p>
      <p>The pandemic of COVID&#x2010;19 affected all age groups in children based on the current studies.<xref rid="jmv26398-bib-0003" ref-type="bibr">
<sup>3</sup>
</xref>, <xref rid="jmv26398-bib-0006" ref-type="bibr">
<sup>6</sup>
</xref>, <xref rid="jmv26398-bib-0061" ref-type="bibr">
<sup>61</sup>
</xref> Our result was consistent with those previous studies that there was no significant difference in age distribution of SARS&#x2010;CoV&#x2010;2 infection among children. The most common clinical manifestations of COVID&#x2010;19 pediatric patients were fever (51%) and cough (41%) from our meta&#x2010;analysis, which were lower than the fever (78.0%&#x2010;92.8%) and cough (57.0%&#x2010;63.4%) in adults.<xref rid="jmv26398-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref>, <xref rid="jmv26398-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="jmv26398-bib-0060" ref-type="bibr">
<sup>60</sup>
</xref> These findings further suggested that children's clinical symptoms were not typical when compared with adults. The frequency of severe illness was 7% in children with COVID&#x2010;19, which was lower than that in adults (25.6%).<xref rid="jmv26398-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> One possible reason might be that children are less likely to have underlying diseases such as diabetes, hypertension, or cardiovascular disease. In addition to the above reason, the fact that innate immune response declines with age could also be important for the difference.<xref rid="jmv26398-bib-0062" ref-type="bibr">
<sup>62</sup>
</xref> The percentage of asymptomatic in children with COVID&#x2010;19 was 20% and deserves full attention to control the ongoing pandemic.</p>
      <p>For the laboratory examination, normal leukocyte counts were up to 70% in children, which was as similar as 69.7% in adults.<xref rid="jmv26398-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref> The reduction of lymphocytes in children was only 16%, but in adults, it went up to 43.1%,<xref rid="jmv26398-bib-0004" ref-type="bibr">
<sup>4</sup>
</xref> 57.4%,<xref rid="jmv26398-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref> and 56%,<xref rid="jmv26398-bib-0063" ref-type="bibr">
<sup>63</sup>
</xref> respectively, reported by previous meta&#x2010;analysis. The reason for these differences may be related to the immune response of different organisms to novel coronavirus. The level of CK&#x2010;MB was raised in 37% of all children, which is one of the classical biomarkers of cardiotoxicity. Subgroup analysis further revealed CK&#x2010;MB was elevated in nearly 88% in children under 1 year old. These results suggested that we should pay special attention to the myocardial damage in children, especially for those under 1year old. It should be noted that the activity of CK&#x2010;MB was detected by immunosuppressive method, which is easy to be affected by the peripheral blood creatine&#x2010;kinase BB (CK&#x2010;BB). In addition, the blood&#x2010;brain barrier in children, especially in infants, is not fully developed, and more CK&#x2010;BB will appear in the peripheral blood, resulting in the high level of CK&#x2010;MB activity.<xref rid="jmv26398-bib-0064" ref-type="bibr">
<sup>64</sup>
</xref>, <xref rid="jmv26398-bib-0065" ref-type="bibr">
<sup>65</sup>
</xref>, <xref rid="jmv26398-bib-0066" ref-type="bibr">
<sup>66</sup>
</xref> In the future, specific studies are still needed to explain the causes and effects of CK&#x2010;MB elevation in children.</p>
      <p>The CT manifestations of COVID&#x2010;19 in pediatric patients are diverse and lack specificity depending on the severity of disease or clinical classification. Normal imaging occurred in 41% pediatric patients in our meta&#x2010;analysis, which are similar to the other two reports with the largest number of pediatric cases so far, the proportion of normal lung CT was 35% (60/171) and 57% (66/115), respectively,<xref rid="jmv26398-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="jmv26398-bib-0058" ref-type="bibr">
<sup>58</sup>
</xref> but, it was infrequent in adults, the rate of normal imaging was only 10%.<xref rid="jmv26398-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref> GGO was the most common performance in children presenting lung abnormality, which most located in the lower lung, outer band, near the pleura, and the scope was small compared with adults.<xref rid="jmv26398-bib-0013" ref-type="bibr">
<sup>13</sup>
</xref>, <xref rid="jmv26398-bib-0015" ref-type="bibr">
<sup>15</sup>
</xref>, <xref rid="jmv26398-bib-0017" ref-type="bibr">
<sup>17</sup>
</xref>, <xref rid="jmv26398-bib-0029" ref-type="bibr">
<sup>29</sup>
</xref>, <xref rid="jmv26398-bib-0035" ref-type="bibr">
<sup>35</sup>
</xref>, <xref rid="jmv26398-bib-0068" ref-type="bibr">
<sup>68</sup>
</xref>, <xref rid="jmv26398-bib-0069" ref-type="bibr">
<sup>69</sup>
</xref> Pediatric patients with GGO was 36%, significantly lower than adults with 80% to 83%.<xref rid="jmv26398-bib-0005" ref-type="bibr">
<sup>5</sup>
</xref>, <xref rid="jmv26398-bib-0067" ref-type="bibr">
<sup>67</sup>
</xref> This may be related to the fact that COVID&#x2010;19 in children shows milder than adults.</p>
      <p>The rate of critical illness in children under 1 year old was 14%, higher than 5% in all children. These results suggested that clinicians should pay more attention to changes in disease activity in children under 1 year old. A total of 33% and 7% suffer from vomiting in children under 1 year old and all children, respectively. Based on all the above facts, it was worth noting that the proportion of infants developing critical cases is relatively high, and the initial symptom often include vomiting. However, due to the limited sample size, large, well&#x2010;designed studies are still needed to confirm these findings.</p>
    </sec>
    <sec id="jmv26398-sec-0190">
      <label>5</label>
      <title>LIMITATION</title>
      <p>This meta&#x2010;analysis has several limitations that should be addressed. First, few cohort studies available for inclusion, and most of them come from China. Second, it's hard to standardize the results of laboratory testing and radiographic imaging from different data sources. Third, more detailed patient information in children under 1 year old is not available in large sample studies at the time of analysis, the results need to be further updated.</p>
    </sec>
    <sec sec-type="conclusions" id="jmv26398-sec-0200">
      <label>6</label>
      <title>CONCLUSION</title>
      <p>The COVID&#x2010;19 pandemic affects all age groups in children and appears to be a mild illness. The common presenting complaints with COVID&#x2010;19 are nonspecific symptoms, such as fever and cough. Normal leukocyte counts and infrequent of lymphopenia tend to be the laboratory characteristics. High incidence of critical illness and vomiting symptoms were as the main features in children under 1 year old. Characteristics of COVID&#x2010;19 in children and adults are different and thus special criteria is still needed for more studies to identify.</p>
    </sec>
    <sec sec-type="COI-statement" id="jmv26398-sec-0220">
      <title>CONFLICT OF INTERESTS</title>
      <p>The authors declare that there are no conflict of interests.</p>
    </sec>
    <sec id="jmv26398-sec-0230">
      <title>AUTHOR CONTRIBUTIONS</title>
      <p>All authors contributed to the intellectual content of this manuscript and approved the final manuscript as submitted. (a) Conception and design: Chunquan Cai, Yongming Shen; (b) collection, assembly of data: Xiaojian Cui, Tongqiang Zhang; (c) administrative support: Ping Si, Yongsheng Xu; (d) data analysis and interpretation: Zhihu Zhao, Wei Guo, Wenwei Guo, Jiayi Zhang; (e) search literatures: Cuicui Dong, Jiafeng Zheng, Ren Na, Lisheng Zheng, Wenliang Li, Zihui Liu, Jinhu Wang, Jia Ma; (f) manuscript writing: all authors; (g) final approval of manuscript: all authors.</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supporting information</title>
      <supplementary-material position="float" content-type="local-data">
        <caption>
          <p>Supporting information</p>
        </caption>
        <media xlink:href="JMV-93-1057-s001.doc">
          <caption>
            <p>Click here for additional data file.</p>
          </caption>
        </media>
      </supplementary-material>
    </sec>
  </body>
  <back>
    <ack id="jmv26398-sec-0210">
      <title>ACKNOWLEDGMENTS</title>
      <p>This work was supported by the National Natural Science Foundation of China (Grant number: 81771589), the Key Project of Tianjin Health Care Professionals (Grant number: 16KG166), and the Program of Tianjin Science and Technology Plan (Grant number 18ZXDBSY00170).</p>
    </ack>
    <sec sec-type="data-availability" id="jmv26398-sec-0250">
      <title>DATA AVAILABILITY STATEMENT</title>
      <p>The original data can be requested reasonably.</p>
    </sec>
    <ref-list content-type="cited-references" id="jmv26398-bibl-0001">
      <title>REFERENCES</title>
      <ref id="jmv26398-bib-0001">
        <label>1</label>
        <mixed-citation publication-type="miscellaneous" id="jmv26398-cit-0001">
<article-title>WHO Coronavirus Disease (COVID&#x2010;19) Dashboard</article-title>. <ext-link xlink:href="https://covid19.who.int/" ext-link-type="uri">https://covid19.who.int/</ext-link>
</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0002">
        <label>2</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0002">
<string-name>
<surname>Dong</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Mo</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>Y</given-names>
</string-name>, et al. <article-title>Epidemiology of COVID&#x2010;19 Among Children in China</article-title>. <source>Pediatrics</source>. <year>2020</year>;<volume>145</volume>(<issue>6</issue>):<elocation-id>e202007</elocation-id>
</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0003">
        <label>3</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0003">
<string-name>
<surname>Pathak</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>Salemi</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Sobers</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Menard</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hambleton</surname>
<given-names>IR</given-names>
</string-name>. <article-title>COVID&#x2010;19 in children in the United States: intensive care admissions, estimated total infected, and projected numbers of severe pediatric cases in 2020</article-title>. <source>J Public Health Manage Pract: JPHMP</source>. <year>2020</year>;<volume>26</volume>(<issue>4</issue>):<fpage>325</fpage>&#x2010;<lpage>333</lpage>.</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0004">
        <label>4</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0004">
<string-name>
<surname>Rodriguez&#x2010;Morales</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Cardona&#x2010;Ospina</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Guti&#xE9;rrez&#x2010;Ocampo</surname>
<given-names>E</given-names>
</string-name>, et al. <article-title>Clinical, laboratory and imaging features of COVID&#x2010;19: a systematic review and meta&#x2010;analysis</article-title>. <source>Travel Med Infect Dis</source>. <year>2020</year>;<volume>34</volume>:<elocation-id>101623</elocation-id>.<pub-id pub-id-type="pmid">32179124</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0005">
        <label>5</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0005">
<string-name>
<surname>Fu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Clinical characteristics of coronavirus disease 2019 (COVID&#x2010;19) in China: a systematic review and meta&#x2010;analysis</article-title>. <source>J Infect</source>. <year>2020</year>;<volume>80</volume>(<issue>6</issue>):<fpage>656</fpage>&#x2010;<lpage>665</lpage>.<pub-id pub-id-type="pmid">32283155</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0006">
        <label>6</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0006">
<string-name>
<surname>Cui</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Children with coronavirus disease 2019: a review of demographic, clinical, laboratory, and imaging features in pediatric patients</article-title>. <source>J Med Virol</source>. <year>2020</year>. <pub-id pub-id-type="doi">10.1002/jmv.26023</pub-id>
</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0007">
        <label>7</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0007">
<string-name>
<surname>Ludvigsson</surname>
<given-names>JF</given-names>
</string-name>. <article-title>Systematic review of COVID&#x2010;19 in children shows milder cases and a better prognosis than adults</article-title>. <source>Acta Paediatr</source>. <year>2020</year>;<volume>109</volume>(<issue>6</issue>):<fpage>1088</fpage>&#x2010;<lpage>1095</lpage>.<pub-id pub-id-type="pmid">32202343</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0008">
        <label>8</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0008">
<string-name>
<surname>de Souza</surname>
<given-names>TH</given-names>
</string-name>, <string-name>
<surname>Nadal</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Nogueira</surname>
<given-names>RJN</given-names>
</string-name>, <string-name>
<surname>Pereira</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Brandao</surname>
<given-names>MB</given-names>
</string-name>. <article-title>Clinical manifestations of children with COVID&#x2010;19: a systematic review</article-title>. <source>Pediatr Pulmonol</source>. <year>2020</year>;<volume>55</volume>:<fpage>1892</fpage>&#x2010;<lpage>1899</lpage>.<pub-id pub-id-type="pmid">32492251</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0009">
        <label>9</label>
        <mixed-citation publication-type="miscellaneous" id="jmv26398-cit-0009">
<collab collab-type="authors">World Health Organization</collab>
. Technical&#x2010;guidance for 2019&#x2010;nCoV RT&#x2010;PCR. <ext-link xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technicalguidance/laboratory-guidance" ext-link-type="uri">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technicalguidance/laboratory-guidance</ext-link>
</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0010">
        <label>10</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0010">
<collab collab-type="authors">Society of Pediatrics CMA, Editorial Board CJoP</collab>
. <article-title>[Recommendations for the diagnosis, prevention and control of the 2019 novel coronavirus infection in children (first interim edition)]</article-title>. <source>Zhonghua Er Ke Za Zhi</source>. <year>2020</year>;<volume>58</volume>(<issue>3</issue>):<fpage>169</fpage>&#x2010;<lpage>174</lpage>.<pub-id pub-id-type="pmid">32135584</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0011">
        <label>11</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0011">
<string-name>
<surname>Murad</surname>
<given-names>MH</given-names>
</string-name>, <string-name>
<surname>Sultan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Haffar</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Bazerbachi</surname>
<given-names>F</given-names>
</string-name>. <article-title>Methodological quality and synthesis of case series and case reports</article-title>. <source>BMJ Evid Based Med</source>. <year>2018</year>;<volume>23</volume>(<issue>2</issue>):<fpage>60</fpage>&#x2010;<lpage>63</lpage>.</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0012">
        <label>12</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0012">
<string-name>
<surname>Barendregt</surname>
<given-names>JJ</given-names>
</string-name>, <string-name>
<surname>Doi</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>YY</given-names>
</string-name>, <string-name>
<surname>Norman</surname>
<given-names>RE</given-names>
</string-name>, <string-name>
<surname>Vos</surname>
<given-names>T</given-names>
</string-name>. <article-title>Meta&#x2010;analysis of prevalence</article-title>. <source>J Epidemiol Community Health</source>. <year>2013</year>;<volume>67</volume>(<issue>11</issue>):<fpage>974</fpage>&#x2010;<lpage>978</lpage>.<pub-id pub-id-type="pmid">23963506</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0013">
        <label>13</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0013">
<string-name>
<surname>Ma</surname>
<given-names>YL</given-names>
</string-name>, <string-name>
<surname>Xia</surname>
<given-names>SY</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Du</surname>
<given-names>WH</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>Q</given-names>
</string-name>. <article-title>[Clinical features of children with SARS&#x2010;CoV&#x2010;2 infection: an analysis of 115 cases]</article-title>. <source>Zhongguo Dang Dai Er Ke Za Zhi</source>. <year>2020</year>;<volume>22</volume>(<issue>4</issue>):<fpage>290</fpage>&#x2010;<lpage>293</lpage>.<pub-id pub-id-type="pmid">32312363</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0014">
        <label>14</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0014">
<string-name>
<surname>Wang</surname>
<given-names>XF</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>YJ</given-names>
</string-name>, et al. <article-title>[Clinical and epidemiological characteristics of 34 children with 2019 novel coronavirus infection in Shenzhen]</article-title>. <source>Zhonghua Er Ke Za Zhi</source>. <year>2020</year>;<volume>58</volume>:<fpage>E008</fpage>.<pub-id pub-id-type="pmid">32062875</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0015">
        <label>15</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0015">
<string-name>
<surname>Wang</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Ju</surname>
<given-names>XL</given-names>
</string-name>, <string-name>
<surname>Xie</surname>
<given-names>F</given-names>
</string-name>, et al. <article-title>[Clinical analysis of 31 cases of 2019 novel coronavirus infection in children from six provinces (autonomous region) of northern China]</article-title>. <source>Zhonghua Er Ke Za Zhi</source>. <year>2020</year>;<volume>58</volume>(<issue>4</issue>):<fpage>269</fpage>&#x2010;<lpage>274</lpage>.<pub-id pub-id-type="pmid">32118389</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0016">
        <label>16</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0016">
<string-name>
<surname>Cai</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>A case series of children with 2019 novel coronavirus infection: clinical and epidemiological features</article-title>. <source>Clin Infect Dis</source>. <year>2020</year>:<elocation-id>ciaa198</elocation-id>.</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0017">
        <label>17</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0017">
<string-name>
<surname>Feng</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Yun</surname>
<given-names>YX</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>XF</given-names>
</string-name>, et al. <article-title>[Analysis of CT features of 15 children with 2019 novel coronavirus infection]</article-title>. <source>Zhonghua Er Ke Za Zhi</source>. <year>2020</year>;<volume>58</volume>(<issue>4</issue>):<fpage>275</fpage>&#x2010;<lpage>278</lpage>.<pub-id pub-id-type="pmid">32234131</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0018">
        <label>18</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0018">
<string-name>
<surname>Su</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ma</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>The different clinical characteristics of corona virus disease cases between children and their families in China&#x2013;the character of children with COVID&#x2010;19</article-title>. <source>Emerg Microbes Infect</source>. <year>2020</year>;<volume>9</volume>(<issue>1</issue>):<fpage>707</fpage>&#x2010;<lpage>713</lpage>.<pub-id pub-id-type="pmid">32208917</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0019">
        <label>19</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0019">
<string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yang</surname>
<given-names>GD</given-names>
</string-name>, <string-name>
<surname>Feng</surname>
<given-names>K</given-names>
</string-name>, et al. <article-title>[Clinical features and chest CT findings of coronavirus disease 2019 in infants and young children]</article-title>. <source>Zhongguo Dang Dai Er Ke Za Zhi</source>. <year>2020</year>;<volume>22</volume>(<issue>3</issue>):<fpage>215</fpage>&#x2010;<lpage>220</lpage>.<pub-id pub-id-type="pmid">32204756</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0020">
        <label>20</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0020">
<string-name>
<surname>Wei</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Fu</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Yu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>ZJ</given-names>
</string-name>. <article-title>Novel coronavirus infection in hospitalized infants under 1 year of age in China</article-title>. <source>JAMA</source>. <year>2020</year>;<volume>323</volume>(<issue>13</issue>):<fpage>1313</fpage>&#x2010;<lpage>1314</lpage>.<pub-id pub-id-type="pmid">32058570</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0021">
        <label>21</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0021">
<string-name>
<surname>Liu</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Detection of Covid&#x2010;19 in children in early january 2020 in Wuhan, China</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>(<issue>14</issue>):<fpage>1370</fpage>&#x2010;<lpage>1371</lpage>.<pub-id pub-id-type="pmid">32163697</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0022">
        <label>22</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0022">
<string-name>
<surname>Cai</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>XS</given-names>
</string-name>, <string-name>
<surname>Ge</surname>
<given-names>YL</given-names>
</string-name>, et al. <article-title>[First case of 2019 novel coronavirus infection in children in Shanghai]</article-title>. <source>Zhonghua Er Ke Za Zhi</source>. <year>2020</year>;<volume>58</volume>(<issue>2</issue>):<fpage>86</fpage>&#x2010;<lpage>87</lpage>.<pub-id pub-id-type="pmid">32102141</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0023">
        <label>23</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0023">
<string-name>
<surname>Zhang</surname>
<given-names>YH</given-names>
</string-name>, <string-name>
<surname>Lin</surname>
<given-names>DJ</given-names>
</string-name>, <string-name>
<surname>Xiao</surname>
<given-names>MF</given-names>
</string-name>, et al. <article-title>[2019 novel coronavirus infection in a three&#x2010;month&#x2010;old baby]</article-title>. <source>Zhonghua Er Ke Za Zhi</source>. <year>2020</year>;<volume>58</volume>(<issue>3</issue>):<fpage>182</fpage>&#x2010;<lpage>184</lpage>.<pub-id pub-id-type="pmid">32135587</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0024">
        <label>24</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0024">
<string-name>
<surname>Ji</surname>
<given-names>LN</given-names>
</string-name>, <string-name>
<surname>Chao</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>YJ</given-names>
</string-name>, et al. <article-title>Clinical features of pediatric patients with COVID&#x2010;19: a report of two family cluster cases</article-title>. <source>World J Pediatr</source>. <year>2020</year>;<volume>16</volume>:<fpage>1</fpage>&#x2010;<lpage>4</lpage>.<pub-id pub-id-type="pmid">32026149</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0025">
        <label>25</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0025">
<string-name>
<surname>Zhang</surname>
<given-names>GX</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>AM</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>[Twin girls infected with SARS&#x2010;CoV&#x2010;2]</article-title>. <source>Zhongguo Dang Dai Er Ke Za Zhi</source>. <year>2020</year>;<volume>22</volume>(<issue>3</issue>):<fpage>221</fpage>&#x2010;<lpage>225</lpage>.<pub-id pub-id-type="pmid">32204757</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0026">
        <label>26</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0026">
<string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>GC</given-names>
</string-name>, <string-name>
<surname>Tao</surname>
<given-names>XW</given-names>
</string-name>, <string-name>
<surname>Zeng</surname>
<given-names>LK</given-names>
</string-name>. <article-title>[SARS&#x2010;CoV&#x2010;2 infection with gastrointestinal symptoms as the first manifestation in a neonate]</article-title>. <source>Zhongguo Dang Dai Er Ke Za Zhi</source>. <year>2020</year>;<volume>22</volume>(<issue>3</issue>):<fpage>211</fpage>&#x2010;<lpage>214</lpage>.<pub-id pub-id-type="pmid">32204755</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0027">
        <label>27</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0027">
<string-name>
<surname>Ruihong</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Xiaomin</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Kaijin</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Jifang</surname>
<given-names>S</given-names>
</string-name>. <article-title>1 case of novel coronavirus pneumonia in children</article-title>. <source>Zhejiang Med J</source>. <year>2020</year>;<volume>42</volume>(<issue>4</issue>):<fpage>305</fpage>&#x2010;<lpage>306</lpage>. 2020.</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0028">
        <label>28</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0028">
<string-name>
<surname>Zeng</surname>
<given-names>LK</given-names>
</string-name>, <string-name>
<surname>Tao</surname>
<given-names>XW</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>WH</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>ZS</given-names>
</string-name>. <article-title>[First case of neonate with COVID&#x2010;19 in China]</article-title>. <source>Zhonghua Er Ke Za Zhi</source>. <year>2020</year>;<volume>58</volume>(<issue>4</issue>):<fpage>279</fpage>&#x2010;<lpage>280</lpage>.<pub-id pub-id-type="pmid">32234132</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0029">
        <label>29</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0029">
<string-name>
<surname>Zhang</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Cui</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Detectable SARS&#x2010;CoV&#x2010;2 viral RNA in feces of three children during recovery period of COVID&#x2010;19 pneumonia</article-title>. <source>J Med Virol</source>. <year>2020</year>;<volume>92</volume>:<fpage>909</fpage>&#x2010;<lpage>914</lpage>.<pub-id pub-id-type="pmid">32222992</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0030">
        <label>30</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0030">
<string-name>
<surname>Zeng</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Xia</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Yuan</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>Neonatal early&#x2010;onset infection with SARS&#x2010;CoV&#x2010;2 in 33 neonates born to mothers with COVID&#x2010;19 in Wuhan, China</article-title>. <source>JAMA Pediatr</source>. <year>2020</year>.<volume>174</volume>(<issue>7</issue>):<fpage>722</fpage>&#x2010;<lpage>725</lpage>.<pub-id pub-id-type="pmid">32215598</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0031">
        <label>31</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0031">
<string-name>
<surname>Kam</surname>
<given-names>KQ</given-names>
</string-name>, <string-name>
<surname>Yung</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>Cui</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>A well infant with coronavirus disease 2019 (COVID&#x2010;19) with high viral load</article-title>. <source>Clin Infect Dis</source>. <year>2020</year>;<volume>71</volume>:<fpage>847</fpage>&#x2010;<lpage>849</lpage>.<pub-id pub-id-type="pmid">32112082</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0032">
        <label>32</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0032">
<string-name>
<surname>Wu</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Xing</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Shi</surname>
<given-names>L</given-names>
</string-name>, et al. <article-title>Co&#x2010;infection and other clinical characteristics of COVID&#x2010;19 in children</article-title>. <source>Pediatrics</source>. <year>2020</year>;<volume>146</volume>:<elocation-id>e20200961</elocation-id>.<pub-id pub-id-type="pmid">32376725</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0033">
        <label>33</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0033">
<string-name>
<surname>Xing</surname>
<given-names>YH</given-names>
</string-name>, <string-name>
<surname>Ni</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>Q</given-names>
</string-name>, et al. <article-title>Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019</article-title>. <source>J Microbiol, Immunol Infection.</source>
<year>2020</year>;<volume>53</volume>:<fpage>473</fpage>&#x2010;<lpage>480</lpage>.</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0034">
        <label>34</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0034">
<string-name>
<surname>Park</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Han</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>KU</given-names>
</string-name>, <string-name>
<surname>Kim</surname>
<given-names>JY</given-names>
</string-name>, <string-name>
<surname>Choi</surname>
<given-names>EH</given-names>
</string-name>. <article-title>First pediatric case of coronavirus disease 2019 in Korea</article-title>. <source>J Korean Med Sci</source>. <year>2020</year>;<volume>35</volume>(<issue>11</issue>):<elocation-id>e124</elocation-id>.<pub-id pub-id-type="pmid">32193905</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0035">
        <label>35</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0035">
<string-name>
<surname>Xia</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Shao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Peng</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>D</given-names>
</string-name>. <article-title>Clinical and CT features in pediatric patients with COVID&#x2010;19 infection: different points from adults</article-title>. <source>Pediatr Pulmonol</source>. <year>2020</year>;<volume>55</volume>(<issue>5</issue>):<fpage>1169</fpage>&#x2010;<lpage>1174</lpage>.<pub-id pub-id-type="pmid">32134205</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0036">
        <label>36</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0036">
<string-name>
<surname>Tagarro</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Epalza</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Santos</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>Screening and severity of coronavirus disease 2019 (COVID&#x2010;19) in children in Madrid, Spain</article-title>. <source>JAMA Pediatr.</source>
<year>2020</year>:<elocation-id>e201346</elocation-id>
</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0037">
        <label>37</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0037">
<string-name>
<surname>Zhu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>R</given-names>
</string-name>, et al. <article-title>Clinical characteristics of a case series of children with coronavirus disease 2019</article-title>. <source>Pediatr Pulmonol</source>. <year>2020</year>;<volume>55</volume>(<issue>6</issue>):<fpage>1430</fpage>&#x2010;<lpage>1432</lpage>.<pub-id pub-id-type="pmid">32270592</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0038">
        <label>38</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0038">
<string-name>
<surname>Qiu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Hong</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Luo</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Song</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>D</given-names>
</string-name>. <article-title>Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID&#x2010;19) in Zhejiang, China: an observational cohort study</article-title>. <source>Lancet Infect Dis</source>. <year>2020</year>;<volume>20</volume>:<fpage>689</fpage>&#x2010;<lpage>696</lpage>.<pub-id pub-id-type="pmid">32220650</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0039">
        <label>39</label>
        <mixed-citation publication-type="miscellaneous" id="jmv26398-cit-0039">
<string-name>
<surname>Yu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Cai</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Dai</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Sun</surname>
<given-names>HJM</given-names>
</string-name>
<article-title>The clinical and epidemiological features and hints of 82 confirmed COVID&#x2010;19 pediatric cases aged 0&#x2010;16 in Wuhan, China</article-title>. <year>2020</year>.</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0040">
        <label>40</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0040">
<string-name>
<surname>Jie</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Wan&#x2010;jun</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Zhi&#x2010;hong</surname>
<given-names>D</given-names>
</string-name>, et al. <article-title>Clinical and epidemiological characteristics of 91 children conformed with COVID&#x2010;19</article-title>. <source>Chin J Nosocomiol.</source>
<year>2020</year>;<volume>30</volume>(<issue>11</issue>):<fpage>1</fpage>&#x2010;<lpage>5</lpage>.</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0041">
        <label>41</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0041">
<string-name>
<surname>Ma</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Hu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tian</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>A single&#x2010;center, retrospective study of COVID&#x2010;19 features in children: a descriptive investigation</article-title>. <source>BMC Med</source>. <year>2020</year>;<volume>18</volume>(<issue>1</issue>):<fpage>123</fpage>.<pub-id pub-id-type="pmid">32370747</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0042">
        <label>42</label>
        <mixed-citation publication-type="miscellaneous" id="jmv26398-cit-0042">
<string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Wu</surname>
<given-names>J</given-names>
</string-name>, et al. Epidemiological and Clinical Characteristics of 74 Children Infected with SARS&#x2010;CoV&#x2010;2 in Family Clusters in Wuhan, China. <year>2020</year>.</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0043">
        <label>43</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0043">
<string-name>
<surname>Qian</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Xue&#x2010;hua</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Zi&#x2010;yan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Jian&#x2010;bo</surname>
<given-names>S</given-names>
</string-name>. <article-title>Clinical and imaging characteristics of children with corona virus disease 2019 (COVID&#x2010;19)</article-title>. <source>Radiol Practic</source>. <year>2020</year>;<volume>35</volume>(<issue>3</issue>):<fpage>277</fpage>&#x2010;<lpage>280</lpage>.</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0044">
        <label>44</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0044">
<string-name>
<surname>Lu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Deng</surname>
<given-names>W</given-names>
</string-name>, et al. <article-title>Symptomatic infection is associated with prolonged duration of viral shedding in mild coronavirus disease 2019: a retrospective study of 110 children in Wuhan</article-title>. <source>Pediatr Infect Dis J.</source>
<year>2020</year>;<volume>39</volume>:<fpage>95</fpage>.</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0045">
        <label>45</label>
        <mixed-citation publication-type="miscellaneous" id="jmv26398-cit-0045">
<string-name>
<surname>Tang</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Xu</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>LJM</given-names>
</string-name>
<article-title>A retrospective study of the clinical characteristics of COVID&#x2010;19 infection in 26 children</article-title>. <year>2020</year>.</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0046">
        <label>46</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0046">
<string-name>
<surname>Zheng</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Liao</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Fan</surname>
<given-names>QH</given-names>
</string-name>, et al. <article-title>Clinical characteristics of children with coronavirus disease 2019 in Hubei, China</article-title>. <source>Curr Med Sci.</source>
<year>2020</year>;<volume>40</volume>(<issue>2</issue>):<fpage>275</fpage>&#x2010;<lpage>280</lpage>.<pub-id pub-id-type="pmid">32207032</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0047">
        <label>47</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0047">
<string-name>
<surname>Shen</surname>
<given-names>Q</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Guo</surname>
<given-names>T</given-names>
</string-name>, et al. <article-title>Novel coronavirus infection in children outside of Wuhan, China</article-title>. <source>Pediatr Pulmonol</source>. <year>2020</year>;<volume>55</volume>(<issue>6</issue>):<fpage>1424</fpage>&#x2010;<lpage>1429</lpage>.<pub-id pub-id-type="pmid">32259403</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0048">
        <label>48</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0048">
<string-name>
<surname>Sun</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>XX</given-names>
</string-name>, et al. <article-title>Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center's observational study</article-title>. <source>World J Pediatr</source>. <year>2020</year>;<volume>16</volume>:<fpage>1</fpage>&#x2010;<lpage>9</lpage>.<pub-id pub-id-type="pmid">32026149</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0049">
        <label>49</label>
        <mixed-citation publication-type="miscellaneous" id="jmv26398-cit-0049">
<string-name>
<surname>Rahimzadeh</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Ekrami Noghabi</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kadkhodaei Elyaderani</surname>
<given-names>F</given-names>
</string-name>, et al. COVID&#x2010;19 infection in Iranian children: a case series of 9 patients. <year>2020</year>;8(2):139&#x2010;144.</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0050">
        <label>50</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0050">
<string-name>
<surname>Liu</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lan</surname>
<given-names>W</given-names>
</string-name>. <article-title>Clinical and CT imaging features of the COVID&#x2010;19 pneumonia: focus on pregnant women and children</article-title>. <source>J Infect</source>. <year>2020</year>;<volume>80</volume>(<issue>5</issue>):<fpage>e7</fpage>&#x2010;<lpage>e13</lpage>.<pub-id pub-id-type="pmid">32171865</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0051">
        <label>51</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0051">
<string-name>
<surname>Wu</surname>
<given-names>HP</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>BF</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>[Clinical features of coronavirus disease 2019 in children aged &lt;18 years in Jiangxi, China: an analysis of 23 cases]</article-title>. <source>Zhongguo Dang Dai Er Ke Za Zhi</source>. <year>2020</year>;<volume>22</volume>(<issue>5</issue>):<fpage>419</fpage>&#x2010;<lpage>424</lpage>.<pub-id pub-id-type="pmid">32434634</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0052">
        <label>52</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0052">
<string-name>
<surname>Tan</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Huang</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zhao</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Zhou</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>JQ</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>XY</given-names>
</string-name>. <article-title>[Clinical features of children with SARS&#x2010;CoV&#x2010;2 infection: an analysis of 13 cases from Changsha, China]</article-title>. <source>Zhongguo Dang Dai Er Ke Za Zhi</source>. <year>2020</year>;<volume>22</volume>(<issue>4</issue>):<fpage>294</fpage>&#x2010;<lpage>298</lpage>.<pub-id pub-id-type="pmid">32312364</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0053">
        <label>53</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0053">
<string-name>
<surname>Liu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhan</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Huaru</surname>
<given-names>X</given-names>
</string-name>, et al. <article-title>Epidemiological and clinical characteristics of 10 children with coronavirus disease (COVID&#x2010;19) in Jinan City</article-title>. <source>J Shandong University (Health Sciences)</source>. <year>2020</year>;<volume>58</volume>(<issue>4</issue>):<fpage>36</fpage>&#x2010;<lpage>39</lpage>.</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0054">
        <label>54</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0054">
<string-name>
<surname>Xiaoguo</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Yan</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jiaan</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhongfa</surname>
<given-names>Z</given-names>
</string-name>. <article-title>Clinical characteristics of novel coronavirus pneumonia in children in Jinan</article-title>. <source>J Shandong University (Health Sciences)</source>. <year>2020</year>;<volume>58</volume>(<issue>3</issue>):<fpage>62</fpage>&#x2010;<lpage>64</lpage>.</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0055">
        <label>55</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0055">
<string-name>
<surname>Xu</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>B</given-names>
</string-name>, et al. <article-title>Characteristics of pediatric SARS&#x2010;CoV&#x2010;2 infection and potential evidence for persistent fecal viral shedding</article-title>. <source>Nat Med</source>. <year>2020</year>;<volume>26</volume>(<issue>4</issue>):<fpage>502</fpage>&#x2010;<lpage>505</lpage>.<pub-id pub-id-type="pmid">32284613</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0056">
        <label>56</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0056">
<string-name>
<surname>Xia</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Xiaomei</surname>
<given-names>L</given-names>
</string-name>. <article-title>Clinical analysis of 1 novel coronavirus infecting pneumonia cases in Yunnan</article-title>. <source>World Latest Medicine Informatio [J]</source>. <year>2020</year>;<volume>20</volume>(<issue>32</issue>).</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0057">
        <label>57</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0057">
<string-name>
<surname>Chen</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>ZS</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>FR</given-names>
</string-name>, et al. <article-title>Frist case of severe childhood novel coronavirus pneumonia in China</article-title>. <source>Zhonghua er ke za zhi&#x2009;=&#x2009;Chinese J Pediatr</source>. <year>2020</year>;<volume>58</volume>:<fpage>E005</fpage>.</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0058">
        <label>58</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0058">
<string-name>
<surname>Lu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Du</surname>
<given-names>H</given-names>
</string-name>, et al. <article-title>SARS&#x2010;CoV&#x2010;2 infection in children</article-title>. <source>N Engl J Med</source>. <year>2020</year>;<volume>382</volume>(<issue>17</issue>):<fpage>1663</fpage>&#x2010;<lpage>1665</lpage>.<pub-id pub-id-type="pmid">32187458</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0059">
        <label>59</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0059">
<string-name>
<surname>Team</surname>
<given-names>CC&#x2010;R</given-names>
</string-name>. <article-title>Coronavirus disease 2019 in children&#x2014;United States, February 12&#x2010;April 2, 2020</article-title>. <source>MMWR Morb Mortal Wkly Rep</source>. <year>2020</year>;<volume>69</volume>(<issue>14</issue>):<fpage>422</fpage>&#x2010;<lpage>426</lpage>.<pub-id pub-id-type="pmid">32271728</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0060">
        <label>60</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0060">
<string-name>
<surname>Grant</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Geoghegan</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Arbyn</surname>
<given-names>M</given-names>
</string-name>, et al. <article-title>The prevalence of symptoms in 24,410 adults infected by the novel coronavirus (SARS&#x2010;CoV&#x2010;2; COVID&#x2010;19): a systematic review and meta&#x2010;analysis of 148 studies from 9 countries</article-title>. <source>PLoS One</source>. <year>2020</year>;<volume>15</volume>(<issue>6</issue>):<elocation-id>e0234765</elocation-id>.<pub-id pub-id-type="pmid">32574165</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0061">
        <label>61</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0061">
<string-name>
<surname>Molloy</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Bearer</surname>
<given-names>CF</given-names>
</string-name>. <article-title>COVID&#x2010;19 in children and altered inflammatory responses</article-title>. <source>Pediatr Res</source>. <year>2020</year>. <pub-id pub-id-type="doi">10.1038/s41390-020-0881-y</pub-id>
</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0062">
        <label>62</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0062">
<string-name>
<surname>Simon</surname>
<given-names>AK</given-names>
</string-name>, <string-name>
<surname>Hollander</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>McMichael</surname>
<given-names>A</given-names>
</string-name>. <article-title>Evolution of the immune system in humans from infancy to old age</article-title>. <source>Proc Biol Sci</source>. <year>2015</year>;<volume>282</volume>(<issue>1821</issue>):<elocation-id>20143085</elocation-id>.<pub-id pub-id-type="pmid">26702035</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0063">
        <label>63</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0063">
<string-name>
<surname>Zhu</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ji</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pang</surname>
<given-names>J</given-names>
</string-name>, et al. <article-title>Clinical characteristics of 3,062 COVID&#x2010;19 patients: a meta&#x2010;analysis</article-title>. <source>J Med Virol</source>. <year>2020</year>. <pub-id pub-id-type="doi">10.1002/jmv.25884</pub-id>
</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0064">
        <label>64</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0064">
<string-name>
<surname>Yan</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Nan&#x2010;nan</surname>
<given-names>X</given-names>
</string-name>. <article-title>Diagnostic value of myocardial troponin I, CK&#x2010;MB, and C reactive protein in children with viral myocarditis</article-title>. <source>Chinese J Lab Diagn</source>. <year>2014</year>;<volume>18</volume>(<issue>04</issue>):<fpage>611</fpage>&#x2010;<lpage>612</lpage>.</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0065">
        <label>65</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0065">
<string-name>
<surname>Jiaqi</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Yanping</surname>
<given-names>f</given-names>
</string-name>, <string-name>
<surname>Aisheng</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Yongge</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Xiaoge</surname>
<given-names>L</given-names>
</string-name>. <article-title>The difference between the normal value of serum creatine kinase MB in children and that in adults</article-title>. <source>Lab Med Clinic</source>. <year>2018</year>;<volume>2</volume>(<issue>02</issue>):<fpage>230</fpage>&#x2010;<lpage>231</lpage>.</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0066">
        <label>66</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0066">
<string-name>
<surname>Rong</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Zhen&#x2010;nan</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Jin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Guang&#x2010;hong</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Xin&#x2010;yu</surname>
<given-names>W</given-names>
</string-name>. <article-title>Clinical evaluation of serum creatine phosphokinase isoenzyme in healthy children at different ages</article-title>. <source>J Chinese Pla Postgraduate Med Sch</source>. <year>2010</year>;<volume>31</volume>(<issue>4</issue>):<fpage>337</fpage>&#x2010;<lpage>338</lpage>.</mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0067">
        <label>67</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0067">
<string-name>
<surname>Bao</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Zhang</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Liu</surname>
<given-names>J</given-names>
</string-name>. <article-title>Coronavirus disease 2019 (COVID&#x2010;19) CT findings: a systematic review and meta&#x2010;analysis</article-title>. <source>J Am Coll Radiol</source>. <year>2020</year>;<volume>17</volume>:<fpage>701</fpage>&#x2010;<lpage>709</lpage>.<pub-id pub-id-type="pmid">32283052</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0068">
        <label>68</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0068">
<string-name>
<surname>Duan</surname>
<given-names>YN</given-names>
</string-name>, <string-name>
<surname>Zhu</surname>
<given-names>YQ</given-names>
</string-name>, <string-name>
<surname>Tang</surname>
<given-names>LL</given-names>
</string-name>, <string-name>
<surname>Qin</surname>
<given-names>JCT</given-names>
</string-name>. <article-title>features of novel coronavirus pneumonia (COVID&#x2010;19) in children</article-title>. <source>Eur Radiol</source>. <year>2020</year>;<volume>30</volume>:<fpage>4427</fpage>&#x2010;<lpage>4433</lpage>.<pub-id pub-id-type="pmid">32291501</pub-id></mixed-citation>
      </ref>
      <ref id="jmv26398-bib-0069">
        <label>69</label>
        <mixed-citation publication-type="journal" id="jmv26398-cit-0069">
<string-name>
<surname>Ma</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Shao</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Wang</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Zhai</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Zheng</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>QJCJR</given-names>
</string-name>. <article-title>High resolution CT features of novel coronavirus pneu monia in children [J]</article-title>. <source>Environ Sci Technol</source>. <year>2020</year>;<volume>54</volume>:<fpage>1005</fpage>&#x2010;<lpage>1201</lpage>.<pub-id pub-id-type="pmid">31904951</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Virol J</journal-id>
      <journal-id journal-id-type="iso-abbrev">Virol J</journal-id>
      <journal-title-group>
        <journal-title>Virology Journal</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1743-422X</issn>
      <publisher>
        <publisher-name>BioMed Central</publisher-name>
        <publisher-loc>London</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">33187528</article-id>
      <article-id pub-id-type="pmc">7665091</article-id>
      <article-id pub-id-type="publisher-id">1452</article-id>
      <article-id pub-id-type="doi">10.1186/s12985-020-01452-5</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Research</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Rapid SARS-CoV-2 antigen detection assay in comparison with real-time RT-PCR assay for laboratory diagnosis of COVID-19 in Thailand</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Chaimayo</surname>
            <given-names>Chutikarn</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kaewnaphan</surname>
            <given-names>Bualan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tanlieng</surname>
            <given-names>Nattaya</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Athipanyasilp</surname>
            <given-names>Niracha</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sirijatuphat</surname>
            <given-names>Rujipas</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chayakulkeeree</surname>
            <given-names>Methee</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Angkasekwinai</surname>
            <given-names>Nasikarn</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sutthent</surname>
            <given-names>Ruengpung</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Puangpunngam</surname>
            <given-names>Nattawut</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tharmviboonsri</surname>
            <given-names>Theerawoot</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pongraweewan</surname>
            <given-names>Orawan</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Chuthapisith</surname>
            <given-names>Suebwong</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sirivatanauksorn</surname>
            <given-names>Yongyut</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kantakamalakul</surname>
            <given-names>Wannee</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-9109-1259</contrib-id>
          <name>
            <surname>Horthongkham</surname>
            <given-names>Navin</given-names>
          </name>
          <address>
            <email>navin.hor@mahidol.ac.th</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution>Department of Microbiology, Faculty of Medicine Siriraj Hospital, </institution><institution>Mahidol University, </institution></institution-wrap>Bangkok, Thailand </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution>Department of Medicine, Faculty of Medicine Siriraj Hospital, </institution><institution>Mahidol University, </institution></institution-wrap>Bangkok, Thailand </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution>Department of Surgery, Faculty of Medicine Siriraj Hospital, </institution><institution>Mahidol University, </institution></institution-wrap>Bangkok, Thailand </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution>Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, </institution><institution>Mahidol University, </institution></institution-wrap>Bangkok, Thailand </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.10223.32</institution-id><institution-id institution-id-type="ISNI">0000 0004 1937 0490</institution-id><institution>Department of Anesthesiology, Faculty of Medicine Siriraj Hospital, </institution><institution>Mahidol University, </institution></institution-wrap>Bangkok, Thailand </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>13</day>
        <month>11</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>13</day>
        <month>11</month>
        <year>2020</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2020</year>
      </pub-date>
      <volume>17</volume>
      <elocation-id>177</elocation-id>
      <history>
        <date date-type="received">
          <day>4</day>
          <month>8</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>5</day>
          <month>11</month>
          <year>2020</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2020</copyright-statement>
        <license license-type="OpenAccess">
          <license-p><bold>Open Access</bold>This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.</license-p>
        </license>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p id="Par1">The Coronavirus disease 2019 (COVID-19) pandemic continues to spread across the world. Hence, there is an urgent need for rapid, simple, and accurate tests to diagnose severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Performance characteristics of the rapid SARS-CoV-2 antigen detection test should be evaluated and compared with the gold standard real-time reverse transcription-polymerase chain reaction (RT-PCR) test for diagnosis of COVID-19 cases.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p id="Par2">The rapid SARS-CoV-2 antigen detection test, Standard&#x2122; Q COVID-19 Ag kit (SD Biosensor&#xAE;, Republic of Korea), was compared with the real-time RT-PCR test, Allplex&#x2122; 2019-nCoV Assay (Seegene&#xAE;, Korea) for detection of SARS-CoV-2 in respiratory specimens. Four hundred fifty-four respiratory samples (mainly nasopharyngeal and throat swabs) were obtained from COVID-19 suspected cases and contact individuals, including pre-operative patients at Siriraj Hospital, Bangkok, Thailand during March&#x2013;May 2020.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p id="Par3">Of 454 respiratory samples, 60 (13.2%) were positive, and 394 (86.8%) were negative for SARS-CoV-2 RNA by real-time RT-PCR assay. The duration from onset to laboratory test in COVID-19 suspected cases and contact individuals ranged from 0 to 14&#xA0;days with a median of 3&#xA0;days. The rapid SARS-CoV-2 antigen detection test&#x2019;s sensitivity and specificity were 98.33% (95% CI, 91.06&#x2013;99.96%) and 98.73% (95% CI, 97.06&#x2013;99.59%), respectively. One false negative test result was from a sample with a high real-time RT-PCR cycle threshold (Ct), while five false positive test results were from specimens of pre-operative patients.</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p id="Par4">The rapid assay for SARS-CoV-2 antigen detection showed comparable sensitivity and specificity with the real-time RT-PCR assay. Thus, there is a potential use of this rapid and simple SARS-CoV-2 antigen detection test as a screening assay.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>COVID-19</kwd>
        <kwd>SARS-CoV-2</kwd>
        <kwd>Rapid antigen</kwd>
        <kwd>RT-PCR</kwd>
        <kwd>Thailand</kwd>
      </kwd-group>
      <funding-group>
        <award-group>
          <funding-source>
            <institution-wrap>
              <institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100013238</institution-id>
              <institution>Faculty of Medicine Siriraj Hospital, Mahidol University</institution>
            </institution-wrap>
          </funding-source>
          <award-id>R016034012</award-id>
          <principal-award-recipient>
            <name>
              <surname>Horthongkham</surname>
              <given-names>Navin</given-names>
            </name>
          </principal-award-recipient>
        </award-group>
      </funding-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; The Author(s) 2020</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Background</title>
      <p id="Par19">The Coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has spread worldwide since its first recorded case in the city of Wuhan, China in December 2019. According to the COVID-19 Dashboard on August 31st, 2020 by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University, over 25 million people in more than 200 countries have been infected and killed more than 840,000 [<xref ref-type="bibr" rid="CR1">1</xref>&#x2013;<xref ref-type="bibr" rid="CR3">3</xref>]. It is expected that these numbers continue to rise, especially in populous countries such as the United States, Brazil, and India. In Thailand, the first documented cases of COVID-19 were two Chinese tourists arriving from the city of Wuhan on January 8th and 13th, 2020, respectively. As of August 31st, 2020, there have been 3,412 confirmed COVID-19 cases with 58 deaths; 2,444 cases were from local transmission [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>]. The Thai government mandated a 14-day State Quarantine for all travelers entering Thailand from abroad. Since May 26th, 2020, no new local transmission cases were documented; new confirmed COVID-19 cases were people who have tested positive while in State Quarantine after returning from abroad [<xref ref-type="bibr" rid="CR5">5</xref>]. SARS-CoV-2 infection causes asymptomatic and mild diseases more than severe pneumonia. Severe cases may develop acute respiratory distress syndrome (ARDS) and death with an average mortality rate of 6% (range 1&#x2013;14.4%) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p>
      <p id="Par20">The real-time reverse transcription-polymerase chain reaction (RT-PCR) assay, which is the current standard test for laboratory diagnosis of SARS-CoV-2 infection, requires at least four hours of operation performed by skilled technicians. Therefore, rapid and accurate tests for SARS-CoV-2 screening are essential to expedite disease prevention and control, as well as screening during pre-operative management for invasive procedures [<xref ref-type="bibr" rid="CR7">7</xref>&#x2013;<xref ref-type="bibr" rid="CR9">9</xref>]. Lateral flow immunoassays using monoclonal anti-SARS-CoV-2 antibodies, which target SARS-CoV-2 antigens, can be the complementary screening tests if their accuracy were comparable to that of the real-time RT-PCR assays [<xref ref-type="bibr" rid="CR10">10</xref>&#x2013;<xref ref-type="bibr" rid="CR13">13</xref>].</p>
      <p id="Par21">Here, we evaluated a rapid SARS-CoV-2 antigen detection test, Standard&#x2122; Q COVID-19 Ag kit (SD Biosensor&#xAE;, Republic of Korea) using 454 respiratory specimens. The performance of this lateral flow immunoassay was compared with the SARS-CoV-2 RT-PCR for viral gene detection assay, Allplex&#x2122; 2019-nCoV Assay (Seegene&#xAE;, Korea). This evaluation is critical before the implementation of the rapid antigen test for screening of SARS-CoV-2 infected individuals.</p>
    </sec>
    <sec id="Sec2">
      <title>Methods</title>
      <sec id="Sec3">
        <title>Ethical issues</title>
        <p id="Par22">This study was approved by the Institutional Review Board of the Faculty of Medicine Siriraj Hospital, Mahidol University (SIRB protocol 463/2563(IRB4); COA: Si 503/2020).</p>
      </sec>
      <sec id="Sec4">
        <title>Clinical specimens</title>
        <p id="Par23">Respiratory samples, mainly nasopharyngeal and throat swabs, were collected from 454 suspected COVID-19 cases, including pre-operative patients at Siriraj Hospital, Mahidol University, Bangkok, Thailand, from March to May 2020. Samples were mixed in 2&#xA0;mL of viral transport media (VTM), consisting of Hanks&#x2019; balanced salt, 0.4% fetal bovine serum, HEPES, antibiotic and antifungal agents. Samples were transported at 2&#x2013;8&#xA0;&#xB0;C to the Microbiology laboratory, Siriraj Hospital, for processing within a few hours. All specimens were processed in biosafety level-3 (BSL-3) and biosafety level-2 enhanced (BSL-2&#x2009;+) facilities with full personal protective equipment.</p>
      </sec>
      <sec id="Sec5">
        <title>Viral RNA Extraction</title>
        <p id="Par24">MagLEAD 12gC automated extraction platform (Precision System Science, Chiba, Japan) was used to extract SARS-CoV-2 RNAs from 200 &#xB5;L of nasopharyngeal and throat swabs. Extraction was performed according to the manufacturer&#x2019;s instructions. Viral RNA was eluted with 100 &#xB5;L buffer and used for RT-PCR assay.</p>
      </sec>
      <sec id="Sec6">
        <title>SARS-CoV-2 RNA detection using real-time RT-PCR</title>
        <p id="Par25">Allplex&#x2122; 2019-nCoV Assay (Seegene, Korea), which targets envelope gene (<italic>E</italic>) of <italic>Sarbecovirus</italic>, and RNA-dependent RNA polymerase (<italic>RdRp</italic>) and nucleocapsid (<italic>N</italic>) genes of SARS-CoV-2, was used for SARS-CoV-2 RNA detection according to the manufacturer&#x2019;s instructions. Briefly, 8 &#x3BC;L of extracted RNA was added to 5 &#x3BC;L of 5X Real-time One-step Buffer, 5 &#x3BC;L of 2019-nCoV MuDT Oligo Mix (2019-nCoV-MOM), 2 &#x3BC;L of Real-time One-step Enzyme, and 5 &#x3BC;L of RNase free water. The CFX-96 real-time thermal cycler (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used for amplification. The conditions consisted of 1 cycle of 20&#xA0;min at 50&#xA0;&#xB0;C, 1&#xA0;min at 95&#xA0;&#xB0;C and followed by 45 cycles of 15&#xA0;s at 94&#xA0;&#xB0;C, 30&#xA0;s at 58&#xA0;&#xB0;C. The result was analysed using Seegene Viewer (Seegene, Korea), in which a cycle threshold value (Ct-value)&#x2009;&lt;&#x2009;40 for all three target genes was defined as a positive result.</p>
      </sec>
      <sec id="Sec7">
        <title>Rapid SARS-CoV-2 antigen detection assay</title>
        <p id="Par26">Standard Q COVID-19 Ag test (SD Biosensor&#xAE;, Chuncheongbuk-do, Republic of Korea) is a rapid chromatographic immunoassay for the detection of SARS-CoV-2 nucleocapsid (N) antigen in respiratory specimens. This rapid antigen test device has two pre-coated lines on the result window: control (C) and test (T) lines. The control (C) region is coated with mouse monoclonal anti-chicken Ig&#x3B3; antibody; the test (T) region is coated with mouse monoclonal anti-SARS-CoV-2 antibody against SARS-CoV-2&#xA0;N antigen. Detectors for SARS-CoV-2&#xA0;N antigen presented in the specimen are mouse monoclonal anti-SARS-CoV-2 antibody conjugated with color particles. The antigen&#x2013;antibody color particle complex migrates via capillary force and is captured by the mouse monoclonal anti-SARS-CoV-2 antibody coated on the test (T) region. The colored test (T) line&#x2019;s intensity depends on the amount of SARS-CoV-2&#xA0;N antigen presented in the sample.</p>
        <p id="Par27">This rapid Ag test kit was used for the detection of SARS-CoV-2 antigen in respiratory samples in this study. Specimens were processed in biosafety level-3 (BSL-3) and biosafety level-2 enhanced (BSL-2&#x2009;+) facilities. Five to ten glass beads were added to the samples in VTM tubes. For highly viscous samples, additional VTM was added to reduce the viscosity. Specimens were mixed using a vortex mixer to disrupt thick mucus. The 200 &#x3BC;L of each nasopharyngeal and throat swab specimen was added to the extraction buffer provided in the kit. The filter nozzle cap was pressed tightly onto the extraction tube. Three drops of the extracted sample were applied on a test device, and the test result was read in 15&#x2013;30&#xA0;min. For positive COVID-19 antigen result, two colored lines of control (C) and test (T) lines were presented.</p>
      </sec>
      <sec id="Sec8">
        <title>Statistical analysis</title>
        <p id="Par28">Descriptive statistics were used to describe general information of patients. Continuous data were presented in mean, standard deviation (SD), median, and range. Categorical data were presented in numbers, percentages, and 95% confidence interval (95% CI). Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) were calculated using an online statistical tool [<xref ref-type="bibr" rid="CR14">14</xref>].</p>
      </sec>
    </sec>
    <sec id="Sec9">
      <title>Results</title>
      <sec id="Sec10">
        <title>Characteristics of Thai COVID-19 cases</title>
        <p id="Par29">Suspected COVID-19 cases and contact individuals were laboratory-confirmed by the gold-standard RT-PCR assay as a national guideline for laboratory diagnosis of COVID-19 [<xref ref-type="bibr" rid="CR15">15</xref>]. A total of 454 respiratory samples, including 447 nasopharyngeal (NP) and throat swabs, four endotracheal aspirates (tracheal suctions), and three sputum samples, were collected from suspected COVID-19 cases and pre-operative patients at Siriraj Hospital from March to May 2020. These respiratory samples were collected from subjects with the following conditions: (1) asymptomatic and upper respiratory tract infection individuals who had contacted with confirmed cases or were from COVID-19 risk areas, (2) clusters with acute respiratory infections, (3) unknown causative agents of pneumonia, (4) travelers screened at a port of entry and in quarantine places, and (5) pre-operative patients. Of the samples tested for COVID-19 (n&#x2009;=&#x2009;454) by real-time RT-PCR assay, Allplex&#x2122; 2019-nCoV Assay, 13.2% (n&#x2009;=&#x2009;60) were positive, while 86.8% (n&#x2009;=&#x2009;394) were negative for SARS-CoV-2 RNA, as shown in Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Supplementary Table S1, Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Table S2.</p>
        <p id="Par30">The median age of Thai COVID-19 cases (n&#x2009;=&#x2009;60) was 38.5&#xA0;years (range 21&#x2013;72). Male patients were found to be 60% of the infected cases (n&#x2009;=&#x2009;36). Of the total COVID-19 cases, 75% (n&#x2009;=&#x2009;45) of patients had direct contact with a variety of confirmed cases in Thailand, such as family members and friends (30%; n&#x2009;=&#x2009;18), people from karaoke bars and pubs (23.3%; n&#x2009;=&#x2009;14), people from boxing stadiums (18.3%; n&#x2009;=&#x2009;11), taxi drivers (1.7%; n&#x2009;=&#x2009;1), and peers in workplaces (1.7%; n&#x2009;=&#x2009;1), as shown in Table <xref rid="Tab1" ref-type="table">1</xref>. Most patients showed signs and symptoms of upper respiratory tract infections (61.7%; n&#x2009;=&#x2009;37). Around 8.3% (n&#x2009;=&#x2009;5) of COVID-19 cases were presented with pneumonia and were admitted to an intensive care unit (ICU). The median time from onset to laboratory tests for SARS-CoV-2 infection (both RT-PCR and rapid antigen detection assays) was three days (range 0&#x2013;14), as shown in Table <xref rid="Tab1" ref-type="table">1</xref> and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Supplementary Table S1.<table-wrap id="Tab1"><label>Table 1</label><caption><p>Characteristics of COVID-19 Thai cases</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Characteristics</th><th align="left">Results</th></tr></thead><tbody><tr><td align="left">Number of COVID-19 cases</td><td align="left">n&#x2009;=&#x2009;60</td></tr><tr><td align="left" colspan="2">Age (years)</td></tr><tr><td align="left">Median (range)</td><td align="left">38.5 (range 21&#x2013;72)</td></tr><tr><td align="left" colspan="2">Gender</td></tr><tr><td align="left">Male</td><td align="left">n&#x2009;=&#x2009;36 (60%)</td></tr><tr><td align="left" colspan="2">Risk factors</td></tr><tr><td align="left">Confirmed case contact</td><td align="left">n&#x2009;=&#x2009;45 (75%): boxing stadiums (n&#x2009;=&#x2009;11), karaoke bars&amp;pubs (n&#x2009;=&#x2009;14), workplaces (n&#x2009;=&#x2009;1), taxi drivers (n&#x2009;=&#x2009;1), family members and friends (n&#x2009;=&#x2009;18)</td></tr><tr><td align="left">Foreign contact</td><td align="left">n&#x2009;=&#x2009;8 (13.3%): UK (n&#x2009;=&#x2009;5), China (n&#x2009;=&#x2009;1), India (n&#x2009;=&#x2009;1), Cambodia (n&#x2009;=&#x2009;1)</td></tr><tr><td align="left">Public area contact</td><td align="left">n&#x2009;=&#x2009;2 (3.3%): public market (n&#x2009;=&#x2009;1), domestic travel (n&#x2009;=&#x2009;1)</td></tr><tr><td align="left">Unspecified</td><td align="left">n&#x2009;=&#x2009;5 (8.3%)</td></tr><tr><td align="left" colspan="2">Diagnoses</td></tr><tr><td align="left">Asymptomatic</td><td align="left">n&#x2009;=&#x2009;3 (5.0%)</td></tr><tr><td align="left">URI</td><td align="left">n&#x2009;=&#x2009;37 (61.7%)</td></tr><tr><td align="left">Fever</td><td align="left">n&#x2009;=&#x2009;11 (18.3%)</td></tr><tr><td align="left">Pneumonia</td><td align="left">n&#x2009;=&#x2009;5 (8.3%)</td></tr><tr><td align="left">Unspecified</td><td align="left">n&#x2009;=&#x2009;4 (6.7%)</td></tr><tr><td align="left" colspan="2">Time from onset to laboratory test (days)</td></tr><tr><td align="left">Median (range)</td><td align="left">3 (range 0&#x2013;14)</td></tr><tr><td align="left" colspan="2">Results of RT-PCR assay</td></tr><tr><td align="left" colspan="2"><italic>Ct-value of E</italic></td></tr><tr><td align="left">Mean&#x2009;&#xB1;&#x2009;SD (min, max)</td><td align="left">22.79&#x2009;&#xB1;&#x2009;6.69 (min 10.49, max 35.02)</td></tr><tr><td align="left" colspan="2"><italic>Ct-value of RdRp</italic></td></tr><tr><td align="left">Mean&#x2009;&#xB1;&#x2009;SD (min, max)</td><td align="left">24.73&#x2009;&#xB1;&#x2009;6.55 (min 13.41, max 39.20)</td></tr><tr><td align="left" colspan="2"><italic>Ct-value of N</italic></td></tr><tr><td align="left">Mean&#x2009;&#xB1;&#x2009;SD (min, max)</td><td align="left">26.09&#x2009;&#xB1;&#x2009;6.47 (min 12.07, max 37.17)</td></tr><tr><td align="left" colspan="2">Results of rapid antigen detection assay</td></tr><tr><td align="left">Positive</td><td align="left">59/60 (98.33%)</td></tr><tr><td align="left">Negative</td><td align="left">1/60 (1.67%)</td></tr></tbody></table></table-wrap></p>
      </sec>
      <sec id="Sec11">
        <title>Real-time RT-PCR and SARS-CoV-2 antigen assays</title>
        <p id="Par31">Real-time RT-PCR (Allplex&#x2122; 2019-nCoV Assay), which targets <italic>E</italic> of <italic>Sarbecovirus</italic>, and <italic>RdRp</italic> and <italic>N</italic> genes of SARS-CoV-2, was used for SARS-CoV-2 RNA detection. The average cycle threshold (Ct) values in COVID-19 positive cases were 22.79&#x2009;&#xB1;&#x2009;6.69 (min 10.49, max 35.02) for <italic>E</italic> gene, 24.73&#x2009;&#xB1;&#x2009;6.55 (min 13.41, max 39.20) for <italic>RdRp</italic> gene, and 26.09&#x2009;&#xB1;&#x2009;6.47 (min 12.07, max 37.17) for <italic>N</italic> gene, as shown in Table <xref rid="Tab1" ref-type="table">1</xref> and Additional file <xref rid="MOESM1" ref-type="media">1</xref>: Supplementary Table S1. The negative RT-PCR results were defined as having a Ct-value higher than 40 for all three target genes (<italic>E</italic>, <italic>RdRp</italic>, <italic>N</italic>).</p>
        <p id="Par32">We evaluated the performance characteristics of SARS-CoV-2 antigen detection (Standard Q COVID-19 Ag test). The results were interpreted as positive when both control (C) and SARS-CoV-2 antigen (T) lines appeared within 30&#xA0;min, as shown in Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>. Comparing SARS-CoV-2 antigen detection to RNA detection by RT-PCR assay, the sensitivity and specificity of rapid SARS-CoV-2 antigen detection to identify COVID-19 were 98.33% (59/60; 95%CI, 91.06&#x2013;99.96%) and 98.73% (389/394; 95%CI, 97.06&#x2013;99.59%), respectively, as shown in Table <xref rid="Tab2" ref-type="table">2</xref>. Of six samples discordant with RT-PCR results, one was false negative, and five were false positive. There were three weakly positive and two positive results. The false negative sample&#x2019;s Ct-values were 31.18 for&#xA0;<italic>E</italic>, 39.2 for&#xA0;<italic>RdRp</italic>, and 35.54 for&#xA0;<italic>N</italic> genes, as shown in Table <xref rid="Tab3" ref-type="table">3</xref> and Additional file <xref rid="MOESM2" ref-type="media">2</xref>: Supplementary Table S2.<fig id="Fig1"><label>Fig. 1</label><caption><p>Interpretation of rapid SARS-CoV-2 antigen detection assay (Standard Q COVID-19 Ag Test). Demonstration of <bold>a</bold> a test strip for viral transport media control, <bold>b</bold> a test strip, which was interpreted as negative SARS-CoV-2 antigen, <bold>c</bold> a test strip, which was interpreted as (weakly) positive SARS-CoV-2 antigen, and <bold>d</bold> a test strip, which was interpreted as positive SARS-CoV-2 antigen. The results were interpreted as positive when both control (<bold>c</bold>) and SARS-CoV-2 antigen (T) lines appeared within 30&#xA0;min</p></caption><graphic xlink:href="12985_2020_1452_Fig1_HTML" id="MO1"/></fig><table-wrap id="Tab2"><label>Table 2</label><caption><p>The sensitivity and specificity of the Standard Q COVID-19 Ag test</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2"/><th align="left" colspan="3">RT-PCR assay (Allplex&#x2122; 2019-nCoV Assay)</th></tr><tr><th align="left">Positive</th><th align="left"><sup>#1</sup>Negative</th><th align="left">Total</th></tr></thead><tbody><tr><td align="left" colspan="4"><italic>Rapid SARS-CoV-2 antigen assay (Standard Q COVID-19 Ag kit)</italic></td></tr><tr><td align="left">Positive</td><td align="left">59</td><td align="left">5</td><td align="left">64</td></tr><tr><td align="left">Negative</td><td align="left">1</td><td align="left">389</td><td align="left">390</td></tr><tr><td align="left">Total</td><td align="left">60</td><td align="left">394</td><td align="left">454</td></tr><tr><td align="left">Sensitivity</td><td align="left" colspan="3">98.33% (59/60; 95%CI, 91.06&#x2013;99.96%)</td></tr><tr><td align="left">Specificity</td><td align="left" colspan="3">98.73% (389/394; 95%CI, 97.06&#x2013;99.59%)</td></tr></tbody></table><table-wrap-foot><p><sup>#1</sup>Negative RT-PCR is defined as having Ct-values of <italic>E</italic>, <italic>RdRp</italic>, and <italic>N</italic> larger than 40</p></table-wrap-foot></table-wrap><table-wrap id="Tab3"><label>Table 3</label><caption><p>Cases with discordant results between the Standard Q COVID-19 Ag test and RT-PCR assays</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Gender</th><th align="left" rowspan="2">Age</th><th align="left" rowspan="2">Initial diagnosis</th><th align="left" rowspan="2">Specimen type</th><th align="left" colspan="3">Ct-value of RT-PCR</th><th align="left" rowspan="2">Rapid Ag test result</th><th align="left" rowspan="2">Interpretation</th></tr><tr><th align="left"><italic>E</italic></th><th align="left"><italic>RdRp</italic></th><th align="left"><italic>N</italic></th></tr></thead><tbody><tr><td align="left">F</td><td align="left">33</td><td align="left">Pneumonia</td><td align="left">NP swab&#x2009;+&#x2009;throat swab</td><td align="left">31.18</td><td align="left">39.20</td><td align="left">35.54</td><td align="left">Negative</td><td align="left">False negative</td></tr><tr><td align="left">F</td><td align="left">67</td><td align="left">Pre-operative</td><td align="left">NP swab&#x2009;+&#x2009;throat swab</td><td align="left">&#x2009;&gt;&#x2009;40</td><td align="left">&#x2009;&gt;&#x2009;40</td><td align="left">&#x2009;&gt;&#x2009;40</td><td align="left">Positive</td><td align="left">False positive</td></tr><tr><td align="left">M</td><td align="left">75</td><td align="left">Pre-operative</td><td align="left">NP swab&#x2009;+&#x2009;throat swab</td><td align="left">&#x2009;&gt;&#x2009;40</td><td align="left">&#x2009;&gt;&#x2009;40</td><td align="left">&#x2009;&gt;&#x2009;40</td><td align="left">Positive</td><td align="left">False positive</td></tr><tr><td align="left">F</td><td align="left">61</td><td align="left">Pre-operative</td><td align="left">NP swab&#x2009;+&#x2009;throat swab</td><td align="left">&#x2009;&gt;&#x2009;40</td><td align="left">&#x2009;&gt;&#x2009;40</td><td align="left">&#x2009;&gt;&#x2009;40</td><td align="left">Positive (weakly)</td><td align="left">False positive</td></tr><tr><td align="left">F</td><td align="left">83</td><td align="left">Pre-operative</td><td align="left">NP swab&#x2009;+&#x2009;throat swab</td><td align="left">&#x2009;&gt;&#x2009;40</td><td align="left">&#x2009;&gt;&#x2009;40</td><td align="left">&#x2009;&gt;&#x2009;40</td><td align="left">Positive (weakly)</td><td align="left">False positive</td></tr><tr><td align="left">F</td><td align="left">64</td><td align="left">Pre-operative</td><td align="left">NP swab&#x2009;+&#x2009;throat swab</td><td align="left">&#x2009;&gt;&#x2009;40</td><td align="left">&#x2009;&gt;&#x2009;40</td><td align="left">&#x2009;&gt;&#x2009;40</td><td align="left">Positive (weakly)</td><td align="left">False positive</td></tr></tbody></table></table-wrap></p>
      </sec>
    </sec>
    <sec id="Sec12">
      <title>Discussion</title>
      <p id="Par33">Molecular tests are the standard laboratory diagnosis to confirm SARS-CoV-2 infection; RT-PCR assays for SARS-CoV-2 RNA detection in clinical specimens are widely used in COVID-19 diagnostic laboratories. There were 183 clinical laboratories in Thailand, including our laboratory at Siriraj Hospital that passed the external quality control of RT-PCR tests by the Department of Medical Science (DMSC), Ministry of Public Health, and was authorized a COVID-19 diagnostic laboratory [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Rapid antigen immunoassays with equivalent sensitivity and specificity to real-time RT-PCR assays will help speed up disease screening. In this study, the commercially available rapid SARS-CoV-2 antigen detection kit (Standard Q COVID-19 Ag test) was compared with the RT-PCR assay (Allplex&#x2122; 2019-nCoV Assay) for detection of SARS-CoV-2 infection.</p>
      <p id="Par34">The sensitivity and specificity of the Standard Q COVID-19 Ag test for rapid detection of SARS-CoV-2 antigen reported by the manufacturer (total n&#x2009;=&#x2009;202; positive n&#x2009;=&#x2009;32; negative n&#x2009;=&#x2009;170) were 84.38% (95% CI, 67.21&#x2013;94.72%) and 100.00% (95% CI, 97.85&#x2013;100%), respectively. The sensitivity of this test was evaluated at a trial site in Malaysia using 32 RT-PCR-positive nasopharyngeal swabs from symptomatic patients. The specificity of this test was evaluated by the R&amp;D team of SD Biosensor using 170 RT-PCR-negative samples. The monoclonal antibody specific to SARS-CoV-2&#xA0;N antigen coated on the Standard Q COVID-19 Ag test was produced from WUHAN-01 strain, which is genetically closely related to the SARS-CoV-2 strains detected in Thailand [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Our results showed higher sensitivity (98.33% vs. 84.38%) but less specificity (98.73% vs. 100.00%) than the manufacturer&#x2019;s results. The difference in our test performance from the manufacturer could be due to various factors, including the batch of kit reagents, the sample quality and level of extracted antigen, and sample handling and processing techniques. We reduced the sample viscosity using glass beads and vortexing before adding to the extraction buffer. The filter nozzle cap provided in the kit also minimized the glutinousness of the samples. A negative test result could be due to lower levels of extracted antigen than the test&#x2019;s detection limit. Our batch of clinical specimens might generally have higher viral loads (low Ct-value) than that of the manufacturer&#x2019;s trial site, which enhanced the chance of antigen detection in our study.</p>
      <p id="Par35">Of 60 RT-PCR-positive samples in our study, the sole false negative result was from the NP and throat swab of a female patient with pneumonia tested for SARS-CoV-2 antigen seven days after disease onset (RT-PCR-positive case no.39). The RT-PCR result of this sample had relatively high Ct-values: 31.18 for <italic>E</italic> gene, 39.2 for <italic>RdRp</italic> gene, and 35.54 for <italic>N</italic> gene, which may explain the negative result of the Standard Q COVID-19 Ag test. However, the Standard Q COVID-19 Ag test correctly detected SARS-CoV-2 antigen from another female patient who also had relatively high Ct-values: 33.49 for <italic>E</italic> gene, 36.94 for <italic>RdRp</italic> gene, and 37.17 for <italic>N</italic> gene (RT-PCR-positive case no.23). This patient was presented with upper respiratory tract infection (URI) and was tested four days after symptom onset [see Additional file 1]. SARS-CoV-2 viral load in upper respiratory specimens was detected at a higher level soon after the symptom onset [<xref ref-type="bibr" rid="CR19">19</xref>]; thus, a higher chance of positive antigen detection at the early phase can be implied. This SARS-CoV-2 antigen detection kit might be recommended for patients at the early time point after symptom onset where higher viral loads are anticipated. As aforementioned, some other factors such as clinical manifestation, duration from disease onset to laboratory test, type of specimens, and how the specimens were collected and processed (sample handling and processing techniques) potentially affect the result interpretation. Of 394 RT-PCR-negative samples from pre-operative cases, five NP and throat swabs were tested positive for SARS-CoV-2 antigen using the Standard Q COVID-19 Ag test. Although it is unclear what caused the discordant result, we observed that thick and highly viscous mucous tended to yield false positive results when tested with the antigen detection kit. For patients with negative SARS-CoV-2 detection by RT-PCR, clinical data (such as underlying diseases or infection with other pathogens) were not included in the study. Therefore, the possibility of cross-reactivity with other antigens cannot be excluded.</p>
      <p id="Par36">Our results showed higher sensitivity of the rapid SARS-CoV-2 antigen test (98.33% by Standard Q COVID-19 Ag test) than other rapid antigen tests previously reported. Previous studies reported a sensitivity of 93.9% (95% CI, 86.5&#x2013;97.4%) by Fluorescence Immunochromatographic Assay for 2019-nCoV Ag Test (Bioeasy Biotechnology Co., Shenzhen, China), 50.0% by COVID-19 Ag Respi-Strip CORIS&#xAE;, and 11.1&#x2013;45.7% by BIOCREDIT COVID-19 Ag (BioVendor Research and Diagnostic Products) [<xref ref-type="bibr" rid="CR10">10</xref>&#x2013;<xref ref-type="bibr" rid="CR12">12</xref>]. The positive and negative predictive values (PPV and NPV) of the assay could not be accurately calculated without the present population prevalence of COVID-19. However, there were five false positive samples tested by the Standard Q COVID-19 Ag test. We can estimate that in a low COVID-19 prevalence area, the PPV for this test is low. Hypothetically, in the 10% COVID-19 prevalence rate, the PPV vs NPV of the Standard Q COVID-19 Ag test would be 89.59% (95% CI, 78.27&#x2013;95.37%) versus 99.81% (95% CI, 98.71&#x2013;99.97%). While in the 1% COVID-19 prevalence rate, the PPV vs NPV of the Standard Q COVID-19 Ag test would be 43.91% (95% CI, 24.66&#x2013;65.17%) versus 99.98% (95% CI, 99.88&#x2013;100.00%). Thus, the Standard Q COVID-19 Ag test might be useful in the high prevalence area.</p>
      <p id="Par37">The advantage of the Standard Q COVID-19 Ag test as a screening for COVID-19 is its simple procedure and quick results with high NPV, but its disadvantage is low PPV in a low prevalence area. Thus, the nucleic acid test (NAT) for SARS-CoV-2 gene detection, which is more sensitive and specific than this lateral flow immunoassay, is still a standard test for COVID-19 diagnosis. Even with its limitations, the rapid SARS-CoV-2 antigen test can benefit all healthcare workers in managing infected individuals in time effectively, especially in rural and outbreak areas. Therefore, a prospective study of the rapid SARS-CoV-2 antigen test in these fields should be performed before the implementation.</p>
    </sec>
    <sec id="Sec13">
      <title>Conclusions</title>
      <p id="Par38">The rapid assay for SARS-CoV-2 antigen detection (Standard&#x2122; Q COVID-19 Ag kit) showed comparable sensitivity (98.33%; 95% CI, 91.06&#x2013;99.96%) and specificity (98.73%; 95% CI, 97.06&#x2013;99.59%) with real-time RT-PCR assay. We believe there is a potential use of this rapid and simple SARS-CoV-2 antigen detection test as a screening assay, especially in a high prevalence area.
</p>
    </sec>
    <sec sec-type="supplementary-material">
      <title>Supplementary information</title>
      <sec id="Sec130">
        <p>
<supplementary-material content-type="local-data" id="MOESM1"><media xlink:href="12985_2020_1452_MOESM1_ESM.xlsx"><caption><p><bold>Additional file 1</bold>. <bold> Table S1</bold>: Rapid antigen test in 60 SARS-CoV-2 RT-PCR-positive cases. Characteristics of each COVID-19 Thai case (n=60) including gender, age, initial diagnosis, specimen type, Ct-value of RT-PCR (<italic>E</italic>, <italic>RdRp</italic>, <italic>N</italic>), RT-PCR result, Standard Q COVID-19 Ag test result, and time from symptom onset to laboratory test are demonstrated. Continuous data were presented in mean, standard deviation (SD), median, and range (min, max).</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2"><media xlink:href="12985_2020_1452_MOESM2_ESM.xlsx"><caption><p><bold>Additional file 2</bold>. <bold> Table S2</bold>: Rapid antigen test in 394 SARS-CoV-2 RT-PCR-negative cases. Characteristics of each SARS-CoV-2 RT-PCR-negative case (n=394) including gender, initial diagnosis, specimen type, Ct-value of RT-PCR (<italic>E</italic>, <italic>RdRp</italic>, <italic>N</italic>), RT-PCR result, Standard Q COVID-19 Ag test result, and time from symptom onset to laboratory test are demonstrated. Continuous data were presented in mean, standard deviation (SD), median, and range (min, max).</p></caption></media></supplementary-material></p>
      </sec>
    </sec>
  </body>
  <back>
    <glossary>
      <title>Abbreviations</title>
      <def-list>
        <def-item>
          <term>Ag</term>
          <def>
            <p id="Par5">Antigen</p>
          </def>
        </def-item>
        <def-item>
          <term>ARDS</term>
          <def>
            <p id="Par6">Acute respiratory distress syndrome</p>
          </def>
        </def-item>
        <def-item>
          <term>BSL</term>
          <def>
            <p id="Par7">Biosafety level</p>
          </def>
        </def-item>
        <def-item>
          <term>COVID-19</term>
          <def>
            <p id="Par8">Coronavirus disease 2019</p>
          </def>
        </def-item>
        <def-item>
          <term>Ct-value</term>
          <def>
            <p id="Par9">Cycle threshold value</p>
          </def>
        </def-item>
        <def-item>
          <term>E</term>
          <def>
            <p id="Par10">Envelope protein</p>
          </def>
        </def-item>
        <def-item>
          <term>N</term>
          <def>
            <p id="Par11">Nucleocapsid protein</p>
          </def>
        </def-item>
        <def-item>
          <term>NAT</term>
          <def>
            <p id="Par12">Nucleic acid test</p>
          </def>
        </def-item>
        <def-item>
          <term>NP</term>
          <def>
            <p id="Par13">Nasopharyngeal</p>
          </def>
        </def-item>
        <def-item>
          <term>NPV</term>
          <def>
            <p id="Par14">Negative predictive value</p>
          </def>
        </def-item>
        <def-item>
          <term>PPV</term>
          <def>
            <p id="Par15">Positive predictive value</p>
          </def>
        </def-item>
        <def-item>
          <term>RdRp</term>
          <def>
            <p id="Par16">RNA-dependent RNA polymerase</p>
          </def>
        </def-item>
        <def-item>
          <term>RT-PCR</term>
          <def>
            <p id="Par17">Real-time reverse transcription-polymerase chain reaction</p>
          </def>
        </def-item>
        <def-item>
          <term>SARS-CoV-2</term>
          <def>
            <p id="Par18">Severe acute respiratory syndrome coronavirus 2</p>
          </def>
        </def-item>
      </def-list>
    </glossary>
    <fn-group>
      <fn>
        <p>
          <bold>Publisher's Note</bold>
        </p>
        <p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
      </fn>
    </fn-group>
    <sec>
      <title>Supplementary information</title>
      <p><bold>Supplementary information</bold> accompanies this paper at 10.1186/s12985-020-01452-5.</p>
    </sec>
    <ack>
      <title>Acknowledgements</title>
      <p>The authors would like to thank the healthcare workers and laboratory teams at Siriraj Hospital, Mahidol University, Bangkok, Thailand for clinical specimen collection and processing. We also acknowledge Liz Albertorio-S&#xE1;ez for assisting in proofreading the manuscript.</p>
    </ack>
    <notes notes-type="author-contribution">
      <title>Authors&#x2019; contributions</title>
      <p>C.C. and R.S. wrote the original draft. C.C., B.K., N.A., N.H. curated laboratory data. R. Sirijatuphat, M.C., N. Angkasekwinai, N.P.,&#xA0;T.T., O.P., S.C., Y.S. recruited and curated clinical data, C.C. and R.S. analysed the data. C.C., B.K., N.T., and N.A. performed the investigation. N.H. and W.K. administered the project. N.H., R.S., and W.K. supervised the study. N.H. acquired funding. All authors read and approved the final manuscript.</p>
    </notes>
    <notes notes-type="funding-information">
      <title>Funding</title>
      <p>This research was partly supported by Faculty of Medicine Siriraj Hospital, Mahidol University, Thailand through grant number R016034012.</p>
    </notes>
    <notes notes-type="data-availability">
      <title>Availability of data and materials</title>
      <p>All data generated or analysed during this study are included in this published article and its additional files.</p>
    </notes>
    <notes id="FPar1">
      <title>Ethics approval and consent to participate</title>
      <p id="Par39">This study was approved by the Institutional Review Board of the Faculty of Medicine Siriraj Hospital, Mahidol University (SIRB Protocol 463/2563(IRB4); COA: Si 503/2020).</p>
    </notes>
    <notes id="FPar2">
      <title>Consent to publication</title>
      <p id="Par40">Not applicable.</p>
    </notes>
    <notes id="FPar3" notes-type="COI-statement">
      <title>Competing interests</title>
      <p id="Par41">All authors declared no conflict of interest. There is no involvement from the companies Seegene or SD Biosensor.</p>
    </notes>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="other">World Health Organization. Coronavirus disease (COVID-19) Weekly epidemiological update and weekly operational update. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports</ext-link>. Accessed 1 Sept 2020.</mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="other">Johns Hopkins Coronavirus Resource Center. <ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/">https://coronavirus.jhu.edu/</ext-link>. Accessed 1 Sept 2020.</mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="other">Worldometer. Coronavirus Cases. <ext-link ext-link-type="uri" xlink:href="https://www.worldometers.info/coronavirus/">https://www.worldometers.info/coronavirus/</ext-link>. Accessed 1 Sept 2020.</mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="other">Okada P, Buathong R, Phuygun S, Thanadachakul T, Parnmen S, Wongboon W, Waicharoen S, Wacharapluesadee S, Uttayamakul S, Vachiraphan A, Chittaganpitch M, Mekha N, Jaenjai N, Iamsirithaworn S, Lee RTC, Maurer-Stroh S. Early transmissions patterns of coronavirus disease 2019 (COVID-19) in travelers from Wuhan to Thailand, January 2020. Surveill. 2020;25(8):pii=2000097. 10.2807/1560-7917.ES.2020.25.8.2000097.</mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="other">Emergency Operation Center, Department of Disease Control, Ministry of Public Health. Corona Virus Disease (COVID-19). <ext-link ext-link-type="uri" xlink:href="https://ddc.moph.go.th/viralpneumonia/eng/index.php">https://ddc.moph.go.th/viralpneumonia/eng/index.php</ext-link>. Accessed 1 Sept 2020.</mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sohrabi</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Alsafi</surname>
              <given-names>Z</given-names>
            </name>
            <name>
              <surname>O&#x2019;Neill</surname>
              <given-names>N</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>World Health Organization declares global emergency: a review of the 2019 novel coronavirus (COVID-19)</article-title>
          <source>Int J Surg</source>
          <year>2020</year>
          <volume>76</volume>
          <fpage>71</fpage>
          <lpage>76</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijsu.2020.02.034</pub-id>
          <pub-id pub-id-type="pmid">32112977</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tang</surname>
              <given-names>YW</given-names>
            </name>
            <name>
              <surname>Schmitz</surname>
              <given-names>JE</given-names>
            </name>
            <name>
              <surname>Persing</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Stratton</surname>
              <given-names>CW</given-names>
            </name>
          </person-group>
          <article-title>Laboratory diagnosis of COVID-19: current issues and challenges</article-title>
          <source>J Clin Microbiol</source>
          <year>2020</year>
          <volume>58</volume>
          <fpage>e00512-20</fpage>
          <pub-id pub-id-type="doi">10.1128/JCM.00512-20</pub-id>
          <pub-id pub-id-type="pmid">32245835</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van Kasterena</surname>
              <given-names>PB</given-names>
            </name>
            <name>
              <surname>Veer</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Brink</surname>
              <given-names>S</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Comparison of commercial RT-PCR diagnostic kits for COVID-19</article-title>
          <source>J Clin Virol</source>
          <year>2020</year>
          <volume>128</volume>
          <fpage>104412</fpage>
          <pub-id pub-id-type="doi">10.1016/j.jcv.2020.104412</pub-id>
          <pub-id pub-id-type="pmid">32416600</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Corman</surname>
              <given-names>VM</given-names>
            </name>
            <name>
              <surname>Landt</surname>
              <given-names>O</given-names>
            </name>
            <name>
              <surname>Kaiser</surname>
              <given-names>M</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR</article-title>
          <source>Euro Surveill</source>
          <year>2020</year>
          <volume>25</volume>
          <fpage>2000045</fpage>
          <pub-id pub-id-type="doi">10.2807/1560-7917.ES.2020.25.3.2000045</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <mixed-citation publication-type="other">Lambert-Niclot S, Cuffel A, Le Pape S, et al. Evaluation of rapid diagnostic assay for detection of SARS-CoV-2 antigen in nasopharyngeal swab. J Clin Microbiol 2020; JCM.00977-20. doi:10.1128/JCM.00977-20.</mixed-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Porte</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Legarraga</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Vollrath</surname>
              <given-names>V</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Evaluation of novel antigen-based rapid detection test for the diagnosis of SARS-CoV-2 in respiratory samples</article-title>
          <source>Int J Infect Dis</source>
          <year>2020</year>
          <volume>S1201&#x2013;9712</volume>
          <issue>20</issue>
          <fpage>30405</fpage>
          <lpage>30407</lpage>
          <pub-id pub-id-type="doi">10.1016/j.ijid.2020.05.098</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mak</surname>
              <given-names>GC</given-names>
            </name>
            <name>
              <surname>Cheng</surname>
              <given-names>PK</given-names>
            </name>
            <name>
              <surname>Lau</surname>
              <given-names>SS</given-names>
            </name>
            <name>
              <surname>Wong</surname>
              <given-names>KK</given-names>
            </name>
            <name>
              <surname>Lau</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Lam</surname>
              <given-names>ET</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Evaluation of rapid antigen test for detection of SARS-CoV-2 virus</article-title>
          <source>J Clin Virol</source>
          <year>2020</year>
          <volume>129</volume>
          <fpage>104500</fpage>
          <pub-id pub-id-type="doi">10.1016/j.jcv.2020.104500</pub-id>
          <pub-id pub-id-type="pmid">32585619</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <mixed-citation publication-type="other">Rachid ZZ, Othman SN, Najihan M, Samat A, Ali UK, KonKen W. Diagnostic performance of COVID-19 serology assays. Malays J Pathol 2020;42(1):13&#x2013;21.</mixed-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <mixed-citation publication-type="other">Schoonjans F. MedCalc's Diagnostic test evaluation calculator. MedCalc. MedCalc Software; 2020. <ext-link ext-link-type="uri" xlink:href="https://www.medcalc.org/calc/diagnostic_test.php">https://www.medcalc.org/calc/diagnostic_test.php</ext-link>. Accessed 1 June 2020.</mixed-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <mixed-citation publication-type="other">Thailand Ministry of Public Health. Diagnostic detection of Novel coronavirus 2019 by real-time RTPCR. 2020.</mixed-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <mixed-citation publication-type="other">Department of Medical Sciences, Ministry of Public Health, Thailand. Diagnostic detection of Novel coronavirus 2019 by real-time RT-PCR. 23 Jan 2020. <ext-link ext-link-type="uri" xlink:href="https://www.who.int/docs/default-source/coronaviruse/conventional-rt-pcr-followed-by-sequencing-fordetection-of-ncov-rirl-nat-inst-health-t.pdf?sfvrsn=42271c6d_4">https://www.who.int/docs/default-source/coronaviruse/conventional-rt-pcr-followed-by-sequencing-fordetection-of-ncov-rirl-nat-inst-health-t.pdf?sfvrsn=42271c6d_4</ext-link>. Accessed 26 Feb 2020.</mixed-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <mixed-citation publication-type="other">Tang X, Wu C, Li X, et al. On the origin and continuing evolution of SARS-CoV-2. Microbiology Natl Sci Rev. 2020 nwaa036, https://doi.org/10.1093/nsr/nwaa036.</mixed-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <mixed-citation publication-type="other">Ceraolo C, Giorgi FM. Genomic variance of the 2019-nCoV coronavirus J Med Virol 2020;92:522&#x2013;528. doi: 10.1002/jmv.25700.</mixed-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zou</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Ruan</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Liang</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Huang</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Hong</surname>
              <given-names>Z</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>SARS-CoV-2 viral load in upper respiratory specimens of infected patients</article-title>
          <source>N Engl J Med</source>
          <year>2020</year>
          <volume>382</volume>
          <issue>12</issue>
          <fpage>1177</fpage>
          <lpage>1179</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMc2001737</pub-id>
          <pub-id pub-id-type="pmid">32074444</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>